https://dev.oncoprescribe.com/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj/2026-01-11T22:18:11-07:00https://dev.oncoprescribe.com/adjuvant-giredestrant-reduces-recurrence-risk-in-er-positive-her2-negative-early-breast-cancer-results-from-the-phase-iii-lidera-trial/2026-01-15T14:40:31-07:00https://dev.oncoprescribe.com/fixed-duration-vs-continuous-targeted-therapy-in-frontline-cll-insights-from-the-phase-iii-cll17-trial/2026-01-15T14:40:18-07:00https://dev.oncoprescribe.com/routine-preoperative-breast-mri-for-early-stage-cancers-may-not-be-beneficial-outcome-data-from-alliance-a011104/2026-01-28T06:17:55-07:00https://dev.oncoprescribe.com/jaypirca-versus-imbruvica-in-treatment-naive-cll-sll-insights-from-the-phase-iii-bruin-cll-314-trial/2026-01-22T07:23:06-07:00https://dev.oncoprescribe.com/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-6/2026-01-28T14:00:12-07:00https://dev.oncoprescribe.com/fda-approves-first-line-enhertu-plus-perjeta-for-her2-positive-metastatic-breast-cancer/2026-01-29T14:54:22-07:00https://dev.oncoprescribe.com/real-world-outcomes-with-cd20xcd3-bispecific-antibodies-in-relapsed-refractory-large-b-cell-lymphoma-insights-from-the-multicenter-realbite-consortium/2026-01-29T14:54:00-07:00https://dev.oncoprescribe.com/exploring-glp-1-receptor-agonists-as-a-novel-adjunct-in-sickle-cell-disease/2026-02-05T17:10:04-07:00https://dev.oncoprescribe.com/reconsidering-menopausal-hormone-therapy-in-brca1-2-carriers-emerging-evidence-challenges-longstanding-concerns/2026-02-05T17:11:23-07:00https://dev.oncoprescribe.com/redefining-first-line-maintenance-in-hr-positive-her2-positive-metastatic-breast-cancer/2026-02-12T17:18:14-07:00https://dev.oncoprescribe.com/late-breaking-abstract-2026-asco-gi-symposium-redefining-first-line-therapy-in-her2-positive-gastroesophageal-adenocarcinoma-with-zanidatamab-based-combinations/2026-02-12T17:17:44-07:00https://dev.oncoprescribe.com/trodelvy-plus-keytruda-in-metastatic-triple-negative-breast-cancer/2026-02-19T15:46:06-07:00https://dev.oncoprescribe.com/final-overall-survival-results-from-the-embark-trial-practice-changing-evidence-in-high-risk-biochemical-recurrence/2026-02-19T15:45:36-07:00https://dev.oncoprescribe.com/expert-perspectives-on-mrd-testing-in-multiple-myeloma/2026-03-04T06:33:09-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-with-paclitaxel-for-platinum-resistant-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma/2026-02-26T07:09:42-07:00https://dev.oncoprescribe.com/fda-approves-calquence-with-venclexta-for-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/2026-02-26T07:10:33-07:00https://dev.oncoprescribe.com/fda-approves-first-line-hernexeos-for-her2-mutant-advanced-nsclc/2026-03-05T13:12:07-07:00https://dev.oncoprescribe.com/adjuvant-nivolumab-for-resected-melanoma-9-year-outcomes/2026-03-05T13:11:30-07:00https://dev.oncoprescribe.com/late-breaking-abstract-2026-asco-gu-symposium-advancing-adjuvant-therapy-in-clear-cell-renal-cell-carcinoma/2026-03-12T06:13:53-07:00https://dev.oncoprescribe.com/expanding-targeted-first-line-options-in-braf-v600e-mutant-metastatic-colorectal-cancer-insights-from-the-breakwater-trial/2026-03-12T06:13:22-07:00https://dev.oncoprescribe.com/reassessing-the-role-of-carboplatin-in-neoadjuvant-therapy-for-her2-positive-breast-cancer-insights-from-the-neocarhp-trial/2026-03-19T06:11:22-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-gi-2026-identifying-a-less-neurotoxic-first-line-backbone-in-metastatic-esophagogastric-cancer-insights-from-the-lyricx-trial/2026-03-19T06:10:44-07:00https://dev.oncoprescribe.com/extrapulmonary-neuroendocrine-carcinoma-clinical-overview-and-advances-in-dll3-targeted-therapy/2026-03-30T19:51:58-07:00https://dev.oncoprescribe.com/fixed-duration-vs-continuous-targeted-therapy-in-frontline-cll-insights-from-the-phase-iii-cll17-trial-2/2026-03-26T06:08:28-07:00https://dev.oncoprescribe.com/apixaban-vs-rivaroxaban-in-acute-vte-practice-changing-insights-for-oncology-clinicians/2026-03-26T06:09:31-07:00https://dev.oncoprescribe.com/this-is-an-example/2026-04-09T09:00:53-07:00https://dev.oncoprescribe.com/akeega-niraparib-and-abiraterone-acetate-2/2026-01-11T21:59:45-07:00https://dev.oncoprescribe.com/rubraca-rucaparib-4/2026-01-11T22:12:54-07:00https://dev.oncoprescribe.com/enhertu-fam-trastuzumab-deruxtecan-nxki-8/2026-01-11T22:03:59-07:00https://dev.oncoprescribe.com/breyanzi-lisocabtagene-maraleucel-5/2026-01-11T21:54:21-07:00https://dev.oncoprescribe.com/jaypirca-pirtobrutinib-3/2026-01-11T21:49:01-07:00https://dev.oncoprescribe.com/imfinzi-durvalumab-9/2026-01-11T21:41:34-07:00https://dev.oncoprescribe.com/keytruda-or-keytruda-qlex-with-padcev/2026-01-11T21:34:09-07:00https://dev.oncoprescribe.com/imdelltra-tarlatamab-dlle-2/2026-01-11T21:21:54-07:00https://dev.oncoprescribe.com/hyrnuo-sevabertinib/2026-01-11T21:15:49-07:00https://dev.oncoprescribe.com/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-5/2026-01-11T21:09:23-07:00https://dev.oncoprescribe.com/koselugo-selumetinib-2/2026-01-11T21:03:17-07:00https://dev.oncoprescribe.com/epkinly-epcoritamab-bysp-3/2026-01-11T20:52:49-07:00https://dev.oncoprescribe.com/poherdy-pertuzumab-dpzb/2026-01-11T20:46:58-07:00https://dev.oncoprescribe.com/komzifti-ziftomenib/2026-01-11T20:40:52-07:00https://dev.oncoprescribe.com/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-4/2026-01-11T20:34:37-07:00https://dev.oncoprescribe.com/revuforj-revumenib-2/2026-01-11T20:28:04-07:00https://dev.oncoprescribe.com/blenrep-belantamab-mafodotin-blmf-2/2026-01-11T20:18:31-07:00https://dev.oncoprescribe.com/libtayo-cemiplimab-rwlc-4/2026-01-11T20:13:13-07:00https://dev.oncoprescribe.com/zepzelca-lurbinectedin-2/2026-01-11T20:06:21-07:00https://dev.oncoprescribe.com/inluriyo-imlunestrant/2026-01-11T18:19:53-07:00https://dev.oncoprescribe.com/keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph/2026-01-11T18:13:24-07:00https://dev.oncoprescribe.com/koselugo-selumetinib/2026-01-11T18:07:57-07:00https://dev.oncoprescribe.com/inlexzo-gemcitabine-intravesical-system/2026-01-11T18:02:53-07:00https://dev.oncoprescribe.com/hernexeos-zongertinib/2026-01-11T17:57:06-07:00https://dev.oncoprescribe.com/modeyso-dordaviprone/2026-01-11T17:51:02-07:00https://dev.oncoprescribe.com/zegfrovy-sunvozertinib/2026-01-11T17:45:03-07:00https://dev.oncoprescribe.com/lynozyfic-linvoseltamab-gcpt/2026-01-11T17:22:38-07:00https://dev.oncoprescribe.com/datroway-datopotamab-deruxtecan-dlnk-2/2026-01-11T16:28:47-07:00https://dev.oncoprescribe.com/monjuvi-tafasitamab-cxix-2/2026-01-11T16:21:42-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-44/2026-01-11T16:06:38-07:00https://dev.oncoprescribe.com/zusduri-mitomycin-intravesical-solution/2026-01-11T15:59:04-07:00https://dev.oncoprescribe.com/ibtrozi-taletrectinib/2026-01-11T15:52:44-07:00https://dev.oncoprescribe.com/nubeqa-darolutamide-3/2026-01-11T15:45:49-07:00https://dev.oncoprescribe.com/neoadjuvant-niraparib-plus-dostarlimab-in-brca-or-palb2-mutated-triple-negative-breast-cancer-phase-ii-tbcrc-056-results/2026-01-08T13:58:36-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2025-teclistamab-plus-daratumumab-redefines-outcomes-in-early-relapsed-multiple-myeloma/2026-01-08T13:54:33-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2025-advancing-first-line-therapy-in-high-risk-nmibc-final-results-from-the-phase-iii-potomac-trial/2026-01-01T10:31:50-07:00https://dev.oncoprescribe.com/reassessing-first-line-chemotherapy-selection-in-metastatic-pdac-insights-from-the-pass-01-trial/2026-01-01T10:31:09-07:00https://dev.oncoprescribe.com/therapeutic-prowess-and-potential-of-multifunctional-therapeutics-a-review-of-bispecific-antibodies/2025-12-30T07:16:51-07:00https://dev.oncoprescribe.com/fda-approves-pirtobrutinib-in-relapsed-refractory-cll-sll/2025-12-25T12:02:15-07:00https://dev.oncoprescribe.com/fda-approves-niraparib-with-abiraterone-acetate-plus-prednisone-for-brca2-mutated-mcspc/2025-12-25T12:02:02-07:00https://dev.oncoprescribe.com/her2climb-05-redefining-first-line-maintenance-therapy-in-her2-positive-metastatic-breast-cancer/2025-12-18T15:38:47-07:00https://dev.oncoprescribe.com/pharos-long-term-efficacy-and-survival-outcomes-with-encorafenib-plus-binimetinib-in-braf-v600e-mutant-metastatic-nsclc/2025-12-18T15:38:31-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2025-early-radioligand-intensification-in-mhspc-key-findings-from-the-phase-iii-psmaddition-trial/2025-12-11T07:17:42-07:00https://dev.oncoprescribe.com/chronic-hepatitis-c-as-a-modifiable-risk-factor-for-pancreatic-cancer-insights-from-a-national-va-cohort/2025-12-11T07:16:58-07:00https://dev.oncoprescribe.com/first-line-sacituzumab-govitecan-in-advanced-triple-negative-breast-cancer/2025-12-04T16:08:00-07:00https://dev.oncoprescribe.com/erspc-final-analysis-long-term-psa-screening-reduces-prostate-cancer-deaths/2025-12-04T16:07:47-07:00https://dev.oncoprescribe.com/precision-medicine-in-practice-timely-use-of-tumor-ngs-remains-suboptimal-in-common-cancers-3/2025-11-27T21:53:14-07:00https://dev.oncoprescribe.com/low-dose-aspirin-reduces-recurrence-in-colorectal-cancer-patients-with-pi3k-pathway-alterations-2/2025-11-27T21:52:56-07:00https://dev.oncoprescribe.com/durvalumab-flot-establishes-new-benchmark-in-curative-intent-therapy-for-gastric-and-gej-cancers/2025-11-20T21:14:55-07:00https://dev.oncoprescribe.com/fda-approves-komzifti-for-relapsed-or-refractory-acute-myeloid-leukemia-with-a-npm1-mutation/2025-11-20T21:12:38-07:00https://dev.oncoprescribe.com/updated-asco-astro-sso-guideline-clarifies-indications-and-best-practices-for-postmastectomy-radiation-therapy-in-breast-cancer/2025-11-13T06:45:32-07:00https://dev.oncoprescribe.com/amivantamab-lazertinib-combination-improves-overall-survival-in-egfr-mutated-advanced-nsclc/2025-11-13T06:43:40-07:00https://dev.oncoprescribe.com/educational-message-precision-medicine-in-mcrc-navigating-complexity-in-the-era-of-targeted-therapy/2025-11-07T13:05:50-07:00https://dev.oncoprescribe.com/endocrine-therapy-omission-in-er-low-early-stage-breast-cancer-linked-to-worse-survival-outcomes-2/2025-11-06T17:41:38-07:00https://dev.oncoprescribe.com/precision-medicine-in-practice-timely-use-of-tumor-ngs-remains-suboptimal-in-common-cancers-2/2025-11-06T17:41:21-07:00https://dev.oncoprescribe.com/real-world-tolerability-of-capecitabine-and-oxaliplatin-capox-in-localized-colorectal-cancer-insights-from-a-single-institution-analysis/2025-10-30T20:30:53-07:00https://dev.oncoprescribe.com/fda-approves-blenrep-combination-for-relapsed-or-refractory-multiple-myeloma/2025-10-30T20:30:36-07:00https://dev.oncoprescribe.com/extended-duration-low-intensity-apixaban-reduces-recurrent-vte-risk-in-patients-with-provoked-events-and-enduring-risk-factors-results-from-the-hi-pro-trial/2025-10-23T16:55:35-07:00https://dev.oncoprescribe.com/fda-approves-tar-200-monotherapy-a-novel-bladder-sparing-strategy-in-bcg-unresponsive-high-risk-nmibc/2025-10-23T16:54:56-07:00https://dev.oncoprescribe.com/maintaining-physician-preference-in-cll-care-and-its-impact-on-outcomes/2025-10-21T15:10:43-07:00https://dev.oncoprescribe.com/polygenic-risk-scores-predict-future-breast-cancer-events-after-in-situ-disease/2025-10-16T16:43:01-07:00https://dev.oncoprescribe.com/fda-approves-libtayo-for-adjuvant-treatment-of-cutaneous-squamous-cell-carcinoma/2025-10-16T16:42:29-07:00https://dev.oncoprescribe.com/fda-approves-zepzelca-plus-tecentriq-for-first-line-maintenance-in-extensive-stage-small-cell-lung-cancer/2025-10-09T11:22:30-07:00https://dev.oncoprescribe.com/underutilization-and-suboptimal-use-of-hypomethylating-agents-in-myelodysplastic-syndromes-insights-from-a-national-medicare-analysis/2025-10-09T11:22:13-07:00https://dev.oncoprescribe.com/fda-approval-of-inluriyo-for-esr1-mutated-er-positive-her2-negative-metastatic-breast-cancer-insights-from-ember-3/2025-10-02T06:01:02-07:00https://dev.oncoprescribe.com/mrd-guided-ibrutinib-venetoclax-therapy-shows-durable-survival-benefit-in-cll-results-from-the-phase-3-flair-trial/2025-10-02T06:00:44-07:00https://dev.oncoprescribe.com/fda-approves-first-subcutaneous-formulation-of-keytruda-keytruda-qlex/2025-09-25T05:30:55-07:00https://dev.oncoprescribe.com/de-escalated-adjuvant-radiotherapy-demonstrates-reduced-long-term-toxicity-in-hpv-associated-oropharyngeal-cancer/2025-09-25T05:29:39-07:00https://dev.oncoprescribe.com/can-2409-in-advanced-nsclc-turning-tumors-into-vaccines/2025-09-18T13:58:59-07:00https://dev.oncoprescribe.com/low-dose-aspirin-reduces-recurrence-in-colorectal-cancer-patients-with-pi3k-pathway-alterations/2025-09-18T13:58:46-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-yervoy-ipilimumab-in-the-first-line-treatment-of-unresectable-or-metastatic-hcc1-5/2025-09-15T19:03:02-07:00https://dev.oncoprescribe.com/hormonal-contraception-and-breast-cancer-risk-in-brca1-2-mutation-carriers/2025-09-11T05:52:31-07:00https://dev.oncoprescribe.com/statins-as-potential-adjuvants-in-immune-checkpoint-inhibitor-therapy-a-comprehensive-meta-analysis/2025-09-11T05:52:17-07:00https://dev.oncoprescribe.com/elinzanetant-reduces-vasomotor-symptoms-in-women-receiving-endocrine-therapy-for-hr-positive-breast-cancer/2025-09-04T05:56:37-07:00https://dev.oncoprescribe.com/fda-grants-accelerated-approval-to-emrelis-for-nsclc-with-high-c-met-protein-overexpression/2025-09-04T05:56:18-07:00https://dev.oncoprescribe.com/fda-approves-zongertinib-for-nsclc-with-her2-tkd-activating-mutations/2025-08-28T05:59:30-07:00https://dev.oncoprescribe.com/tafasitamab-plus-lenalidomide-and-rituximab-improves-outcomes-in-relapsed-refractory-follicular-lymphoma-results-from-the-phase-iii-inmind-trial/2025-08-28T05:59:18-07:00https://dev.oncoprescribe.com/pirtobrutinib-in-relapsed-refractory-cll-sll-after-prior-cbtki-phase-iii-bruin-cll-321-results/2025-08-21T09:24:28-07:00https://dev.oncoprescribe.com/tarlatamab-sets-new-standard-in-recurrent-small-cell-lung-cancer-results-from-dellphi-304/2025-08-21T09:22:08-07:00https://dev.oncoprescribe.com/adjuvant-atezolizumab-in-resected-nsclc-five-year-outcomes-from-impower010/2025-08-14T09:17:22-07:00https://dev.oncoprescribe.com/innovating-multiple-myeloma-care-iraklia-confirms-on-body-injector-for-subcutaneous-isatuximab-as-a-safe-effective-alternative-to-iv-delivery/2025-08-14T09:17:05-07:00https://dev.oncoprescribe.com/endocrine-therapy-omission-in-er-low-early-stage-breast-cancer-linked-to-worse-survival-outcomes/2025-08-07T16:23:29-07:00https://dev.oncoprescribe.com/neoadjuvant-pd-1-blockade-promotes-organ-preservation-in-early-stage-mismatch-repair-deficient-solid-tumors/2025-08-07T16:23:11-07:00https://dev.oncoprescribe.com/precision-approaches-in-stage-iii-nsclc-a-new-standard-of-care/2025-07-31T07:38:33-07:00https://dev.oncoprescribe.com/destiny-gastric04-trastuzumab-deruxtecan-improves-survival-over-ramucirumab-plus-paclitaxel-in-her2-positive-gastric-and-gej-cancers/2025-07-31T07:38:19-07:00https://dev.oncoprescribe.com/precision-medicine-in-practice-timely-use-of-tumor-ngs-remains-suboptimal-in-common-cancers/2025-07-24T05:24:37-07:00https://dev.oncoprescribe.com/practice-changing-insights-in-myeloma-prevention-darzalex-shows-landmark-results-in-high-risk-smoldering-myeloma-aquila-trial/2025-07-24T05:23:52-07:00https://dev.oncoprescribe.com/opdivo-qvantigtm-nivolumab-hyaluronidase-nvhy-is-delivered-via-subcutaneous-injection-streamlining-administration-for-eligible-patients1/2025-07-21T19:46:11-07:00https://dev.oncoprescribe.com/management-of-locally-advanced-rectal-cancer-asco-guideline-clinical-insights/2025-07-17T16:46:44-07:00https://dev.oncoprescribe.com/three-year-overall-survival-with-opdualag-in-advanced-melanoma/2025-07-17T16:40:36-07:00https://dev.oncoprescribe.com/breakwater-trial-establishes-encorafenib-combination-with-cetuximab-plus-mfolfox6-as-a-first-line-standard-for-braf-v600e-mutated-mcrc/2025-07-10T05:37:49-07:00https://dev.oncoprescribe.com/fda-approves-perioperative-keytruda-for-resectable-locally-advanced-head-and-neck-squamous-cell-carcinoma/2025-07-10T05:37:28-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2025-targeting-esr1-mutations-in-advanced-breast-cancer-phase-3-veritac-2-validates-vepdegestrant-as-a-promising-next-generation-endocrine-therapy/2025-07-24T06:19:08-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2025-tarlatamab-sets-new-standard-in-recurrent-small-cell-lung-cancer-results-from-dellphi-304/2025-07-24T06:23:12-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2025-amplitude-trial-defining-a-new-treatment-paradigm-in-hrr-altered-mcspc/2025-06-26T05:39:34-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2025-cassandra-phase-3-trial-neoadjuvant-paxg-improves-event-free-survival-in-resectable-and-borderline-resectable-pdac/2025-06-26T05:39:15-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2025-redefining-the-first-line-standard-destiny-breast09-highlights-t-dxd-plus-pertuzumab-as-a-potential-new-benchmark-in-her2-metastatic-breast-cancer/2025-07-09T20:26:04-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2025-rusfertide-in-polycythemia-vera-phase-3-verify-trial-highlights-a-practice-changing-approach-to-managing-hematocrit-and-phlebotomy-burden/2026-03-20T09:11:06-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2025-serena-6-a-ctdna-guided-switch-to-camizestrant-improves-pfs-in-hr-positive-her2-negative-advanced-breast-cancer/2025-06-12T11:50:48-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2025-durvalumab-plus-flot-demonstrates-significant-efs-improvement-in-resectable-gastric-and-ge-junction-cancers-interim-results-from-the-phase-3-matterhorn-tri/2025-06-12T11:50:21-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2025-adjuvant-immunotherapy-improves-outcomes-in-stage-iii-dmmr-colon-cancer-results-from-the-atomic-trial/2025-06-05T16:04:22-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2025-a-new-era-for-high-risk-resected-head-and-neck-cancer-nivolumab-adds-disease-free-survival-benefit-in-nivopostop-trial/2025-06-05T16:03:47-07:00https://dev.oncoprescribe.com/fda-grants-accelerated-approval-to-emrelis-for-nsclc-with-high-c-met-overexpression/2025-05-29T05:49:44-07:00https://dev.oncoprescribe.com/landmark-analysis-from-persist-2-links-pacritinib-response-to-survival-benefit-in-myelofibrosis-with-thrombocytopenia/2025-05-29T05:39:02-07:00https://dev.oncoprescribe.com/zynyz-retifanlimab-dlwr-2/2025-05-27T17:22:13-07:00https://dev.oncoprescribe.com/emrelis-telisotuzumab-vedotin-tllv/2025-05-27T17:15:18-07:00https://dev.oncoprescribe.com/welireg-belzutifan-3/2025-05-27T17:09:18-07:00https://dev.oncoprescribe.com/avmapki-avutometinib-and-fakzynja-defactinib-co-pack/2025-05-27T17:03:54-07:00https://dev.oncoprescribe.com/penpulimab-kcqx/2025-05-27T16:53:50-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-with-yervoy-ipilimumab-2/2025-05-27T16:42:28-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-with-yervoy-ipilimumab/2025-05-27T16:13:33-07:00https://dev.oncoprescribe.com/imfinzi-durvalumab-8/2025-05-27T16:03:12-07:00https://dev.oncoprescribe.com/pluvicto-lutetium-lu-177-vipivotide-tetraxetan-2/2025-05-27T15:41:58-07:00https://dev.oncoprescribe.com/cabometyx-cabozantinib-5/2025-05-27T15:34:50-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-43/2025-05-27T15:23:10-07:00https://dev.oncoprescribe.com/romvimza-vimseltinib/2025-05-27T15:16:40-07:00https://dev.oncoprescribe.com/adcetris-brentuximab-vedotin-6/2025-05-27T15:10:17-07:00https://dev.oncoprescribe.com/gomekli-mirdametinib/2025-05-27T14:52:49-07:00https://dev.oncoprescribe.com/grafapex-treosulfan/2025-05-27T14:44:36-07:00https://dev.oncoprescribe.com/enhertu-fam-trastuzumab-deruxtecan-nxki-7/2025-05-27T14:35:44-07:00https://dev.oncoprescribe.com/dihydropyrimidine-dehydrogenase-dpd-deficiency/2025-05-27T14:27:16-07:00https://dev.oncoprescribe.com/datroway-datopotamab-deruxtecan-dlnk/2025-05-27T14:18:57-07:00https://dev.oncoprescribe.com/lumakras-sotorasib-with-vectibix-panitumumab/2025-05-27T14:10:43-07:00https://dev.oncoprescribe.com/calquence-acalabrutinib-with-bendamustine-and-rituximab/2025-05-27T14:00:27-07:00https://dev.oncoprescribe.com/fda-approves-zynyz-for-squamous-cell-carcinoma-of-the-anal-canal/2025-05-21T20:38:57-07:00https://dev.oncoprescribe.com/pregnancy-specific-glycoproteins-linked-to-poorer-prognosis-in-female-lung-adenocarcinoma-patients/2025-05-21T20:38:19-07:00https://dev.oncoprescribe.com/rising-incidence-of-pancreatic-and-colorectal-adenocarcinoma-among-younger-populations/2025-05-15T06:22:43-07:00https://dev.oncoprescribe.com/underutilization-of-treatment-intensification-in-mcspc-persistent-gaps-between-guidelines-and-practice/2025-05-15T06:22:20-07:00https://dev.oncoprescribe.com/zongertinib-shows-promising-efficacy-and-safety-in-her2-mutant-nsclc-insights-from-the-beamion-lung-1-trial/2025-05-08T14:49:37-07:00https://dev.oncoprescribe.com/perioperative-keytruda-reshapes-the-treatment-landscape-for-resectable-locally-advanced-hnscc/2025-05-08T14:49:02-07:00https://dev.oncoprescribe.com/prostate-cancer-screening-with-polygenic-risk-score/2025-05-01T16:04:01-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-plus-yervoy-for-unresectable-or-metastatic-msi-h-mmr-deficient-colorectal-cancer/2025-04-24T06:47:55-07:00https://dev.oncoprescribe.com/metabolic-syndrome-and-breast-cancer-prognosis-a-comprehensive-meta-analysis-highlights-urgent-need-for-integrated-survivorship-strategies/2025-04-24T06:47:42-07:00https://dev.oncoprescribe.com/emerging-biomarker-insights-in-esophageal-squamous-cell-carcinoma-notch1-mutations-as-a-predictor-of-anti-pd-1-benefit/2025-04-16T21:14:29-07:00https://dev.oncoprescribe.com/optimizing-long-term-anticoagulation-in-cancer-associated-thrombosis-insights-from-the-api-cat-trial/2025-04-16T21:14:14-07:00https://dev.oncoprescribe.com/exploring-the-emerging-her2-low-and-her2-ultralow-subtypes-in-breast-cancer-therapy-advancements/2025-04-15T13:58:56-07:00https://dev.oncoprescribe.com/germline-and-somatic-genomic-testing-for-metastatic-prostate-cancer-asco-guideline/2025-04-10T06:01:46-07:00https://dev.oncoprescribe.com/zynlonta-in-combination-with-rituximab-shows-dramatic-activity-in-high-risk-follicular-lymphoma/2025-04-10T06:00:25-07:00https://dev.oncoprescribe.com/fda-approves-radioligand-therapy-with-pluvicto-before-chemotherapy-in-castrate-resistant-prostate-cancer/2025-04-03T06:13:37-07:00https://dev.oncoprescribe.com/kadcyla-improves-overall-survival-in-residual-her2-positive-breast-cancer/2025-04-03T06:13:25-07:00https://dev.oncoprescribe.com/bizengri-for-non-small-cell-lung-cancer-and-pancreatic-adenocarcinoma/2025-03-27T19:30:53-07:00https://dev.oncoprescribe.com/adjuvant-keytruda-improves-disease-free-survival-in-muscle-invasive-urothelial-carcinoma-2/2025-03-27T19:27:16-07:00https://dev.oncoprescribe.com/development-of-pac-mann-assay-for-early-detection-of-pancreatic-ductal-adenocarcinoma/2025-03-20T18:16:42-07:00https://dev.oncoprescribe.com/ongoing-benefit-with-enfortumab-vedotin-plus-pembrolizumab-in-metastatic-urothelial-carcinoma/2025-03-20T18:16:06-07:00https://dev.oncoprescribe.com/late-breaking-abstract-2025-asco-gi-symposium-circulating-tumor-dna-ctdna-as-a-predictive-biomarker-for-celecoxib-benefit-in-stage-iii-colon-cancer-insights-from-calgb-swog-80702/2025-03-13T06:23:06-07:00https://dev.oncoprescribe.com/advancing-prostate-cancer-treatment-the-efficacy-of-primary-partial-gland-cryoablation/2025-03-13T06:22:36-07:00https://dev.oncoprescribe.com/breakthroughs-in-targeted-therapy-for-low-grade-serous-ovarian-carcinoma/2025-03-11T15:33:28-07:00https://dev.oncoprescribe.com/late-breaking-abstract-2025-asco-gi-symposium-personalized-neoantigen-vaccine-in-metastatic-colorectal-cancer/2025-03-06T08:51:06-07:00https://dev.oncoprescribe.com/survival-benefits-with-perioperative-imfinzi-combined-with-neoadjuvant-chemotherapy-in-muscle-invasive-bladder-cancer/2025-03-06T08:50:23-07:00https://dev.oncoprescribe.com/late-breaking-abstract-2025-asco-gu-cancers-symposium-talazoparib-plus-enzalutamide-improves-overall-survival-in-mcrpc/2025-02-27T09:42:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-2025-asco-gi-symposium-aspirin-reduces-recurrence-in-colorectal-cancer-patients-with-pi3k-pathway-alterations/2025-02-27T09:41:24-07:00https://dev.oncoprescribe.com/revolutionizing-treatment-newer-agents-and-innovations-mcrc-management/2025-02-24T23:00:44-07:00https://dev.oncoprescribe.com/ai-tool-scorpio-predicts-overall-survival-in-patients-receiving-therapy-with-immune-checkpoint-inhibitors/2025-02-20T16:21:05-07:00https://dev.oncoprescribe.com/fda-approves-adcetris-with-lenalidomide-and-rituximab-for-relapsed-and-refractory-diffuse-large-b-cell-lymphoma/2025-02-20T16:18:35-07:00https://dev.oncoprescribe.com/anthracycline-plus-taxane-based-adjuvant-therapy-for-high-risk-early-stage-breast-cancer/2025-02-13T07:10:17-07:00https://dev.oncoprescribe.com/late-breaking-abstract-2025-asco-gi-symposium-opdivo-plus-yervoy-superior-to-opdivo-alone-in-msi-h-mmr-deficient-metastatic-colorectal-cancer/2025-02-13T07:09:53-07:00https://dev.oncoprescribe.com/signatera-ctdna-assay-can-guide-therapy-in-early-stage-colorectal-cancer/2025-02-06T07:25:25-07:00https://dev.oncoprescribe.com/superior-overall-survival-with-lobectomy-compared-to-wedge-resection-in-early-stage-lung-cancer/2025-02-06T07:25:07-07:00https://dev.oncoprescribe.com/fda-approves-datroway-for-advanced-metastatic-hr-positive-her-negative-breast-cancer/2025-01-30T07:30:51-07:00https://dev.oncoprescribe.com/fda-highlights-importance-of-dpd-deficiency-discussions-with-patients-prior-to-capecitabine-or-fluorouracil-treatment/2025-01-30T07:23:41-07:00https://dev.oncoprescribe.com/five-year-follow-up-analysis-continues-to-show-long-term-survival-in-patients-with-pd-l1/2025-01-27T21:20:32-07:00https://dev.oncoprescribe.com/prolonged-survival-benefit-with-lynparza-in-brca-mutated-early-stage-breast-cancer/2025-01-23T07:03:12-07:00https://dev.oncoprescribe.com/fda-approves-lumakras-with-vectibix-for-kras-g12c-mutated-colorectal-cancer/2025-01-23T07:02:21-07:00https://dev.oncoprescribe.com/fda-grants-accelerated-approval-to-bizengri-for-non-small-cell-lung-cancer-and-pancreatic-adenocarcinoma/2025-01-16T16:59:15-07:00https://dev.oncoprescribe.com/fda-grants-accelerated-approval-to-braftovi-with-erbitux-and-mfolfox6-for-metastatic-crc-with-a-braf-v600e-mutation/2025-01-16T16:58:43-07:00https://dev.oncoprescribe.com/opdivo-qvantig-nivolumab-and-hyaluronidase-nvhy/2025-01-11T16:31:08-07:00https://dev.oncoprescribe.com/braftovi-encorafenib/2025-01-11T16:20:53-07:00https://dev.oncoprescribe.com/ensacove-ensartinib/2025-01-11T16:14:43-07:00https://dev.oncoprescribe.com/ryoncil-remestemcel-l-rknd/2025-01-11T16:09:21-07:00https://dev.oncoprescribe.com/unloxcyt-cosibelimab-ipdl/2025-01-11T15:56:22-07:00https://dev.oncoprescribe.com/adjuvant-keytruda-improves-disease-free-survival-in-muscle-invasive-urothelial-carcinoma/2025-01-09T11:08:32-07:00https://dev.oncoprescribe.com/10-year-survival-benefit-in-advanced-melanoma-with-opdivo-plus-yervoy/2025-01-09T11:05:48-07:00https://dev.oncoprescribe.com/no-additional-benefit-when-oxaliplatin-is-added-to-5-fu-based-adjuvant-chemotherapy-in-high-risk-stage-ii-colon-cancer/2025-01-02T17:24:49-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-qvantig-for-subcutaneous-injection/2025-01-02T17:23:04-07:00https://dev.oncoprescribe.com/ivonescimab-may-be-superior-to-pembrolizumab-as-first-line-treatment-in-nsclc-2/2024-12-26T10:46:35-07:00https://dev.oncoprescribe.com/immune-checkpoint-inhibitor-therapy-and-cardiovascular-adverse-events-2/2024-12-26T10:45:26-07:00https://dev.oncoprescribe.com/defining-durability-with-augtyro-repotrectinib-the-next-generation-tki-for-ros1-nsclc/2024-12-25T23:10:44-07:00https://dev.oncoprescribe.com/avoiding-chest-wall-irradiation-after-mastectomy-in-intermediate-risk-breast-cancer/2024-12-19T17:04:56-07:00https://dev.oncoprescribe.com/fixed-duration-calquence-plus-venclexta-for-previously-untreated-cll/2024-12-19T17:01:03-07:00https://dev.oncoprescribe.com/enhertu-after-endocrine-therapy-in-advanced-breast-cancer/2024-12-12T16:56:00-07:00https://dev.oncoprescribe.com/rybrevant-plus-lazcluze-versus-tagrisso-in-previously-untreated-egfr-mutated-advanced-nsclc/2024-12-12T16:54:35-07:00https://dev.oncoprescribe.com/imfinzi-durvalumab-7/2024-12-08T18:20:38-07:00https://dev.oncoprescribe.com/bizengri-zenocutuzumab-zbco/2024-12-08T18:15:22-07:00https://dev.oncoprescribe.com/ziihera-zanidatamab-hrii/2024-12-08T18:06:59-07:00https://dev.oncoprescribe.com/revuforj-revumenib/2024-12-08T17:09:03-07:00https://dev.oncoprescribe.com/aucatzyl-obecabtagene-autoleucel/2024-12-08T16:58:40-07:00https://dev.oncoprescribe.com/scemblix-asciminib-2/2024-12-08T16:49:59-07:00https://dev.oncoprescribe.com/vyloy-zolbetuximab-clzb/2024-12-07T10:16:16-07:00https://dev.oncoprescribe.com/itovebi-inavolisib/2024-12-07T10:08:06-07:00https://dev.oncoprescribe.com/fda-approves-imfinzi-after-chemoradiotherapy-in-limited-stage-small-cell-lung-cancer/2024-12-05T16:50:36-07:00https://dev.oncoprescribe.com/stockholm3-blood-test-identifies-aggressive-prostate-cancer-2/2024-12-05T16:49:57-07:00https://dev.oncoprescribe.com/tagrisso-after-chemoradiotherapy-in-stage-iii-egfr-mutated-nsclc/2024-11-28T16:34:40-07:00https://dev.oncoprescribe.com/fda-grants-accelerated-approval-to-ziiherafor-metastatic-her2-positive-biliary-tract-cancer/2024-11-28T16:34:00-07:00https://dev.oncoprescribe.com/fda-approves-revuforj-for-acute-leukemia-with-kmt2a-translocation/2024-11-21T16:44:36-07:00https://dev.oncoprescribe.com/early-detection-of-pancreatic-cancer-with-an-exosome-based-liquid-biopsy-2/2024-11-21T15:10:15-07:00https://dev.oncoprescribe.com/fda-grants-accelerated-approval-to-scemblixreg-for-newly-diagnosed-chronic-myeloid-leukemia/2024-11-14T17:21:51-07:00https://dev.oncoprescribe.com/adjuvant-tafinlar-plus-mekinist-in-stage-iii-melanoma-10-year-follow-up/2024-11-14T17:05:25-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2024-addition-of-xtandi-to-xofigo-significantly-improved-survival-in-metastatic-castrate-resistant-prostate-cancer/2024-11-07T06:56:10-07:00https://dev.oncoprescribe.com/sarclisa-with-vrd-regimen-for-transplant-ineligible-newly-diagnosed-multiple-myeloma/2024-11-07T06:55:40-07:00https://dev.oncoprescribe.com/imfinzi-after-chemoradiotherapy-in-limited-stage-small-cell-lung-cancer/2024-10-31T05:54:29-07:00https://dev.oncoprescribe.com/superior-outcomes-with-first-line-opdivo-versus-adcetris-in-advanced-classical-hodgkin-lymphoma/2024-10-31T05:53:50-07:00https://dev.oncoprescribe.com/neoadjuvant-immunotherapy-in-early-breast-cancer/2024-10-24T05:41:08-07:00https://dev.oncoprescribe.com/fda-approves-vyloy-with-chemotherapy-for-biomarker-positive-gastric-or-gej-adenocarcinoma/2024-10-24T05:40:43-07:00https://dev.oncoprescribe.com/liquid-biopsy-may-predict-survival-in-metastatic-prostate-cancer/2024-10-17T15:19:20-07:00https://dev.oncoprescribe.com/measuring-lymphocyte-count-may-predict-response-to-car-t-cell-therapy-in-multiple-myeloma/2024-10-17T15:18:58-07:00https://dev.oncoprescribe.com/enhertu-effective-against-brain-metastases-in-patients-with-her2-breast-cancer/2024-10-10T06:54:23-07:00https://dev.oncoprescribe.com/fda-approves-perioperative-opdivo-in-resectable-lung-cancer/2024-10-10T06:54:00-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-21/2024-10-06T22:01:30-07:00https://dev.oncoprescribe.com/retevmo-selpercatinib-6/2024-10-06T21:55:27-07:00https://dev.oncoprescribe.com/tagrisso-osimertinib-6/2024-10-06T21:50:20-07:00https://dev.oncoprescribe.com/sarclisa-isatuximab-irfc-3/2024-10-06T21:45:08-07:00https://dev.oncoprescribe.com/rybrevant-amivantamab-vmjw-3/2024-10-06T21:35:07-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-42/2024-10-06T21:29:37-07:00https://dev.oncoprescribe.com/kisqali-ribociclib-3/2024-10-06T21:24:00-07:00https://dev.oncoprescribe.com/tecentriq-hybreza-atezolizumab-and-hyaluronidase-tqjs/2024-10-06T21:13:50-07:00https://dev.oncoprescribe.com/lazcluze-lazertinib-plus-rybrevant-amivantamab-vmjw/2024-10-06T21:04:22-07:00https://dev.oncoprescribe.com/imfinzi-durvalumab-6/2024-10-06T20:54:24-07:00https://dev.oncoprescribe.com/niktimvo-axatilimab-csfr/2024-10-06T20:44:45-07:00https://dev.oncoprescribe.com/voranigo-vorasidenib/2024-10-06T20:37:17-07:00https://dev.oncoprescribe.com/tecelra-afamitresgene-autoleucel/2024-10-06T20:26:23-07:00https://dev.oncoprescribe.com/jemperli-dostarlimab-gxly-5/2024-10-06T20:19:20-07:00https://dev.oncoprescribe.com/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-3/2024-10-06T20:12:55-07:00https://dev.oncoprescribe.com/epkinly-epcoritamab-bysp-2/2024-10-06T20:04:48-07:00https://dev.oncoprescribe.com/krazati-adagrasib-2/2024-10-06T19:58:57-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-41/2024-10-06T19:52:45-07:00https://dev.oncoprescribe.com/blincyto-blinatumomab-4/2024-10-06T19:44:57-07:00https://dev.oncoprescribe.com/imfinzi-durvalumab-5/2024-10-06T18:40:54-07:00https://dev.oncoprescribe.com/augtyro-repotrectinib-2/2024-10-06T16:56:16-07:00https://dev.oncoprescribe.com/retevmo-selpercatinib-5/2024-10-06T16:50:30-07:00https://dev.oncoprescribe.com/rytelo-imetelstat/2024-10-06T16:44:53-07:00https://dev.oncoprescribe.com/breyanzi-lisocabtagene-maraleucel-4/2024-10-06T16:37:58-07:00https://dev.oncoprescribe.com/retevmo-selpercatinib-4/2024-10-06T16:20:06-07:00https://dev.oncoprescribe.com/imdelltra-tarlatamab-dlle/2024-10-06T16:11:35-07:00https://dev.oncoprescribe.com/breyanzi-lisocabtagene-maraleucel-3/2024-10-06T16:06:12-07:00https://dev.oncoprescribe.com/tivdak-tisotumab-vedotin-tftv-2/2024-10-06T15:59:32-07:00https://dev.oncoprescribe.com/ojemda-tovorafenib/2024-10-06T15:52:00-07:00https://dev.oncoprescribe.com/lutathera-lutetium-lu-177-dotatate-2/2024-10-06T15:45:34-07:00https://dev.oncoprescribe.com/anktiva-nogapendekin-alfa-inbakicept-pmln/2024-10-06T15:32:20-07:00https://dev.oncoprescribe.com/alecensa-alectinib-3/2024-10-06T15:24:57-07:00https://dev.oncoprescribe.com/enhertu-fam-trastuzumab-deruxtecan-nxki-6/2024-10-06T15:16:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2024-adjuvant-kisqali-shows-deepening-benefit-in-patients-with-early-stage-breast-cancer/2024-10-03T06:22:55-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-congress-2024-imfinzi-along-with-neoadjuvant-chemotherapy-improves-survival-in-muscle-invasive-bladder-cancer/2024-10-03T06:22:36-07:00https://dev.oncoprescribe.com/fda-approves-rybrevant-plus-chemotherapy-for-egfr-mutated-nsclc/2024-09-26T16:33:39-07:00https://dev.oncoprescribe.com/fda-approves-sarclisa-with-vrd-regimen-for-newly-diagnosed-multiple-myeloma/2024-09-26T16:33:17-07:00https://dev.oncoprescribe.com/ivonescimab-may-be-superior-to-pembrolizumab-as-first-line-treatment-in-nsclc/2024-09-19T16:11:03-07:00https://dev.oncoprescribe.com/optimal-approach-for-integrating-immune-checkpoint-inhibitors-in-early-stage-breast-cancer-a-meta-analysis/2024-09-19T16:10:43-07:00https://dev.oncoprescribe.com/unfulfilled-potential-the-gap-in-genetic-testing-for-breast-cancer-patients/2024-09-12T06:04:12-07:00https://dev.oncoprescribe.com/immune-checkpoint-inhibitor-therapy-and-cardiovascular-adverse-events/2024-09-12T06:03:29-07:00https://dev.oncoprescribe.com/avoiding-regional-nodal-irradiation-after-neoadjuvant-chemotherapy-in-some-breast-cancer-patients-2/2024-09-07T02:55:05-07:00https://dev.oncoprescribe.com/sotorasib-plus-panitumumab-in-refractory-colorectal-cancer-with-mutated-kras-g12c-3/2024-09-07T02:54:41-07:00https://dev.oncoprescribe.com/tagrisso-after-chemoradiotherapy-in-stage-iii-egfr-mutated-non-small-cell-lung-cancer/2024-08-30T18:13:47-07:00https://dev.oncoprescribe.com/enfortumab-vedotin-plus-pembrolizumab-a-breakthrough-in-locally-advanced-or-metastatic-urothelial-carcinoma-2/2024-08-30T18:12:40-07:00https://dev.oncoprescribe.com/early-detection-of-pancreatic-cancer-with-an-exosome-based-liquid-biopsy/2024-11-20T19:48:49-07:00https://dev.oncoprescribe.com/lung-cancer-risk-with-vaping-and-cigarette-smoking/2024-08-21T19:55:05-07:00https://dev.oncoprescribe.com/cannabis-use-increases-the-risk-of-head-and-neck-cancer/2024-08-15T18:38:56-07:00https://dev.oncoprescribe.com/fda-approves-lymphir-for-relapsed-and-refractory-cutaneous-t-cell-lymphoma/2024-08-15T18:38:13-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-docetaxel-may-be-preferable-taxane-for-black-women-to-mitigate-taxane-induced-peripheral-neuropathy/2024-08-08T05:53:59-07:00https://dev.oncoprescribe.com/five-year-outcomes-with-first-line-opdivo-plus-yervoy-and-a-limited-course-of-chemotherapy/2024-08-08T05:53:21-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-switching-to-verzenio-post-cdk4-6-inhibitor-progression-may-improve-outcomes-in-hr-positive-her2-negative-breast-cancer/2024-08-01T05:56:07-07:00https://dev.oncoprescribe.com/fixed-duration-calquence-plus-venetoclax-significantly-improved-pfs-in-previously-untreated-cll/2024-08-01T05:54:30-07:00https://dev.oncoprescribe.com/what-is-the-real-world-evidence-for-the-effectiveness-of-mogamulizumab-in-patients-with-mycosis-fungoides-and-sezary-syndrome/2024-07-29T19:22:31-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-integrating-carboplatin-in-early-stage-triple-negative-breast-cancer/2024-07-25T05:29:50-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-adcetris-combination-improves-overall-survival-in-relapsed-and-refractory-diffuse-large-b-cell-lymphoma/2024-07-25T05:29:27-07:00https://dev.oncoprescribe.com/elahere-mirvetuximab-soravtansine-gynx-2/2024-07-24T19:09:19-07:00https://dev.oncoprescribe.com/iclusig-ponatinib-2/2024-07-24T18:59:30-07:00https://dev.oncoprescribe.com/fda-approves-telomerase-inhibitor-rytelo-for-low-to-intermediate-risk-myelodysplastic-syndromes/2024-07-18T08:34:19-07:00https://dev.oncoprescribe.com/fda-approves-tivdak-for-recurrent-or-metastatic-cervical-cancer/2024-07-18T08:33:50-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-sustained-improvement-in-relapse-free-survival-with-personalized-mrna-cancer-vaccine-plus-keytruda-in-resected-high-risk-melanoma/2024-07-11T12:54:10-07:00https://dev.oncoprescribe.com/radioligand-therapy-before-chemotherapy-in-castrate-resistant-prostate-cancer/2024-07-11T12:53:28-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-subcutaneous-versus-intravenous-rybrevant-in-refractory-egfr-mutated-advanced-nsclc/2024-07-04T20:26:04-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-blenrep-pomalidomide-and-dexamethasone-in-multiple-myeloma/2024-07-04T20:24:52-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-long-term-outcomes-with-lorbrena-in-alk-positive-non-small-cell-lung-cancer/2024-06-27T06:04:21-07:00https://dev.oncoprescribe.com/fda-approves-krazati-with-erbitux-for-kras-g12c-mutated-colorectal-cancer/2024-06-27T06:03:52-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-krazati-superior-to-docetaxel-in-kras-g12c-mutated-non-small-cell-lung-cancer/2024-06-20T16:00:47-07:00https://dev.oncoprescribe.com/duration-of-androgen-deprivation-therapy-with-postoperative-radiotherapy-for-prostate-cancer-24-months-versus-6-months/2024-06-20T16:00:27-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-enhertu-improves-pfs-in-hr-positive-her2-low-and-her-ultralow-metastatic-breast-cancer/2024-06-12T19:28:08-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-imfinzi-as-consolidation-treatment-for-limited-stage-small-cell-lung-cancer/2024-06-12T19:27:45-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-tagrisso-after-chemoradiotherapy-in-stage-iii-egfr-mutated-non-small-cell-lung-cancer/2024-06-06T06:18:03-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2024-scemblix-superior-to-other-tkis-in-newly-diagnosed-chronic-myeloid-leukemia/2024-06-06T06:17:21-07:00https://dev.oncoprescribe.com/benign-breast-disease-and-increased-breast-cancer-risk-2/2024-05-30T15:09:18-07:00https://dev.oncoprescribe.com/gene-therapy-for-sickle-cell-disease/2024-05-30T15:08:27-07:00https://dev.oncoprescribe.com/fda-approves-bispecific-t-cell-engager-imdelltra-for-small-cell-lung-cancer/2024-05-23T17:19:17-07:00https://dev.oncoprescribe.com/fda-approves-breyanzi-for-relapsed-refractory-follicular-lymphoma/2024-05-23T17:18:59-07:00https://dev.oncoprescribe.com/bispecific-immune-checkpoint-inhibitor-improves-survival-in-gastric-and-gej-cancer-regardless-of-pd-l1-status/2024-05-16T16:01:52-07:00https://dev.oncoprescribe.com/de-escalation-of-treatment-for-hpv-associated-oropharyngeal-cancer/2024-05-16T16:01:26-07:00https://dev.oncoprescribe.com/benefits-of-neoadjuvant-chemoimmunotherapy-in-early-stage-non-small-cell-lung-cancer/2024-05-09T15:08:48-07:00https://dev.oncoprescribe.com/100-percent-biochemical-recurrence-free-survival-with-apalutamide-plus-adt-in-high-risk-prostate-cancer-following-radical-prostatectomy/2024-05-09T15:08:25-07:00https://dev.oncoprescribe.com/cardiovascular-adverse-events-associated-with-bispecific-t-cell-engager-therapy/2024-05-02T15:29:25-07:00https://dev.oncoprescribe.com/minimal-residual-disease-status-predicts-outcome-in-patients-with-previously-untreated-follicular-lymphoma/2024-05-02T15:25:08-07:00https://dev.oncoprescribe.com/new-asco-guideline-recommends-germline-testing-in-all-newly-diagnosed-breast-cancer-patients-65-years-or-younger-2/2024-04-25T14:21:39-07:00https://dev.oncoprescribe.com/sotorasib-plus-panitumumab-in-refractory-colorectal-cancer-with-mutated-kras-g12c-2/2024-04-25T14:21:15-07:00https://dev.oncoprescribe.com/fda-approves-alecensa-as-adjuvant-treatment-for-alk-positive-non-small-cell-lung-cancer/2024-04-18T15:19:03-07:00https://dev.oncoprescribe.com/long-term-benefits-of-rubraca-maintenance-in-newly-diagnosed-ovarian-cancer/2024-04-18T15:15:26-07:00https://dev.oncoprescribe.com/omitting-axillary-lymph-node-dissection-in-breast-cancer-with-sentinel-node-metastases/2024-04-11T17:28:35-07:00https://dev.oncoprescribe.com/fda-approves-enhertu-for-unresectable-or-metastatic-her2-positive-solid-tumors/2024-04-11T17:27:15-07:00https://dev.oncoprescribe.com/april-2024-current-tumor-agnostic-therapies/2024-04-10T19:40:49-07:00https://dev.oncoprescribe.com/enfortumab-vedotin-plus-pembrolizumab-a-breakthrough-in-locally-advanced-or-metastatic-urothelial-carcinoma/2024-04-04T09:22:43-07:00https://dev.oncoprescribe.com/novel-prognostic-factors-for-treatment-free-remission-in-chronic-myeloid-leukemia/2024-04-04T06:03:26-07:00https://dev.oncoprescribe.com/neoadjuvant-keytruda-plus-chemotherapy-significantly-improves-efs-in-early-stage-high-risk-triple-negative-breast-cancer/2024-03-28T06:11:52-07:00https://dev.oncoprescribe.com/metformin-may-reduce-the-risk-of-cancers-especially-gi-malignancies/2024-03-28T06:11:30-07:00https://dev.oncoprescribe.com/fda-approves-breyanzi-first-car-t-cell-therapy-for-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/2024-03-21T15:21:39-07:00https://dev.oncoprescribe.com/fda-approves-tevimbra-for-advanced-esophageal-squamous-cell-carcinoma/2024-03-21T15:21:16-07:00https://dev.oncoprescribe.com/fda-approves-rybrevant-in-combination-with-chemotherapy-for-advanced-nsclc-with-egfr-exon-20-insertion-mutations/2024-03-14T16:45:49-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-in-combination-with-chemotherapy-for-the-first-line-treatment-of-advanced-urothelial-carcinoma/2024-03-14T16:45:23-07:00https://dev.oncoprescribe.com/brukinsa-zanubrutinib-5/2024-03-07T23:37:31-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-20/2024-03-07T23:26:12-07:00https://dev.oncoprescribe.com/besponsa-inotuzumab-ozogamicin-2/2024-03-07T23:17:24-07:00https://dev.oncoprescribe.com/rybrevant-amivantamab-vmjw-2/2024-03-07T23:05:41-07:00https://dev.oncoprescribe.com/tagrisso-osimertinib-5/2024-03-07T22:51:09-07:00https://dev.oncoprescribe.com/amtagvi-lifileucel/2024-03-07T22:37:08-07:00https://dev.oncoprescribe.com/tepmetko-tepotinib-2/2024-03-07T22:17:33-07:00https://dev.oncoprescribe.com/onivyde-irinotecan-liposome/2024-03-07T22:06:16-07:00https://dev.oncoprescribe.com/stockholm3-blood-test-identifies-aggressive-prostate-cancer/2024-03-07T05:31:14-07:00https://dev.oncoprescribe.com/fda-approves-onivyde-for-first-line-treatment-of-metastatic-pancreatic-adenocarcinoma/2024-03-07T05:29:03-07:00https://dev.oncoprescribe.com/circulating-tumor-dna-can-be-used-as-an-early-marker-of-immunotherapy-response/2024-02-29T13:45:12-07:00https://dev.oncoprescribe.com/late-breaking-abstract-2024-asco-gu-cancers-symposium-adjuvant-keytruda-improves-overall-survival-in-renal-cell-carcinoma/2024-02-29T13:43:26-07:00https://dev.oncoprescribe.com/pregnancy-after-breast-cancer-treatment-in-brca-carriers/2024-02-21T13:54:49-07:00https://dev.oncoprescribe.com/late-breaking-abstract-2024-asco-gu-cancers-symposium-subcutaneous-nivolumab-offers-efficiency-and-efficacy-in-renal-cell-carcinoma/2024-02-21T13:54:19-07:00https://dev.oncoprescribe.com/avoiding-regional-nodal-irradiation-after-neoadjuvant-chemotherapy-in-some-breast-cancer-patients/2024-02-15T16:42:10-07:00https://dev.oncoprescribe.com/prostate-cancer-foundation-screening-guidelines-for-prostate-cancer-in-black-men-in-the-united-states/2024-03-07T22:24:32-07:00https://dev.oncoprescribe.com/durable-survival-with-opdivo-nivolumab-chemotherapy-fluoropyrimidine-and-platinum-based-vs-chemotherapy-alone-a-first-line-treatment-of-metastatic-gastric-cancer-gastroesophageal-juncti/2024-02-13T11:14:41-07:00https://dev.oncoprescribe.com/balversa-erdafitinib-2/2024-02-11T10:44:11-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-40/2024-02-11T10:34:41-07:00https://dev.oncoprescribe.com/padcev-enfortumab-vedotin-ejfv-3/2024-02-11T09:29:42-07:00https://dev.oncoprescribe.com/welireg-belzutifan-2/2024-02-11T09:14:34-07:00https://dev.oncoprescribe.com/iwilfin-eflornithine/2024-02-11T09:03:52-07:00https://dev.oncoprescribe.com/jaypirca-pirtobrutinib-2/2024-02-09T17:13:07-07:00https://dev.oncoprescribe.com/ogsiveo-nirogacestat/2024-02-09T17:07:48-07:00https://dev.oncoprescribe.com/xtandi-enzalutamide-4/2024-02-09T17:03:40-07:00https://dev.oncoprescribe.com/truqap-capivasertib/2024-02-09T16:57:51-07:00https://dev.oncoprescribe.com/new-asco-guideline-recommends-germline-testing-in-all-newly-diagnosed-breast-cancer-patients-65-years-or-younger/2024-02-08T17:15:10-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2023-oral-ibrutinib-venetoclax-combination-improved-outcomes-in-mantle-cell-lymphoma/2024-02-08T17:08:16-07:00https://dev.oncoprescribe.com/neoadjuvant-chemoimmunotherapy-improves-pathologic-complete-response-rates-in-early-stage-er-positive-her2-negative-breast-cancer/2024-02-01T07:12:29-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2023-pomalidomide-reduces-epistaxis-and-improves-quality-of-life-in-hereditary-hemorrhagic-telangiectasia/2024-02-01T07:12:05-07:00https://dev.oncoprescribe.com/dato-dxd-for-patients-with-hr-positive-her2-negative-advanced-breast-cancer/2024-01-25T15:53:59-07:00https://dev.oncoprescribe.com/chronic-lymphocytic-leukemia-therapy-guided-by-minimal-residual-disease/2024-01-25T15:47:58-07:00https://dev.oncoprescribe.com/tukysa-plus-kadcyla-in-advanced-her2-positive-breast-cancer/2024-01-18T07:22:37-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2023-erg-is-a-new-predisposition-gene-for-bone-marrow-failure-and-hematological-malignancy/2024-01-18T07:22:11-07:00https://dev.oncoprescribe.com/benign-breast-disease-and-increased-breast-cancer-risk/2024-01-11T06:43:15-07:00https://dev.oncoprescribe.com/sotorasib-plus-panitumumab-in-refractory-colorectal-cancer-with-mutated-kras-g12c/2024-01-11T06:42:48-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-39/2024-01-04T16:01:32-07:00https://dev.oncoprescribe.com/augtyro-repotrectinib/2024-01-04T15:53:43-07:00https://dev.oncoprescribe.com/fruzaqla-fruquintinib/2024-01-04T15:47:01-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-38/2024-01-04T15:38:48-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-37/2024-01-04T15:31:07-07:00https://dev.oncoprescribe.com/loqtorz-toripalimab-tpzi/2024-01-04T15:22:05-07:00https://dev.oncoprescribe.com/fda-approves-two-gene-therapies-to-treat-patients-with-sickle-cell-disease/2024-01-04T06:34:54-07:00https://dev.oncoprescribe.com/fda-approves-augtyro-for-ros1-positive-non-small-cell-lung-cancer/2024-01-04T06:33:48-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2023-daratumumab-combination-superior-to-vrd-in-newly-diagnosed-multiple-myeloma/2023-12-28T17:55:36-07:00https://dev.oncoprescribe.com/fda-approves-welireg-for-advanced-renal-cell-carcinoma/2023-12-28T17:55:11-07:00https://dev.oncoprescribe.com/less-frequent-mammography-after-curative-treatment-in-older-women-with-breast-cancer/2023-12-21T14:38:19-07:00https://dev.oncoprescribe.com/biomarker-driven-elahere-in-fr-alpha-positive-platinum-resistant-ovarian-cancer/2023-12-21T14:37:54-07:00https://dev.oncoprescribe.com/omitting-adjuvant-radiation-therapy-in-younger-low-risk-postmenopausal-patients/2023-12-14T06:49:34-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-with-chemotherapy-for-her2-negative-gastric-or-ge-junction-adenocarcinoma/2023-12-14T06:46:39-07:00https://dev.oncoprescribe.com/fda-approves-xtandi-for-non-metastatic-castrate-sensitive-prostate-cancer-with-biochemical-recurrence/2023-12-07T15:53:14-07:00https://dev.oncoprescribe.com/fda-approves-jaypirca-for-chronic-lymphocytic-leukemia/2023-12-07T15:52:53-07:00https://dev.oncoprescribe.com/fda-approves-truqap-with-fulvestrant-for-advanced-breast-cancer/2023-11-30T16:17:14-07:00https://dev.oncoprescribe.com/osimertinib-plus-chemotherapy-superior-to-osimertinib-alone-in-advanced-egfr-mutated-non-small-cell-lung-cancer-2/2023-11-30T16:16:49-07:00https://dev.oncoprescribe.com/fda-approves-pembrolizumab-with-chemotherapy-for-biliary-tract-cancer/2023-11-23T12:58:19-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2023-welireg-significantly-improves-outcomes-in-advanced-pretreated-clear-cell-renal-cell-carcinoma/2023-11-23T12:57:53-07:00https://dev.oncoprescribe.com/fda-approves-fruquintinib-in-refractory-metastatic-colorectal-cancer/2023-11-16T16:39:20-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-congress-2023-perioperative-opdivo-plus-chemotherapy-improves-survival-in-resectable-non-small-cell-lung-cancer/2023-11-16T16:38:40-07:00https://dev.oncoprescribe.com/first-line-reblozyl-superior-to-epoetin-alfa-in-lower-risk-myelodysplastic-syndromes/2023-11-09T07:08:59-07:00https://dev.oncoprescribe.com/fda-approves-nivolumab-for-adjuvant-treatment-of-stage-iib-c-melanoma/2023-11-09T07:08:24-07:00https://dev.oncoprescribe.com/amivantamab-plus-chemotherapy-with-and-without-lazertinib-after-progression-on-osimertinib-in-advanced-lung-cancer/2023-11-02T06:53:36-07:00https://dev.oncoprescribe.com/fda-approves-ivosidenib-for-myelodysplastic-syndromes/2023-11-02T06:43:11-07:00https://dev.oncoprescribe.com/tibsovo-ivosidenib-5/2023-10-28T14:16:53-07:00https://dev.oncoprescribe.com/rozlytrek-entrectinib-3/2023-10-28T14:11:09-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-36/2023-10-28T14:04:07-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-19/2023-10-28T13:55:06-07:00https://dev.oncoprescribe.com/braftovi-encorafenib-and-mektovi-binimetinib-2/2023-10-28T13:50:01-07:00https://dev.oncoprescribe.com/bosulif-bosutinib-3/2023-10-28T10:51:41-07:00https://dev.oncoprescribe.com/temodar-temozolomide/2023-10-28T10:42:05-07:00https://dev.oncoprescribe.com/hepzato-kit-melphalan-for-injection-hepatic-delivery-system/2023-10-28T10:34:53-07:00https://dev.oncoprescribe.com/elrexfio-elranatamab-bcmm/2023-10-28T10:28:46-07:00https://dev.oncoprescribe.com/akeega-niraparib-and-abiraterone-acetate/2023-10-28T10:22:24-07:00https://dev.oncoprescribe.com/talvey-talquetamab-tgvs/2023-10-28T10:16:21-07:00https://dev.oncoprescribe.com/gavreto-pralsetinib-3/2023-10-28T10:10:15-07:00https://dev.oncoprescribe.com/lonsurf-trifluridine-and-tipiracil-with-bevacizumab/2023-10-28T10:05:05-07:00https://dev.oncoprescribe.com/jemperli-dostarlimab-gxly-4/2023-10-28T09:55:13-07:00https://dev.oncoprescribe.com/vanflyta-quizartinib/2023-10-28T09:46:45-07:00https://dev.oncoprescribe.com/talzenna-talazoparib-with-enzalutamide/2023-10-28T09:37:00-07:00https://dev.oncoprescribe.com/columvi-glofitamab-gxbm/2023-10-28T09:29:58-07:00https://dev.oncoprescribe.com/lynparza-olaparib-9/2023-10-28T09:02:06-07:00https://dev.oncoprescribe.com/epkinly-epcoritamab-bysp/2023-10-28T08:47:43-07:00https://dev.oncoprescribe.com/polivy-polatuzumab-vedotin-piiq-2/2023-10-28T08:39:42-07:00https://dev.oncoprescribe.com/single-blood-test-for-multi-cancer-early-detection/2023-10-26T05:45:49-07:00https://dev.oncoprescribe.com/keytruda-in-combination-with-her2-blockade-improves-pfs-in-gastric-and-ge-junction-cancer/2023-10-26T05:45:12-07:00https://dev.oncoprescribe.com/fda-approves-perioperative-keytruda-for-resectable-early-stage-non-small-cell-lung-cancer/2023-10-19T11:04:07-07:00https://dev.oncoprescribe.com/hair-relaxer-use-and-risk-of-uterine-cancer/2023-10-19T11:03:00-07:00https://dev.oncoprescribe.com/adjuvant-keytruda-in-resected-nsclc-irrespective-of-pd-l1-expression/2023-10-12T12:03:24-07:00https://dev.oncoprescribe.com/long-term-overall-survival-benefit-with-vidaza-plus-venclexta-in-elderly-aml-patients-2/2023-10-12T12:02:02-07:00https://dev.oncoprescribe.com/non-hormonal-treatments-for-menopausal-symptoms-na-menopause-society-2023-position-statement/2023-10-05T14:04:29-07:00https://dev.oncoprescribe.com/zolbetuximab-plus-capox-in-biomarker-positive-advanced-gastric-or-gej-cancer/2023-10-05T14:03:48-07:00https://dev.oncoprescribe.com/osimertinib-plus-chemotherapy-superior-to-osimertinib-alone-in-advanced-egfr-mutated-non-small-cell-lung-cancer/2023-09-28T06:19:04-07:00https://dev.oncoprescribe.com/germline-testing-to-identify-11-genes-linked-to-aggressive-prostate-cancer/2023-09-28T06:18:31-07:00https://dev.oncoprescribe.com/fda-approves-pralsetinib-for-non-small-cell-lung-cancer-with-ret-gene-fusions/2023-09-20T20:21:04-07:00https://dev.oncoprescribe.com/fda-approves-momelotinib-for-patients-with-myelofibrosis-and-anemia/2023-09-20T20:20:43-07:00https://dev.oncoprescribe.com/omisirge-omidubicel-onlv/2023-09-16T16:07:41-07:00https://dev.oncoprescribe.com/padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab/2023-09-16T16:02:18-07:00https://dev.oncoprescribe.com/zynyz-retifanlimab-dlwr/2023-09-16T15:51:58-07:00https://dev.oncoprescribe.com/tafinlar-dabrafenib-and-mekinist-trametinib-2/2023-09-16T15:44:47-07:00https://dev.oncoprescribe.com/verzenio-abemaciclib-4/2023-09-16T15:37:33-07:00https://dev.oncoprescribe.com/jemperli-dostarlimab-gxly-3/2023-09-16T15:31:53-07:00https://dev.oncoprescribe.com/trodelvy-sacituzumab-govitecan-hziy-2/2023-09-16T15:24:59-07:00https://dev.oncoprescribe.com/fda-approves-akeega-for-metastatic-castration-resistant-prostate-cancer-with-brca1-2-mutations/2023-09-14T05:31:27-07:00https://dev.oncoprescribe.com/duration-of-anticoagulation-therapy-in-cancer-patients-with-isolated-distal-deep-vein-thrombosis/2023-09-14T05:30:43-07:00https://dev.oncoprescribe.com/targeting-esr1-mutations-in-estrogen-positive-advanced-breast-cancer/2023-09-12T05:57:08-07:00https://dev.oncoprescribe.com/fda-approves-lonsurf-with-bevacizumab-for-advanced-refractory-colorectal-cancer/2023-09-07T06:25:22-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-vorasidenib-a-novel-idh1-2-inhibitor-may-be-the-new-standard-of-care-for-low-grade-gliomas/2023-09-07T06:25:00-07:00https://dev.oncoprescribe.com/omitting-radiotherapy-after-breast-conserving-surgery-in-luminal-a-breast-cancer/2023-08-31T17:08:44-07:00https://dev.oncoprescribe.com/tucatinib-plus-trastuzumab-for-her2-positive-metastatic-colorectal-cancer/2023-08-31T17:05:50-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-toripalimab-plus-chemotherapy-improves-progression-free-survival-in-metastatic-triple-negative-breast-cancer/2023-08-24T12:57:35-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-bcma-directed-car-t-cell-therapy-cilta-cel-in-lenalidomide-refractory-multiple-myeloma/2023-08-24T12:56:41-07:00https://dev.oncoprescribe.com/perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer/2023-08-17T05:48:40-07:00https://dev.oncoprescribe.com/selinexor-maintenance-in-advanced-endometrial-cancer/2023-08-17T05:42:17-07:00https://dev.oncoprescribe.com/ovarian-ablation-or-suppression-may-lower-the-risk-of-breast-cancer-recurrence/2023-08-09T20:17:14-07:00https://dev.oncoprescribe.com/fda-approves-quizartinib-for-newly-diagnosed-acute-myeloid-leukemia/2023-08-09T20:16:49-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-chemotherapy-de-escalation-using-pet-response-adapted-strategy-in-patients-with-her2-positive-early-breast-cancer/2023-08-03T05:38:40-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-tumor-treating-fields-plus-standard-of-care-improves-overall-survival-in-patients-with-metastatic-non-small-cell-lung-cancer/2023-08-03T05:37:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-biomarker-driven-elahere-improves-survival-in-platinum-resistant-ovarian-cancer/2023-07-27T14:58:36-07:00https://dev.oncoprescribe.com/fixed-dose-versus-standard-dose-capecitabine-in-metastatic-breast-cancer/2023-07-27T14:58:04-07:00https://dev.oncoprescribe.com/clinical-pearls-on-abemaciclib/2023-07-24T21:27:42-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-first-line-versus-second-line-use-of-cdk4-6-inhibitors-in-advanced-hr-positive-her-negative-breast-cancer/2023-07-20T09:06:32-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-superior-outcomes-with-first-line-nivolumab-versus-brentuximab-vedotin-in-advanced-classical-hodgkin-lymphoma/2023-07-20T09:06:12-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-enhertu-effective-in-multiple-her2-expressing-solid-tumors/2023-07-13T05:55:06-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-avoiding-radiation-therapy-in-select-patients-with-locally-advanced-rectal-cancer/2023-07-13T05:42:11-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-overall-survival-with-tagrisso-in-resected-egfr-mutated-nsclc/2023-07-06T06:16:50-07:00https://dev.oncoprescribe.com/significant-survival-benefit-with-nalirifox-in-previously-untreated-metastatic-pancreatic-cancer/2023-07-06T06:16:19-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2023-adjuvant-treatment-with-ribociclib-in-early-breast-cancer/2023-06-29T15:57:56-07:00https://dev.oncoprescribe.com/fda-approves-glofitamab-for-relapsed-or-refractory-large-b-cell-lymphomas/2023-06-29T15:48:18-07:00https://dev.oncoprescribe.com/capivasertib-in-advanced-hormone-receptor-positive-breast-cancer/2023-06-22T06:53:40-07:00https://dev.oncoprescribe.com/platelet-transfusion-before-central-venous-catheter-placement-in-patients-with-thrombocytopenia/2023-06-22T06:53:09-07:00https://dev.oncoprescribe.com/association-between-duration-of-immunotherapy-and-overall-survival-in-advanced-non-small-cell-lung-cancer/2023-06-15T19:18:38-07:00https://dev.oncoprescribe.com/overall-survival-with-darzalex-revlimid-and-dexamethasone-in-previously-treated-multiple-myeloma-pollux/2023-06-15T19:17:39-07:00https://dev.oncoprescribe.com/pathologic-complete-response-and-individual-patient-prognosis-after-neoadjuvant-chemotherapy-plus-anti-her2-therapy-in-early-breast-cancer/2023-06-08T06:30:53-07:00https://dev.oncoprescribe.com/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-asco-guideline-update/2026-01-09T14:08:15-07:00https://dev.oncoprescribe.com/whole-exome-sequencing-identifies-cancer-predisposition-syndromes-missed-by-current-screening-guidelines/2023-06-01T16:30:19-07:00https://dev.oncoprescribe.com/fda-approves-bispecific-antibody-epkinly-for-aggressive-non-hodgkin-lymphomas/2023-06-01T16:28:52-07:00https://dev.oncoprescribe.com/breast-conserving-surgery-with-or-without-irradiation-in-early-breast-cancer-2/2023-05-25T15:35:01-07:00https://dev.oncoprescribe.com/first-line-time-limited-venetoclax-combinations-in-chronic-lymphocytic-leukemia/2023-05-25T15:34:40-07:00https://dev.oncoprescribe.com/interrupting-endocrine-therapy-to-attempt-pregnancy-after-breast-cancer/2023-05-18T16:29:00-07:00https://dev.oncoprescribe.com/lonsurf-plus-bevacizumab-improves-overall-survival-in-advanced-refractory-colorectal-cancer/2023-05-18T16:28:23-07:00https://dev.oncoprescribe.com/her2dx-genomic-assay-predicts-pathological-response-in-early-stage-her2-positive-breast/2023-05-11T06:13:26-07:00https://dev.oncoprescribe.com/treatment-of-oligometastatic-non-small-cell-lung-cancer-an-astro-estro-clinical-practice-guideline/2023-05-11T06:11:14-07:00https://dev.oncoprescribe.com/orserdu-for-esr-1-mutated-advanced-breast-cancer/2023-05-04T05:35:12-07:00https://dev.oncoprescribe.com/brukinsa-for-first-line-treatment-of-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/2023-05-04T05:33:01-07:00https://dev.oncoprescribe.com/fda-approves-polivy-for-untreated-diffuse-large-b-cell-lymphoma/2023-04-27T05:00:18-07:00https://dev.oncoprescribe.com/pembrolizumab-plus-chemotherapy-improves-overall-survival-in-advanced-biliary-tract-cancer/2023-04-27T04:57:15-07:00https://dev.oncoprescribe.com/personalized-mrna-cancer-vaccine-in-combination-with-keytruda-improves-relapse-free-survival-in-resected-high-risk-melanoma/2023-04-20T18:41:04-07:00https://dev.oncoprescribe.com/ctdna-analysis-in-resectable-colorectal-cancer-and-efficacy-of-adjuvant-chemotherapy/2023-04-20T18:32:26-07:00https://dev.oncoprescribe.com/fda-approves-trodelvy-for-hr-positive-breast-cancer/2023-04-13T06:15:51-07:00https://dev.oncoprescribe.com/fda-approves-enfortumab-vedotin-with-pembrolizumab-for-advanced-urothelial-carcinoma/2023-04-13T05:59:48-07:00https://dev.oncoprescribe.com/orserdu-elacestrant/2023-04-12T06:24:31-07:00https://dev.oncoprescribe.com/jaypirca-pirtobrutinib/2023-04-12T06:15:40-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-35/2023-04-12T06:01:02-07:00https://dev.oncoprescribe.com/brukinsa-zanubrutinib-4/2023-04-12T05:50:51-07:00https://dev.oncoprescribe.com/tremelimumab-in-combination-with-durvalumab-and-chemotherapy-in-metastatic-non-small-cell-lung-cancer-the-phase-iii-poseidon-study/2023-04-06T06:33:42-07:00https://dev.oncoprescribe.com/real-world-experience-of-anti-bcma-car-t-cell-therapy-in-multiple-myeloma/2023-04-06T06:33:04-07:00https://dev.oncoprescribe.com/zolbetuximab-plus-chemotherapy-improves-survival-in-cldn18-2-positive-metastatic-gastric-and-gastroesophageal-junction-cancer/2023-03-30T14:50:16-07:00https://dev.oncoprescribe.com/avoiding-radiotherapy-in-bulky-early-stage-classical-hodgkin-lymphoma/2023-03-30T14:49:50-07:00https://dev.oncoprescribe.com/capivasertib-plus-fulvestrant-improves-progression-free-survival-in-advanced-hormone-receptor-positive-breast-cancer/2023-03-23T05:53:13-07:00https://dev.oncoprescribe.com/brukinsa-superior-to-imbruvica-in-relapsed-refractory-cll-sll-2/2023-03-23T05:52:54-07:00https://dev.oncoprescribe.com/nalirifox-improves-overall-survival-in-patients-with-metastatic-pancreatic-cancer/2023-03-15T21:01:06-07:00https://dev.oncoprescribe.com/biomarkers-may-predict-response-to-enfortumab-vedotin-in-advanced-urothelial-cancer/2023-03-15T21:00:36-07:00https://dev.oncoprescribe.com/fda-expands-adjuvant-verzenio-indication-in-high-risk-early-breast-cancer/2023-03-09T19:51:55-07:00https://dev.oncoprescribe.com/five-year-outcomes-with-keytruda-plus-chemotherapy-in-metastatic-nonsquamous-non-small-cell-lung-cancer/2023-03-09T19:43:04-07:00https://dev.oncoprescribe.com/stk11-mutation/2023-03-08T20:34:44-07:00https://dev.oncoprescribe.com/5794-2/2023-03-08T20:35:45-07:00https://dev.oncoprescribe.com/folate-receptor-alpha/2023-03-08T20:38:16-07:00https://dev.oncoprescribe.com/esr1-gene-mutation/2023-03-28T19:59:43-07:00https://dev.oncoprescribe.com/overall-survival-benefit-with-pembrolizumab-in-advanced-gastric-cancer/2023-03-02T18:55:25-07:00https://dev.oncoprescribe.com/rucaparib-or-physicians-choice-of-therapy-in-metastatic-prostate-cancer/2023-03-02T18:54:45-07:00https://dev.oncoprescribe.com/tukysa-tucatinib-2/2023-03-19T15:36:03-07:00https://dev.oncoprescribe.com/lunsumio-mosunetuzumab-axgb-2/2023-03-02T07:12:10-07:00https://dev.oncoprescribe.com/breast-conserving-surgery-with-or-without-irradiation-in-early-breast-cancer/2023-02-23T06:57:14-07:00https://dev.oncoprescribe.com/lobar-or-sublobar-resection-for-peripheral-stage-ia-non-small-cell-lung-cancer/2023-02-23T06:46:15-07:00https://dev.oncoprescribe.com/a-positive-trial-for-hormone-receptor-positive-breast-cancer-survivors-desiring-pregnancy/2023-02-16T11:48:37-07:00https://dev.oncoprescribe.com/fda-approves-jaypirca-for-relapsed-or-refractory-mantle-cell-lymphoma/2023-02-16T11:48:21-07:00https://dev.oncoprescribe.com/fda-approves-adjuvant-keytruda-in-nsclc-irrespective-of-pd-l1-expression/2023-02-09T07:48:59-07:00https://dev.oncoprescribe.com/low-dose-dasatinib-as-frontline-therapy-in-newly-diagnosed-chronic-myeloid-leukemia/2023-02-09T07:48:17-07:00https://dev.oncoprescribe.com/egfr-exon-20-insertion-mutations-these-are-not-your-common-egfr-mutations/2023-02-07T12:48:45-07:00https://dev.oncoprescribe.com/fda-approves-orserdu-for-esr-1-mutated-advanced-breast-cancer/2023-02-02T17:26:36-07:00https://dev.oncoprescribe.com/long-term-overall-survival-benefit-with-vidaza-plus-venclexta-in-elderly-aml-patients/2023-02-02T17:00:05-07:00https://dev.oncoprescribe.com/fda-approves-tucatinib-with-trastuzumab-for-colorectal-cancer/2023-01-26T07:14:06-07:00https://dev.oncoprescribe.com/fda-approves-brukinsa-for-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/2023-01-26T07:13:45-07:00https://dev.oncoprescribe.com/tailorx-long-term-update-for-patients-with-early-stage-breast-cancer/2023-01-19T16:02:15-07:00https://dev.oncoprescribe.com/sequential-conditioning-and-allogeneic-hematopoietic-cell-transplantation-without-prior-remission-induction-chemotherapy-in-aml/2023-01-19T15:52:44-07:00https://dev.oncoprescribe.com/fda-approves-first-gene-therapy-for-bladder-cancer/2023-01-12T15:50:21-07:00https://dev.oncoprescribe.com/fda-approves-bispecific-antibody-lunsumio-for-follicular-lymphoma/2023-01-12T15:44:44-07:00https://dev.oncoprescribe.com/lunsumio-mosunetuzumab-axgb/2023-01-08T10:51:28-07:00https://dev.oncoprescribe.com/adstiladrin-nadofaragene-firadenovec-vncg/2023-01-08T10:46:07-07:00https://dev.oncoprescribe.com/xeloda-capecitabine-tablets/2023-01-08T10:39:47-07:00https://dev.oncoprescribe.com/krazati-adagrasib/2023-01-08T10:34:48-07:00https://dev.oncoprescribe.com/tecentriq-atezolizumab-9/2023-01-08T10:29:34-07:00https://dev.oncoprescribe.com/rezlidhia-olutasidenib/2023-01-08T10:24:23-07:00https://dev.oncoprescribe.com/rylaze-asparaginase-erwinia-chrysanthemi-recombinant-rywn-2/2023-01-08T10:15:53-07:00https://dev.oncoprescribe.com/elahere-mirvetuximab-soravtansine-gynx/2023-01-08T10:07:23-07:00https://dev.oncoprescribe.com/imjudo-tremelimumab-2/2023-01-08T10:00:08-07:00https://dev.oncoprescribe.com/adcetris-brentuximab-vedotin-5/2023-01-08T09:51:19-07:00https://dev.oncoprescribe.com/libtayo-cemiplimab-rwlc-3/2023-01-08T09:44:23-07:00https://dev.oncoprescribe.com/tecvayli-teclistamab-cqyv/2023-01-08T09:39:17-07:00https://dev.oncoprescribe.com/imjudo-tremelimumab/2023-01-08T09:33:15-07:00https://dev.oncoprescribe.com/lytgobi-futibatinib/2023-01-08T09:13:35-07:00https://dev.oncoprescribe.com/retevmo-selpercatinib-3/2023-01-08T09:07:34-07:00https://dev.oncoprescribe.com/retevmo-selpercatinib-2/2023-01-08T08:53:16-07:00https://dev.oncoprescribe.com/pedmark-sodium-thiosulfate/2023-01-08T08:43:42-07:00https://dev.oncoprescribe.com/neoadjuvant-chemotherapy-endocrine-therapy-and-targeted-therapy-for-breast-cancer-asco-updated-guideline/2023-01-05T07:30:36-07:00https://dev.oncoprescribe.com/tumor-infiltrating-lymphocyte-therapy-in-advanced-refractory-melanoma/2023-01-05T07:03:29-07:00https://dev.oncoprescribe.com/biomarkers-for-adjuvant-endocrine-and-chemotherapy-in-early-stage-breast-cancer-asco-guideline-update/2022-12-29T06:43:24-07:00https://dev.oncoprescribe.com/landmark-five-year-overall-survival-rates-for-opdivo-and-yervoy-combination-in-advanced-nsclc/2022-12-29T06:41:48-07:00https://dev.oncoprescribe.com/tukysa-combination-in-her2-positive-metastatic-breast-cancer-patients-with-brain-metastases/2022-12-22T07:12:17-07:00https://dev.oncoprescribe.com/fda-grants-accelerated-approval-to-krazati-for-kras-g12c-mutated-nsclc/2022-12-22T06:59:43-07:00https://dev.oncoprescribe.com/sustained-benefit-with-adjuvant-verzenio-in-high-risk-early-breast-cancer/2022-12-14T21:32:50-07:00https://dev.oncoprescribe.com/unprecedented-progression-free-survival-with-sarclisa-plus-kyprolis-and-dexamethasone-in-relapsed-multiple-myeloma/2022-12-14T21:20:53-07:00https://dev.oncoprescribe.com/imfinzi-durvalumab-4/2022-12-14T12:20:58-07:00https://dev.oncoprescribe.com/pemazyre-pemigatinib-2/2022-12-14T12:14:42-07:00https://dev.oncoprescribe.com/imbruvica-ibrutinib-5/2022-12-14T12:07:12-07:00https://dev.oncoprescribe.com/enhertu-fam-trastuzumab-deruxtecan-nxki-5/2022-12-14T12:02:06-07:00https://dev.oncoprescribe.com/tabrecta-capmatinib-2/2022-12-14T11:54:23-07:00https://dev.oncoprescribe.com/long-term-lung-cancer-survival-rates-with-low-dose-ct-screening/2022-12-08T06:54:00-07:00https://dev.oncoprescribe.com/fda-approves-rezlidhia-for-acute-myeloid-leukemia/2022-12-08T06:38:38-07:00https://dev.oncoprescribe.com/fda-approves-biomarker-driven-elahere-for-platinum-resistant-ovarian-cancer/2022-12-01T07:12:04-07:00https://dev.oncoprescribe.com/xtandi-monotherapy-versus-active-surveillance-in-patients-with-low-risk-or-intermediate-risk-localized-prostate-cancer/2022-12-01T07:03:09-07:00https://dev.oncoprescribe.com/fda-approves-libtayo-in-combination-with-chemotherapy-for-non-small-cell-lung-cancer/2022-11-24T13:29:14-07:00https://dev.oncoprescribe.com/tafinlar-and-mekinist-versus-opdivo-plus-yervoy-for-patients-with-advanced-braf-mutant-melanoma-the-dreamseq-trial/2022-11-24T13:28:53-07:00https://dev.oncoprescribe.com/association-of-gut-microbiome-with-immune-checkpoint-inhibitor-response-in-advanced-melanoma-2/2022-11-17T22:02:57-07:00https://dev.oncoprescribe.com/nubeqa-combination-improves-overall-survival-in-metastatic-hormone-sensitive-prostate-cancer-2/2022-11-17T15:54:18-07:00https://dev.oncoprescribe.com/xpovio-selinexor-a-treatment-approved-for-multiple-myeloma-as-early-as-first-relapse/2022-11-15T10:09:55-07:00https://dev.oncoprescribe.com/brukinsa-superior-to-imbruvica-in-relapsed-refractory-cll-sll/2022-11-10T12:45:12-07:00https://dev.oncoprescribe.com/rnf43-mutations-predict-response-to-anti-braf-egfr-combination-therapy-in-braf-v600e-metastatic-colorectal-cancer/2022-11-10T12:44:33-07:00https://dev.oncoprescribe.com/fda-approves-tecvayli-for-relapsed-or-refractory-multiple-myeloma/2022-11-03T16:41:48-07:00https://dev.oncoprescribe.com/fda-approves-imjudo-plus-imfinzi-for-patients-with-advanced-hepatocellular-carcinoma/2022-11-03T16:40:46-07:00https://dev.oncoprescribe.com/nubeqa-darolutamide-2/2022-10-31T09:01:24-07:00https://dev.oncoprescribe.com/enhertu-fam-trastuzumab-deruxtecan-nxki-4/2022-10-31T09:02:43-07:00https://dev.oncoprescribe.com/improved-outcomes-with-early-switch-to-fulvestrant-plus-palbociclib-in-esr1-mutated-advanced-breast-cancer/2022-10-26T19:25:42-07:00https://dev.oncoprescribe.com/elevated-white-cell-count-and-risk-of-thrombotic-events-in-polycythemia-vera-2/2022-10-26T19:25:11-07:00https://dev.oncoprescribe.com/association-between-polycystic-ovary-syndrome-and-risk-of-pancreatic-cancer/2022-10-19T21:46:24-07:00https://dev.oncoprescribe.com/lung-cancer-screening-with-low-dose-ct-associated-with-favorable-stage-shift-and-improved-survival-2/2026-01-19T13:02:28-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-for-the-adjuvant-treatment-of-high-risk-urothelial-carcinoma/2022-10-18T05:10:55-07:00https://dev.oncoprescribe.com/fda-grants-accelerated-approval-to-lytgobi-for-cholangiocarcinoma/2022-10-13T06:06:08-07:00https://dev.oncoprescribe.com/expansion-of-cancer-risk-profile-beyond-breast-and-ovarian-cancer-for-brca1-and-brca2-pathogenic-variants-2/2022-10-13T06:02:39-07:00https://dev.oncoprescribe.com/fda-grants-tumor-agnostic-accelerated-approval-to-retevmo/2022-10-05T20:18:51-07:00https://dev.oncoprescribe.com/avoiding-radioiodine-therapy-following-thyroidectomy-in-patients-with-low-risk-thyroid-cancer-2/2022-10-05T20:05:25-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2022-padcev-plus-keytruda-in-previously-untreated-cisplatin-ineligible-patients-with-locally-advanced-or-metastatic-urothelial-cancer/2022-09-29T05:51:01-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2022-neoadjuvant-keytruda-with-chemoradiation-in-locally-advanced-head-and-neck-squamous-cell-carcinoma/2022-09-29T05:33:57-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2022-abemaciclib-plus-transtuzumab-versus-chemotherapy-in-hr-positive-her2-positive-advanced-breast-cancer/2022-09-22T06:18:42-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2022-cabometyx-opdivo-and-yervoy-in-previously-untreated-advanced-renal-cell-carcinoma/2022-09-22T06:04:18-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-congress-2022-apalutamide-plus-androgen-deprivation-therapy-in-biochemically-relapsed-prostate-cancer/2022-09-21T06:25:43-07:00https://dev.oncoprescribe.com/fda-grants-regular-approval-to-tabrecta-for-metastatic-non-small-cell-lung-cancer/2022-09-14T19:31:18-07:00https://dev.oncoprescribe.com/fda-approves-imfinzi-in-combination-with-chemotherapy-for-advanced-biliary-tract-cancer/2022-09-08T06:26:30-07:00https://dev.oncoprescribe.com/neoadjuvant-chemotherapy-and-organ-preservation-in-rectal-cancer/2022-09-08T06:19:57-07:00https://dev.oncoprescribe.com/opdualag-nivolumab-and-relatlimab-rmbw-a-new-dual-i-o-option-in-the-1l-treatment-of-metastatic-melanoma/2022-09-05T12:44:07-07:00https://dev.oncoprescribe.com/fda-grants-accelerated-approval-to-enhertu-for-her2-mutant-non-small-cell-lung-cancer/2022-08-31T20:29:09-07:00https://dev.oncoprescribe.com/overall-survival-benefit-with-sarclisa-plus-pomalyst-and-dexamethasone-in-relapsed-and-refractory-myeloma/2022-08-31T20:15:22-07:00https://dev.oncoprescribe.com/premmplus-hereditary-cancer-risk-assessment-tool-may-identify-people-likely-to-benefit-from-multigene-panel-testing/2022-08-25T05:59:14-07:00https://dev.oncoprescribe.com/efficacy-of-low-dose-decitabine-and-azacitidine-in-lower-risk-myelodysplastic-syndrome/2022-08-25T05:44:29-07:00https://dev.oncoprescribe.com/elacestrant-in-er-positive-her2-negative-metastatic-breast-cancer/2022-08-18T05:57:34-07:00https://dev.oncoprescribe.com/lynparza-superior-to-next-generation-hormonal-drug-in-crpc-patients-with-homologous-recombination-repair-gene-alterations-2/2022-08-18T07:25:15-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-landmark-five-year-overall-survival-rates-for-opdivo-and-yervoy-combination-in-nsclc/2022-08-11T14:22:42-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-docetaxel-as-radiosensitizer-improves-overall-survival-in-cisplatin-ineligible-head-and-neck-cancer/2022-08-11T14:21:36-07:00https://dev.oncoprescribe.com/adcetris-improves-overall-survival-in-stage-iii-or-iv-hodgkins-lymphoma/2022-08-04T16:48:13-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-improved-distant-metastasis-free-survival-with-adjuvant-keytruda-in-high-risk-stage-ii-melanoma/2022-08-04T16:40:25-07:00https://dev.oncoprescribe.com/xalkori-crizotinib-3/2022-08-03T20:26:08-07:00https://dev.oncoprescribe.com/breyanzi-lisocabtagene-maraleucel-2/2022-08-03T20:18:43-07:00https://dev.oncoprescribe.com/tafinlar-dabrafenib-and-mekinist-trametinib/2022-08-03T20:11:53-07:00https://dev.oncoprescribe.com/kymriah-tisagenlecleucel-3/2022-08-03T19:55:47-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-and-yervoy-ipilimumab-2/2022-08-03T19:47:55-07:00https://dev.oncoprescribe.com/tibsovo-ivosidenib-4/2022-08-03T19:35:16-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-rubraca-monotherapy-as-maintenance-treatment-in-newly-diagnosed-ovarian-cancer-2/2022-07-29T13:35:50-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-nimotuzumab-significantly-improves-overall-survival-in-k-ras-wild-type-advanced-pancreatic-cancer/2022-07-27T21:09:10-07:00https://dev.oncoprescribe.com/vidaza-azacitidine/2022-07-25T13:41:19-07:00https://dev.oncoprescribe.com/enhertu-fam-trastuzumab-deruxtecan-nxki-3/2022-07-25T12:04:44-07:00https://dev.oncoprescribe.com/vijoice-alpelisib/2022-07-25T11:42:36-07:00https://dev.oncoprescribe.com/yescarta-axicabtagene-ciloleucel-3/2022-07-25T11:28:20-07:00https://dev.oncoprescribe.com/pluvicto-lutetium-lu-177-vipivotide-tetraxetan/2022-07-25T10:44:14-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-34/2022-07-25T10:35:35-07:00https://dev.oncoprescribe.com/opdualag-nivolumab-and-relatlimab-rmbw/2022-07-25T10:02:56-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-folfoxiri-plus-bevacizumab-in-unresectable-colorectal-cancer-with-liver-metastases/2022-07-20T21:09:47-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-rvd-plus-autologous-stem-cell-transplantation-and-revlimid-maintenance-improves-pfs-in-multiple-myeloma/2022-07-20T20:53:10-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-enhertu-for-her2-low-advanced-breast-cancer/2022-07-13T20:53:45-07:00https://dev.oncoprescribe.com/screening-for-pancreatic-cancer-results-in-early-detection-and-improved-overall-survival/2022-07-13T20:51:49-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-kisqali-with-switch-endocrine-therapy-following-progression-on-a-prior-cdk4-6-inhibitor-in-hr-her2-negative-metastatic-breast-cancer/2022-07-07T06:12:31-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-panitumumab-combined-with-mfolfox6-improves-overall-survival-in-left-sided-ras-wild-type-metastatic-colorectal-cancer/2022-07-07T06:09:12-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-survival-benefit-with-trodelvy-in-hormone-receptor-positive-her2-negative-metastatic-breast-cancer/2022-06-29T20:53:20-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-adagrasib-in-kras-g12c-mutated-non-small-cell-lung-cancer/2022-06-29T20:45:43-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-adjuvant-radiotherapy-may-be-omitted-in-select-patients-with-luminal-a-breast-cancer/2022-06-22T21:04:33-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-circulating-tumor-dna-in-the-peripheral-blood-can-guide-adjuvant-therapy-decision-in-stage-ii-colon-cancer/2022-06-22T21:00:55-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2022-imbruvica-plus-bendamustine-and-rituximab-for-older-patients-with-untreated-mantle-cell-lymphoma/2022-06-16T07:03:37-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-combination-for-advanced-esophageal-carcinoma/2022-06-16T07:00:44-07:00https://dev.oncoprescribe.com/consider-guideline-recommended-biomarker-testing-as-an-integral-component-of-nsclc-care/2022-06-13T20:55:52-07:00https://dev.oncoprescribe.com/fda-approves-kymriah-for-relapsed-or-refractory-follicular-lymphoma/2022-06-08T20:09:11-07:00https://dev.oncoprescribe.com/imfinzi-in-combination-with-chemotherapy-improves-overall-survival-in-advanced-biliary-tract-cancer/2022-06-08T19:57:19-07:00https://dev.oncoprescribe.com/mutations-of-stk11-kras-genes-and-efficacy-of-immunotherapy-in-nsclc/2022-06-02T06:17:14-07:00https://dev.oncoprescribe.com/imfinzi-plus-tremelimumab-significantly-improves-overall-survival-in-advanced-hepatocellular-carcinoma/2022-06-02T06:00:53-07:00https://dev.oncoprescribe.com/factors-associated-with-mortality-among-cancer-patients-with-covid-19-infection-compared-with-those-without-cancer/2022-05-30T19:56:24-07:00https://dev.oncoprescribe.com/long-term-disease-free-survival-benefits-with-adjuvant-opdivo-in-urothelial-carcinoma/2022-05-26T17:46:35-07:00https://dev.oncoprescribe.com/expansion-of-cancer-risk-profile-beyond-breast-and-ovarian-cancer-for-brca1-and-brca2-pathogenic-variants/2022-05-18T21:13:03-07:00https://dev.oncoprescribe.com/segmentectomy-versus-lobectomy-in-small-sized-peripheral-non-small-cell-lung-cancer/2022-05-18T20:57:37-07:00https://dev.oncoprescribe.com/fda-grants-regular-approval-to-enhertu-for-breast-cancer/2022-05-12T05:38:26-07:00https://dev.oncoprescribe.com/lower-gastrointestinal-endoscopy-before-age-50-years-reduces-risk-for-colorectal-cancer-among-women/2022-05-12T05:23:45-07:00https://dev.oncoprescribe.com/risk-of-coagulopathy-persists-for-several-months-after-covid-19/2022-05-04T18:54:46-07:00https://dev.oncoprescribe.com/darzalex-plus-kyprolis-and-dexamethasone-in-relapsed-or-refractory-multiple-myeloma/2022-05-04T18:43:27-07:00https://dev.oncoprescribe.com/investigator-and-health-systems-insights-on-real-world-evidence-associated-with-a-first-generation-btk-inhibitor-in-patients-with-cll-sll/2022-05-03T06:18:54-07:00https://dev.oncoprescribe.com/lung-cancer-screening-with-low-dose-ct-associated-with-favorable-stage-shift-and-improved-survival/2022-04-27T19:43:53-07:00https://dev.oncoprescribe.com/tibsovo-and-vidaza-combo-improve-survival-in-idh1-mutated-acute-myeloid-leukemia/2022-04-27T19:28:08-07:00https://dev.oncoprescribe.com/overall-survival-at-2-years-with-lumakras-for-kras-g12c-positive-non-small-cell-lung-cancer/2022-04-20T20:53:16-07:00https://dev.oncoprescribe.com/genetically-adjusted-psa-values-may-improve-the-accuracy-of-prostate-cancer-detection/2022-04-20T20:40:05-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-chemotherapy-fluoropyrimidine-platinum-based-for-the-first-line-1l-treatment-of-metastatic-gastric-cancer-gastroesophageal-junction-cancer-and-esophageal-adenocarcino/2022-04-19T06:06:18-07:00https://dev.oncoprescribe.com/lynparza-olaparib-8/2022-04-15T09:50:14-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-18/2022-04-15T09:41:31-07:00https://dev.oncoprescribe.com/carvykti-ciltacabtagene/2022-04-15T09:35:44-07:00https://dev.oncoprescribe.com/kimmtrak-tebentafusp-tebn/2022-04-15T09:27:42-07:00https://dev.oncoprescribe.com/orencia-abatacept/2022-04-15T09:15:41-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-33/2022-04-15T09:06:28-07:00https://dev.oncoprescribe.com/rituxan-rituximab-2/2022-04-15T09:00:20-07:00https://dev.oncoprescribe.com/darzalex-faspro-daratumumab-hyaluronidase-fihj/2022-04-15T08:46:51-07:00https://dev.oncoprescribe.com/cytalux-pafolacianine/2022-04-15T08:37:06-07:00https://dev.oncoprescribe.com/tukysa-in-pretreated-her2-positive-metastatic-breast-cancer-with-and-without-brain-metastases-final-overall-survival-analysis/2022-04-14T05:47:25-07:00https://dev.oncoprescribe.com/early-stage-multi-cancer-detection-using-an-extracellular-vesicle-protein-based-blood-test/2022-04-14T05:32:43-07:00https://dev.oncoprescribe.com/fda-approves-neoadjuvant-opdivo-and-chemotherapy-combination-for-early-stage-non-small-cell-lung-cancer/2022-04-07T06:02:27-07:00https://dev.oncoprescribe.com/fda-approves-yescarta-for-second-line-treatment-of-large-b-cell-lymphoma/2022-04-07T05:53:07-07:00https://dev.oncoprescribe.com/fyarro-sirolimus-protein-bound-particles-for-injectable-suspension-albumin-bound/2022-04-01T13:04:57-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-32/2022-04-01T12:57:03-07:00https://dev.oncoprescribe.com/scemblix-asciminib/2022-04-01T12:53:14-07:00https://dev.oncoprescribe.com/tecentriq-atezolizumab-8/2022-04-01T12:49:03-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-31/2022-04-01T12:43:12-07:00https://dev.oncoprescribe.com/verzenio-abemaciclib-3/2022-04-01T12:31:09-07:00https://dev.oncoprescribe.com/public-human-genetic-variant-databases/2022-04-01T12:24:45-07:00https://dev.oncoprescribe.com/tecartus-brexucabtagene-autoleucel/2022-04-01T12:21:55-07:00https://dev.oncoprescribe.com/jakafi-ruxolitinib-3/2022-04-01T12:16:56-07:00https://dev.oncoprescribe.com/tivdak-tisotumab-vedotin-tftv/2022-04-01T12:10:30-07:00https://dev.oncoprescribe.com/fda-approves-psma-targeted-therapy-for-metastatic-castrate-resistant-prostate-cancer/2022-03-31T10:51:49-07:00https://dev.oncoprescribe.com/fda-approves-single-agent-keytruda-for-advanced-endometrial-carcinoma/2022-03-31T10:51:30-07:00https://dev.oncoprescribe.com/kisqali-plus-femara-improves-overall-survival-in-advanced-breast-cancer/2022-03-24T05:09:22-07:00https://dev.oncoprescribe.com/fda-approves-lag-3-inhibitor-opdualag-and-opvido-in-advanced-untreated-melanoma/2022-03-24T04:51:25-07:00https://dev.oncoprescribe.com/acute-myeloid-leukemia/2022-03-23T05:48:58-07:00https://dev.oncoprescribe.com/association-of-gut-microbiome-with-immune-checkpoint-inhibitor-response-in-advanced-melanoma/2022-03-17T16:34:48-07:00https://dev.oncoprescribe.com/avoiding-radioiodine-therapy-following-thyroidectomy-in-patients-with-low-risk-thyroid-cancer/2022-10-05T20:02:04-07:00https://dev.oncoprescribe.com/pet-response-based-radiotherapy-de-escalation-in-p16-positive-oropharyngeal-cancer/2022-03-10T06:54:15-07:00https://dev.oncoprescribe.com/lynparza-superior-to-next-generation-hormonal-drug-in-crpc-patients-with-homologous-recombination-repair-gene-alterations/2022-03-10T06:38:33-07:00https://dev.oncoprescribe.com/nubeqa-combination-improves-overall-survival-in-metastatic-hormone-sensitive-prostate-cancer/2022-03-03T18:04:38-07:00https://dev.oncoprescribe.com/smoking-cessation-after-lung-cancer-diagnosis-improves-overall-survival/2022-03-03T18:04:17-07:00https://dev.oncoprescribe.com/platelet-to-lymphocyte-ratio-predicts-the-efficacy-of-keytruda-in-patients-with-urothelial-carcinoma/2022-02-24T16:39:45-07:00https://dev.oncoprescribe.com/cytoreductive-surgery-for-relapsed-ovarian-cancer-improves-overall-survival/2022-02-24T16:27:45-07:00https://dev.oncoprescribe.com/cabometyx-cabozantinib-4/2022-02-18T08:34:25-07:00https://dev.oncoprescribe.com/exkivity-mobocertinib/2022-02-18T08:25:18-07:00https://dev.oncoprescribe.com/brukinsa-zanubrutinib-3/2022-02-18T08:17:32-07:00https://dev.oncoprescribe.com/brukinsa-zanubrutinib-2/2022-02-18T07:48:42-07:00https://dev.oncoprescribe.com/cancer-risks-associated-with-brca1-and-brca2-pathogenic-variants/2022-02-17T20:52:36-07:00https://dev.oncoprescribe.com/opdivo-combination-improves-overall-survival-in-advanced-esophageal-carcinoma/2022-02-17T20:51:50-07:00https://dev.oncoprescribe.com/general-review-an-approved-treatment-option-for-acute-myeloid-leukemia/2022-02-14T20:33:19-07:00https://dev.oncoprescribe.com/overall-survival-benefit-with-the-addition-of-capecitabine-to-adjuvant-chemotherapy/2022-02-10T08:55:26-07:00https://dev.oncoprescribe.com/fda-approves-enjaymo-for-cold-agglutinin-disease/2022-02-10T08:46:39-07:00https://dev.oncoprescribe.com/consolidation-and-maintenance-in-newly-diagnosed-multiple-myeloma/2022-02-03T17:45:40-07:00https://dev.oncoprescribe.com/lag-3-inhibitor-relatlimab-and-opvido-in-advanced-untreated-melanoma/2022-02-03T17:22:21-07:00https://dev.oncoprescribe.com/adjuvant-verzenio-in-high-risk-early-stage-breast-cancer-updated-efficacy-and-ki-67-analysis/2022-01-26T20:09:54-07:00https://dev.oncoprescribe.com/enhertu-in-her2-mutant-non-small-cell-lung-cancer/2022-01-26T19:58:23-07:00https://dev.oncoprescribe.com/elacestrant-in-metastatic-breast-cancer-progressing-on-cdk4-6-therapy-and-esr1-mutant-subtype/2022-01-20T12:27:01-07:00https://dev.oncoprescribe.com/blood-test-plus-risk-model-may-predict-who-may-benefit-from-lung-cancer-screening/2022-01-20T12:26:39-07:00https://dev.oncoprescribe.com/defining-patient-groups-with-triple-negative-breast-cancer-who-derive-benefit-from-keytruda-plus-chemotherapy/2022-01-13T07:15:22-07:00https://dev.oncoprescribe.com/elevated-white-cell-count-and-risk-of-thrombotic-events-in-polycythemia-vera/2022-01-13T07:25:09-07:00https://dev.oncoprescribe.com/acute-myeloid-leukemia-who-is-an-appropriate-candidate-for-onureg-azacitidine-tablets/2022-01-10T22:05:03-07:00https://dev.oncoprescribe.com/daprodustat-a-new-oral-therapy-for-anemia-in-patients-with-chronic-kidney-disease/2022-01-06T12:13:46-07:00https://dev.oncoprescribe.com/long-term-survival-benefit-with-maintenance-onureg-in-aml-patients/2022-01-06T12:11:01-07:00https://dev.oncoprescribe.com/postmenopausal-women-with-node-positive-breast-cancer-may-not-benefit-from-chemotherapy/2021-12-30T08:27:40-07:00https://dev.oncoprescribe.com/polivy-in-previously-untreated-diffuse-large-b-cell-lymphoma/2021-12-30T08:09:05-07:00https://dev.oncoprescribe.com/risk-of-cardiovascular-diseases-among-older-breast-cancer-survivors-2/2021-12-23T17:16:41-07:00https://dev.oncoprescribe.com/kras-variant-status-and-outcomes-with-immune-checkpoint-inhibitor-based-therapy-in-advanced-non-small-cell-lung-cancer-2/2021-12-23T17:13:58-07:00https://dev.oncoprescribe.com/duration-of-adjuvant-aromatase-inhibitor-therapy-in-postmenopausal-breast-cancer-2/2021-12-16T08:04:51-07:00https://dev.oncoprescribe.com/updated-data-on-fixed-duration-venclexta-for-frontline-chronic-lymphocytic-leukemia-2/2021-12-16T08:04:02-07:00https://dev.oncoprescribe.com/stereotactic-ablative-radiotherapy-non-inferior-to-surgery-in-operable-stage-i-non-small-cell-lung-cancer/2021-12-09T16:32:23-07:00https://dev.oncoprescribe.com/chemoradiotherapy-followed-by-consolidation-chemotherapy-as-total-neoadjuvant-therapy-in-locally-advanced-rectal-cancer/2021-12-09T16:28:49-07:00https://dev.oncoprescribe.com/sintilimab-for-patients-with-pretreated-egfr-mutated-non-small-cell-lung-cancer/2021-12-02T16:21:05-07:00https://dev.oncoprescribe.com/anti-bcma-car-t-cell-therapy-for-multiple-myeloma/2021-12-02T16:20:21-07:00https://dev.oncoprescribe.com/non-hodgkin-lymphoma-treated-with-b-cell-depleting-immunotherapy-may-result-in-prolonged-hospital-stay-and-higher-morbidity-after-covid-19-infection/2021-11-25T07:08:49-07:00https://dev.oncoprescribe.com/artificial-intelligence-can-determine-appropriate-chemotherapy-regimen-in-advanced-colorectal-cancer/2021-11-25T07:06:24-07:00https://dev.oncoprescribe.com/genetic-testing-in-older-women-with-breast-cancer/2021-11-17T22:52:10-07:00https://dev.oncoprescribe.com/initial-management-of-noncastrate-prostate-cancer-asco-guideline-update/2021-11-17T22:28:19-07:00https://dev.oncoprescribe.com/association-of-age-at-smoking-initiation-and-cessation-with-risk-of-cancer-mortality/2021-11-11T08:11:20-07:00https://dev.oncoprescribe.com/keytruda-for-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/2021-11-11T07:26:09-07:00https://dev.oncoprescribe.com/fda-approves-scemblix-for-chronic-myeloid-leukemia/2021-11-04T11:52:40-07:00https://dev.oncoprescribe.com/randomized-controlled-trial-of-central-venous-access-devices-for-the-delivery-of-systemic-anticancer-therapy/2021-11-04T11:42:18-07:00https://dev.oncoprescribe.com/duration-of-extended-adjuvant-letrozole-after-tamoxifen-in-postmenopausal-women-with-early-stage-breast-cancer/2021-10-27T20:12:02-07:00https://dev.oncoprescribe.com/ash-2021-guidelines-for-management-of-vte-in-patients-with-cancer-2/2021-10-27T20:11:38-07:00https://dev.oncoprescribe.com/omitting-axillary-lymph-node-dissection-in-patients-with-clinically-positive-axillary-lymph-nodes-treated-with-neoadjuvant-chemotherapy/2021-10-20T20:17:10-07:00https://dev.oncoprescribe.com/fda-approves-tecentriq-as-adjuvant-treatment-for-non-small-cell-lung-cancer/2021-10-20T20:06:54-07:00https://dev.oncoprescribe.com/association-between-antibiotic-use-and-colorectal-cancer/2021-10-14T06:17:51-07:00https://dev.oncoprescribe.com/durable-survival-benefit-with-first-line-opdivo-plus-yervoy-and-a-limited-course-of-chemotherapy/2021-10-14T06:17:07-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2021-adjuvant-keytruda-for-high-risk-stage-ii-melanoma/2021-10-06T21:07:14-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2021-keytruda-plus-chemotherapy-in-advanced-cervical-cancer/2021-10-06T20:57:55-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2021-enhertu-superior-to-kadcyla-in-patients-with-her2-positive-metastatic-breast-cancer/2021-09-29T21:23:43-07:00https://dev.oncoprescribe.com/psma-targeted-therapy-improves-overall-survival-in-metastatic-prostate-cancer/2021-09-29T20:46:56-07:00https://dev.oncoprescribe.com/keytruda-in-combination-with-chemotherapy-improves-overall-survival-in-triple-negative-breast-cancer/2021-09-23T06:25:42-07:00https://dev.oncoprescribe.com/fda-approves-exkivity-for-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations/2021-09-23T06:08:18-07:00https://dev.oncoprescribe.com/updated-overall-survival-with-kisqali-plus-faslodex-in-advanced-breast-cancer/2021-09-15T20:20:26-07:00https://dev.oncoprescribe.com/infection-risk-in-multiple-myeloma-patients-receiving-new-generation-therapies/2021-09-15T20:01:00-07:00https://dev.oncoprescribe.com/real-world-evidence-what-can-it-inform-us-about-the-second-line-treatment-of-metastatic-squamous-nsclc/2021-09-14T05:28:35-07:00https://dev.oncoprescribe.com/maintenance-rubraca-in-patients-with-advanced-pancreatic-cancer-with-a-pathogenic-germline-or-somatic-variant-in-brca1-brca2-or-palb2/2021-09-08T20:55:40-07:00https://dev.oncoprescribe.com/fda-approves-trodelvy-for-advanced-urothelial-cancer/2021-09-08T20:38:52-07:00https://dev.oncoprescribe.com/noninvasive-evaluation-for-myelodysplastic-syndrome-in-patients-with-unexplained-anemia/2021-09-02T06:07:28-07:00https://dev.oncoprescribe.com/tibsovo-improves-survival-in-idh1-mutated-advanced-cholangiocarcinoma-2/2021-09-02T06:12:23-07:00https://dev.oncoprescribe.com/myelodysplastic-syndromes-managing-anemia-due-to-ineffective-erythropoiesis-in-patients-with-mds-requiring-rbc-transfusions/2021-08-30T20:55:20-07:00https://dev.oncoprescribe.com/tibsovo-ivosidenib-3/2021-08-28T07:27:42-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-17/2021-08-28T07:17:29-07:00https://dev.oncoprescribe.com/jemperli-dostarlimab-gxly-2/2021-08-28T07:10:12-07:00https://dev.oncoprescribe.com/welireg-belzutifan/2021-08-28T07:02:28-07:00https://dev.oncoprescribe.com/lenvima-lenvatinib-plus-keytruda-pembrolizumab/2021-08-28T06:51:55-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-30/2021-08-28T06:34:57-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-in-combination-with-lenvima-lenvatinib/2021-08-28T06:25:58-07:00https://dev.oncoprescribe.com/rezurock-belumosudil/2021-08-28T06:09:36-07:00https://dev.oncoprescribe.com/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-2/2021-08-28T06:01:23-07:00https://dev.oncoprescribe.com/padcev-enfortumab-vedotin-ejfv-2/2021-08-28T05:53:20-07:00https://dev.oncoprescribe.com/rylaze-asparaginase-erwinia-chrysanthemi-recombinant-rywn/2021-08-28T05:43:19-07:00https://dev.oncoprescribe.com/immune-checkpoint-inhibitor-therapy-and-risk-of-venous-thromboembolism/2021-08-26T06:18:04-07:00https://dev.oncoprescribe.com/fda-approves-lenvima-plus-keytruda-for-advanced-renal-cell-carcinoma/2021-08-26T05:54:12-07:00https://dev.oncoprescribe.com/ayvakit-avapritinib-2/2021-08-19T08:51:27-07:00https://dev.oncoprescribe.com/truseltiq-infigratinib/2021-08-19T08:52:05-07:00https://dev.oncoprescribe.com/kras-variant-status-and-outcomes-with-immune-checkpoint-inhibitor-based-therapy-in-advanced-non-small-cell-lung-cancer/2021-12-23T17:12:40-07:00https://dev.oncoprescribe.com/long-term-results-in-prostate-cancer-patients-after-short-term-androgen-suppression-and-radiation-dose-escalation/2021-08-18T20:09:49-07:00https://dev.oncoprescribe.com/duration-of-adjuvant-aromatase-inhibitor-therapy-in-postmenopausal-breast-cancer/2021-08-11T20:14:27-07:00https://dev.oncoprescribe.com/calquence-may-be-safer-than-imbruvica-in-cll-patients/2021-08-11T20:03:32-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-for-high-risk-early-stage-triple-negative-breast-cancer/2021-08-05T06:15:47-07:00https://dev.oncoprescribe.com/no-difference-in-overall-survival-between-r-chop-and-r-epoch-in-advanced-myc-rearranged-double-hit-or-triple-hit-dlbcl/2021-08-05T05:58:00-07:00https://dev.oncoprescribe.com/de-escalated-neoadjuvant-dual-anti-her2-blockade-and-survival-outcomes-in-early-breast-cancer/2021-07-29T11:47:46-07:00https://dev.oncoprescribe.com/keytruda-versus-adcetris-in-relapsed-or-refractory-classical-hodgkin-lymphoma/2021-07-29T11:34:48-07:00https://dev.oncoprescribe.com/circulating-tumor-dna-as-a-biomarker-in-advanced-colorectal-cancer/2021-07-22T07:20:17-07:00https://dev.oncoprescribe.com/long-term-survival-benefit-in-advanced-melanoma-with-opdivo-plus-yervoy/2021-07-22T07:19:59-07:00https://dev.oncoprescribe.com/antibiotic-use-and-early-onset-colon-cancer-in-younger-individuals/2021-07-14T20:27:10-07:00https://dev.oncoprescribe.com/updated-data-on-fixed-duration-venclexta-for-frontline-chronic-lymphocytic-leukemia/2021-07-14T20:10:25-07:00https://dev.oncoprescribe.com/risk-of-cardiovascular-diseases-among-older-breast-cancer-survivors/2021-07-08T16:13:14-07:00https://dev.oncoprescribe.com/subcutaneous-darzalex-plus-pomalyst-and-dexamethasone-improves-progression-free-survival-in-relapsed-or-refractory-multiple-myeloma/2021-07-08T16:03:25-07:00https://dev.oncoprescribe.com/adjuvant-tecentriq-improves-disease-free-survival-in-early-stage-non-small-cell-lung-cancer/2021-07-13T12:41:58-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-plus-trastuzumab-and-chemotherapy-for-her2-positive-gastric-or-gastroesophageal-junction-cancer/2021-07-01T05:33:45-07:00https://dev.oncoprescribe.com/lumakras-sotorasib/2021-06-27T20:19:44-07:00https://dev.oncoprescribe.com/rybrevant-amivantamab-vmjw/2021-06-27T20:21:52-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-16/2021-06-27T20:21:03-07:00https://dev.oncoprescribe.com/platinum-chemotherapy-inferior-to-xeloda-in-triple-negative-breast-cancer-following-neoadjuvant-chemotherapy/2021-06-23T21:36:24-07:00https://dev.oncoprescribe.com/darzalex-with-revlimid-and-dexamethasone-improves-overall-survival-in-newly-diagnosed-multiple-myeloma/2021-06-23T21:16:26-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2021-psma-targeted-radioligand-therapy-improves-progression-free-survival-and-overall-survival-in-metastatic-prostate-cancer/2021-06-17T06:00:37-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2021-adjuvant-keytruda-improves-disease-free-survival-in-renal-cell-carcinoma/2021-06-17T05:45:14-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2021-adjuvant-lynparza-improves-disease-free-survival-in-brca-positive-breast-cancer/2021-06-16T22:21:28-07:00https://dev.oncoprescribe.com/adjuvant-treatment-with-opdivo-in-muscle-invasive-urothelial-carcinoma/2021-06-16T21:44:42-07:00https://dev.oncoprescribe.com/fda-approves-lumakras-for-kras-g12c-mutated-non-small-cell-lung-cancer/2021-06-03T06:02:47-07:00https://dev.oncoprescribe.com/fda-approves-truseltiq-for-metastatic-cholangiocarcinoma/2021-06-03T05:42:47-07:00https://dev.oncoprescribe.com/fda-approves-bispecific-antibody-rybrevant-for-metastatic-non-small-cell-lung-cancer/2021-05-27T06:55:22-07:00https://dev.oncoprescribe.com/ai-derived-molecular-signature-predicts-first-line-oxaliplatin-based-chemotherapy-benefit-in-advanced-crc/2021-05-27T05:51:57-07:00https://dev.oncoprescribe.com/70-gene-risk-signature-may-determine-long-term-benefit-of-endocrine-therapy-in-premenopausal-breast-cancer-patients/2021-05-19T20:47:58-07:00https://dev.oncoprescribe.com/final-analysis-confirms-superior-os-benefit-with-erleada-in-metastatic-castrate-sensitive-prostate-cancer/2021-05-19T20:37:21-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-29/2021-05-16T09:33:18-07:00https://dev.oncoprescribe.com/zynlonta-loncastuximab-tesirine-lpyl/2021-05-16T09:20:04-07:00https://dev.oncoprescribe.com/jemperli-dostarlimab-gxly/2021-05-16T09:04:26-07:00https://dev.oncoprescribe.com/neoadjuvant-chemotherapy-in-locally-advanced-rectal-cancer/2021-05-12T20:47:02-07:00https://dev.oncoprescribe.com/somatic-tumor-mutations-and-risk-for-thrombosis/2021-05-12T20:30:32-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-15/2021-05-06T17:30:17-07:00https://dev.oncoprescribe.com/trodelvy-sacituzumab-govitecan-2/2021-05-06T17:07:23-07:00https://dev.oncoprescribe.com/trodelvy-sacituzumab-govitecan/2021-05-06T16:57:23-07:00https://dev.oncoprescribe.com/sarclisa-isatuximab-irfc-2/2021-05-06T06:15:23-07:00https://dev.oncoprescribe.com/abecma-idecabtagene-vicleucel/2021-05-06T06:23:01-07:00https://dev.oncoprescribe.com/keytruda-plus-platinum-and-fluoropyrimidine/2021-05-06T05:54:57-07:00https://dev.oncoprescribe.com/five-year-efficacy-outcomes-with-keytruda-versus-chemotherapy-in-metastatic-nsclc/2021-05-05T19:37:09-07:00https://dev.oncoprescribe.com/lenvima-plus-keytruda-for-advanced-renal-cell-carcinoma/2021-05-05T19:18:05-07:00https://dev.oncoprescribe.com/fda-approves-libtayo-for-non-small-cell-lung-cancer-with-high-pd-l1-expression/2021-04-29T05:23:06-07:00https://dev.oncoprescribe.com/fda-approves-antibody-drug-conjugate-zynlonta-for-large-b-cell-lymphoma/2021-04-29T05:15:26-07:00https://dev.oncoprescribe.com/role-of-chemotherapy-in-postmenopausal-women-with-node-positive-early-breast-cancer/2021-04-21T21:01:00-07:00https://dev.oncoprescribe.com/asco-guideline-parp-inhibitors-in-the-management-of-ovarian-cancer-2/2021-04-21T20:39:32-07:00https://dev.oncoprescribe.com/fda-grants-regular-approval-to-trodelvy-for-advanced-triple-negative-breast-cancer/2021-04-14T21:13:57-07:00https://dev.oncoprescribe.com/prostate-cancer-risk-associated-with-familial-and-hereditary-cancer-syndromes/2021-04-14T20:37:26-07:00https://dev.oncoprescribe.com/radiation-therapy-for-small-cell-lung-cancer-asco-guideline-endorsement-of-an-astro-guideline/2021-04-08T06:20:33-07:00https://dev.oncoprescribe.com/fda-approves-sarclisa-combination-for-relapsed-or-refractory-myeloma/2021-04-08T06:03:25-07:00https://dev.oncoprescribe.com/fda-approves-anti-bcma-car-t-cell-therapy-for-relapsed-or-refractory-multiple-myeloma/2021-04-01T06:33:31-07:00https://dev.oncoprescribe.com/fda-approves-first-line-keytruda-in-combination-with-chemotherapy-for-esophageal-or-gastroesophageal-carcinoma/2021-04-01T06:11:54-07:00https://dev.oncoprescribe.com/advances-in-triple-negative-breast-cancer/2021-04-01T05:34:03-07:00https://dev.oncoprescribe.com/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-and-oh-cco-joint-guideline-update/2021-03-25T06:16:00-07:00https://dev.oncoprescribe.com/fda-approves-therasphere-y-90-glass-microspheres-for-hepatocellular-carcinoma/2021-03-25T05:46:16-07:00https://dev.oncoprescribe.com/sugar-sweetened-beverages-may-increase-breast-cancer-mortality/2021-03-18T06:15:15-07:00https://dev.oncoprescribe.com/fda-approves-pepaxto-for-relapsed-or-refractory-multiple-myeloma/2021-03-18T06:04:21-07:00https://dev.oncoprescribe.com/fotivda-tivozanib/2021-03-14T16:47:16-07:00https://dev.oncoprescribe.com/yescarta-axicabtagene-ciloleucel-2/2021-03-14T16:48:42-07:00https://dev.oncoprescribe.com/lorbrena-lorlatinib-2/2021-03-11T17:46:19-07:00https://dev.oncoprescribe.com/pepaxto-melphalan-flufenamide/2021-03-11T17:40:22-07:00https://dev.oncoprescribe.com/worse-outcomes-from-covid-19-infection-in-lymphoma-patients-treated-with-anti-cd20-monoclonal-antibodies/2021-03-11T07:10:03-07:00https://dev.oncoprescribe.com/fda-approves-lorbrena-for-advanced-alk-positive-lung-cancer/2021-03-11T06:58:03-07:00https://dev.oncoprescribe.com/role-of-aspirin-in-colorectal-cancer-prevention-and-mortality/2021-03-04T08:31:16-07:00https://dev.oncoprescribe.com/padcev-prolongs-overall-survival-in-metastatic-urothelial-carcinoma/2021-03-04T08:10:57-07:00https://dev.oncoprescribe.com/margenza-superior-to-trastuzumab-in-heavily-pretreated-her2-positive-breast-cancer/2021-02-25T06:30:10-07:00https://dev.oncoprescribe.com/2021-asco-gu-cancers-symposium-apalutamide-and-abiraterone-plus-prednisone-improves-pfs-in-chemo-naive-mcrpc-patients/2021-02-25T06:16:51-07:00https://dev.oncoprescribe.com/advances-with-first-line-dual-immunotherapies-in-metastatic-non-small-cell-lung-cancer/2021-02-22T17:45:17-07:00https://dev.oncoprescribe.com/ash-2021-guidelines-for-management-of-vte-in-patients-with-cancer/2021-02-18T12:50:20-07:00https://dev.oncoprescribe.com/fda-approves-libtayo-for-advanced-basal-cell-carcinoma/2021-02-18T12:15:41-07:00https://dev.oncoprescribe.com/libtayo-cemiplimab-rwlc-2/2021-02-11T13:33:25-07:00https://dev.oncoprescribe.com/breyanzi-lisocabtagene-maraleucel/2021-02-11T13:20:51-07:00https://dev.oncoprescribe.com/ukoniq-umbralisib/2021-02-11T13:09:58-07:00https://dev.oncoprescribe.com/key-breast-cancer-risk-genes-identified-from-two-large-studies/2021-02-11T07:56:26-07:00https://dev.oncoprescribe.com/fda-approves-ukoniq-for-relapsed-or-refractory-marginal-zone-and-follicular-lymphomas/2021-02-11T07:40:07-07:00https://dev.oncoprescribe.com/tepmetko-tepotinib/2021-02-04T14:36:26-07:00https://dev.oncoprescribe.com/tibsovo-improves-survival-in-idh1-mutated-advanced-cholangiocarcinoma/2021-02-04T06:57:01-07:00https://dev.oncoprescribe.com/real-world-data-surgery-improves-survival-in-treatment-responsive-metastatic-breast-cancer/2021-02-11T07:17:23-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-plus-cabometyx-in-newly-diagnosed-advanced-kidney-cancer/2021-01-28T07:27:05-07:00https://dev.oncoprescribe.com/maintenance-therapy-with-ninlaro-in-transplantation-ineligible-multiple-myeloma-patients/2021-01-28T07:08:19-07:00https://dev.oncoprescribe.com/opdivo-and-cabometyx/2021-01-27T20:13:15-07:00https://dev.oncoprescribe.com/darzalex-faspro-daratumumab-plus-hyaluronidase/2021-01-27T19:58:51-07:00https://dev.oncoprescribe.com/enhertu-fam-trastuzumab-deruxtecan-nxki-2/2021-01-27T18:14:44-07:00https://dev.oncoprescribe.com/xalkori-crizotinib-2/2021-01-27T18:05:28-07:00https://dev.oncoprescribe.com/adjuvant-verzenio-with-endocrine-therapy-in-high-risk-early-stage-breast-cancer/2021-02-11T07:18:10-07:00https://dev.oncoprescribe.com/pet-directed-therapy-for-limited-stage-diffuse-large-b-cell-lymphoma/2021-01-21T07:02:51-07:00https://dev.oncoprescribe.com/first-line-keytruda-superior-to-chemotherapy-in-metastatic-msi-h-dmmr-colorectal-cancer/2021-01-14T07:12:23-07:00https://dev.oncoprescribe.com/genomics-identify-patients-with-smoldering-myeloma-at-risk-of-developing-multiple-myeloma/2021-01-14T06:55:08-07:00https://dev.oncoprescribe.com/the-evolution-of-therapeutics-for-patients-with-arcc/2021-01-11T20:43:00-07:00https://dev.oncoprescribe.com/chemotherapy-can-be-spared-in-majority-of-postmenopausal-women-with-node-positive-early-breast-cancer/2021-01-07T07:25:54-07:00https://dev.oncoprescribe.com/osteonecrosis-of-the-jaw-with-zoledronic-acid-treatment/2021-01-07T07:09:30-07:00https://dev.oncoprescribe.com/asco-guideline-parp-inhibitors-in-the-management-of-ovarian-cancer/2020-12-31T13:28:18-07:00https://dev.oncoprescribe.com/fda-approves-xpovio-for-relapsed-or-refractory-multiple-myeloma/2020-12-31T12:44:25-07:00https://dev.oncoprescribe.com/tagrisso-osimertinib-4/2020-12-27T20:58:56-07:00https://dev.oncoprescribe.com/orgovyx-relugolix/2020-12-27T20:49:07-07:00https://dev.oncoprescribe.com/xpovio-selinexor-3/2020-12-27T20:41:28-07:00https://dev.oncoprescribe.com/margenza-margetuximab-cmkb/2020-12-27T20:33:31-07:00https://dev.oncoprescribe.com/fda-approves-margenza-for-her2-positive-metastatic-breast-cancer/2020-12-24T07:56:41-07:00https://dev.oncoprescribe.com/fda-approves-orgovyx-for-advanced-prostate-cancer/2020-12-24T07:45:26-07:00https://dev.oncoprescribe.com/ongoing-benefit-with-verzenio-in-high-risk-early-stage-breast-cancer/2020-12-17T07:15:01-07:00https://dev.oncoprescribe.com/ash-2020-subcutaneous-darzalex-plus-pomalidomide-and-dexamethasone-in-relapsed-or-refractory-multiple-myeloma/2020-12-17T06:45:39-07:00https://dev.oncoprescribe.com/considerations-in-the-treatment-of-metastatic-pancreas-cancer/2020-12-15T21:03:55-07:00https://dev.oncoprescribe.com/crispr-cas9-gene-editing-technique-may-cure-sickle-cell-disease-and-beta-thalassemia/2020-12-17T07:15:56-07:00https://dev.oncoprescribe.com/salvage-yervoy-and-opdivo-combination-after-prior-immune-checkpoint-inhibitor-therapy-in-advanced-rcc/2020-12-10T06:52:37-07:00https://dev.oncoprescribe.com/gavreto-pralsetinib-2/2020-12-07T21:08:45-07:00https://dev.oncoprescribe.com/danyelza-naxitamab/2020-12-07T20:51:41-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-28/2020-12-07T20:56:19-07:00https://dev.oncoprescribe.com/adjuvant-trastuzumab-monotherapy-for-older-patients-with-her-2-positive-breast-cancer/2020-12-03T07:32:45-07:00https://dev.oncoprescribe.com/high-tumor-mutational-burden-predicts-response-to-keytruda/2020-12-03T07:10:59-07:00https://dev.oncoprescribe.com/challenges-and-unmet-needs-in-squamous-non-small-cell-lung-cancer/2021-06-08T15:45:05-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-plus-chemotherapy-for-triple-negative-breast-cancer/2020-11-26T12:25:09-07:00https://dev.oncoprescribe.com/rubraca-in-metastatic-castrate-resistant-prostate-cancer-with-brca-mutations/2020-11-26T12:29:19-07:00https://dev.oncoprescribe.com/nerlynx-combination-superior-to-tykerb-combination-in-advanced-her2-positive-breast-cancer/2020-11-19T06:58:46-07:00https://dev.oncoprescribe.com/chemotherapy-free-first-line-induction-and-consolidation-treatment-for-acute-lymphocytic-leukemia/2020-11-19T06:42:41-07:00https://dev.oncoprescribe.com/universal-genetic-testing-detects-more-inherited-mutations-than-guideline-based-approach/2020-11-12T06:57:56-07:00https://dev.oncoprescribe.com/lynparza-superior-to-chemotherapy-in-brca-mutated-platinum-sensitive-advanced-ovarian-cancer/2020-11-12T06:40:25-07:00https://dev.oncoprescribe.com/single-agent-trilaciclib-prevents-multilineage-myelosuppression-during-chemotherapy/2020-11-04T21:14:15-07:00https://dev.oncoprescribe.com/adjuvant-tagrisso-in-resected-egfr-mutated-non-small-cell-lung-cancer/2020-11-04T21:11:27-07:00https://dev.oncoprescribe.com/asco-guideline-on-treatment-of-metastatic-carcinoma-and-myeloma-of-the-femur/2020-10-29T06:23:06-07:00https://dev.oncoprescribe.com/gilotrif-in-egfr-positive-non-small-cell-lung-cancer-harboring-uncommon-mutations/2020-10-29T05:52:20-07:00https://dev.oncoprescribe.com/american-society-of-clinical-oncology-policy-statement-on-skin-cancer-prevention/2020-10-22T06:01:37-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-plus-yervoy-for-malignant-pleural-mesothelioma/2020-10-22T05:56:36-07:00https://dev.oncoprescribe.com/venclexta-venetoclax-5/2020-10-21T19:09:52-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-27/2020-10-21T19:00:15-07:00https://dev.oncoprescribe.com/opdivo-plus-yervoy/2020-10-21T18:41:35-07:00https://dev.oncoprescribe.com/gavreto-pralsetinib/2020-10-21T18:33:26-07:00https://dev.oncoprescribe.com/immune-checkpoint-inhibitors-associated-with-high-activity-in-msi-h-cancers/2020-10-15T11:01:04-07:00https://dev.oncoprescribe.com/risk-of-prostate-cancer-associated-with-familial-and-hereditary-cancer-syndromes/2020-10-15T06:34:05-07:00https://dev.oncoprescribe.com/minimal-residual-disease-testing-in-multiple-myeloma-the-time-has-arrived/2020-10-08T18:56:48-07:00https://dev.oncoprescribe.com/kras-g12c-inhibition-with-sotorasib-in-advanced-solid-tumors/2020-10-08T16:59:02-07:00https://dev.oncoprescribe.com/five-year-analysis-of-adjuvant-tafinlar-plus-mekinist-in-stage-iii-melanoma/2020-10-08T16:38:32-07:00https://dev.oncoprescribe.com/dcis-and-risk-of-death-from-breast-cancer/2020-10-01T06:21:50-07:00https://dev.oncoprescribe.com/optimal-duration-of-immune-checkpoint-inhibitors-in-advanced-non-small-cell-lung-cancer/2020-10-01T06:00:38-07:00https://dev.oncoprescribe.com/verzenio-plus-endocrine-therapy-improves-disease-free-survival-in-early-breast-cancer/2020-09-26T15:13:27-07:00https://dev.oncoprescribe.com/opdivo-plus-cabometyx-combination-doubles-progression-free-survival-in-newly-diagnosed-advanced-kidney-cancer/2020-09-24T09:13:59-07:00https://dev.oncoprescribe.com/fda-approves-gavreto-for-metastatic-ret-fusion-positive-non-small-cell-lung-cancer/2020-09-16T20:52:16-07:00https://dev.oncoprescribe.com/fda-approves-darzalex-plus-kyprolis-and-dexamethasone-for-multiple-myeloma/2020-09-16T20:38:54-07:00https://dev.oncoprescribe.com/precision-medicine-in-pancreatic-cancer-may-improve-overall-survival/2020-09-10T12:58:05-07:00https://dev.oncoprescribe.com/first-line-folfoxiri-plus-bevacizumab-may-be-a-preferable-strategy-for-metastatic-colorectal-cancer/2020-09-10T12:46:49-07:00https://dev.oncoprescribe.com/onureg-azacitidine-tablets/2020-09-07T12:24:53-07:00https://dev.oncoprescribe.com/kyprolis-and-darzalex/2020-09-07T12:26:19-07:00https://dev.oncoprescribe.com/novel-ultrasensitive-liquid-biopsy-detects-minimal-residual-disease-in-early-stage-breast-cancer/2020-09-02T22:41:39-07:00https://dev.oncoprescribe.com/association-between-immune-related-adverse-events-and-recurrence-free-survival-in-stage-iii-melanoma/2020-09-02T22:19:17-07:00https://dev.oncoprescribe.com/immunotherapy-benefits-all-patient-groups-with-advanced-cancer/2020-08-27T06:32:49-07:00https://dev.oncoprescribe.com/vidaza-plus-venclexta-for-elderly-patients-with-aml/2020-08-27T05:51:01-07:00https://dev.oncoprescribe.com/favorable-outcomes-with-kadcyla-in-her2-breast-cancer-irrespective-of-mutational-status/2020-09-07T12:05:43-07:00https://dev.oncoprescribe.com/next-generation-sequencing-superior-to-single-gene-testing-in-advanced-nsclc/2020-09-07T12:05:10-07:00https://dev.oncoprescribe.com/blenrep-belantamab-mafodotin-blmf/2020-08-19T16:06:05-07:00https://dev.oncoprescribe.com/monjuvi-tafasitamab-cxix/2020-08-19T15:57:08-07:00https://dev.oncoprescribe.com/first-line-cyramza-plus-erlotinib-for-egfr-mutated-non-small-cell-lung-cancer/2020-08-13T06:19:09-07:00https://dev.oncoprescribe.com/fda-approves-monjuvi-for-diffuse-large-b-cell-lymphoma/2020-08-13T05:58:42-07:00https://dev.oncoprescribe.com/fda-approves-oral-inqovi-for-myelodysplastic-syndromes/2020-08-06T07:03:01-07:00https://dev.oncoprescribe.com/fda-approves-io-in-combination-with-targeted-therapies-for-braf-positive-advanced-melanoma/2020-08-06T06:51:58-07:00https://dev.oncoprescribe.com/tecentriq/2020-08-02T16:11:01-07:00https://dev.oncoprescribe.com/tecartus/2020-08-02T16:01:45-07:00https://dev.oncoprescribe.com/inqovi-decitabine-and-cedazuridine/2020-08-02T16:14:49-07:00https://dev.oncoprescribe.com/the-transition-to-biosimilars-managing-payor-challenges/2020-08-01T14:12:17-07:00https://dev.oncoprescribe.com/enhertu-improves-overall-survival-in-previously-treated-her2-positive-gastric-cancer/2020-07-30T06:48:47-07:00https://dev.oncoprescribe.com/xtandi-improves-overall-survival-in-nonmetastatic-castration-resistant-prostate-cancer/2020-07-30T06:06:22-07:00https://dev.oncoprescribe.com/first-line-keytruda-plus-chemotherapy-significantly-improves-pfs-in-pd-l1-high-triple-negative-breast-cancer/2020-09-25T17:58:54-07:00https://dev.oncoprescribe.com/psma-targeted-imaging-for-biochemically-recurrent-prostate-cancer/2020-07-23T05:52:31-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-for-tumor-mutational-burden-high-solid-tumors/2020-07-16T06:54:01-07:00https://dev.oncoprescribe.com/enhertu-demonstrates-promising-clinical-activity-in-her2-positive-non-small-cell-lung-cancer/2020-07-16T06:30:39-07:00https://dev.oncoprescribe.com/piqray-effective-after-progression-on-cdk-inhibition-in-advanced-breast-cancer/2020-07-09T06:24:15-07:00https://dev.oncoprescribe.com/overall-survival-benefit-with-frontline-opdivo-plus-yervoy-and-limited-chemotherapy-in-nsclc/2020-07-09T06:25:22-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2020-local-therapy-does-not-extend-survival-in-newly-diagnosed-metastatic-breast-cancer/2020-07-02T08:11:08-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2020-fda-approves-bavencio-for-maintenance-treatment-in-advanced-urothelial-carcinoma/2020-07-02T08:01:57-07:00https://dev.oncoprescribe.com/bavencio-avelumab-3/2020-07-02T07:08:35-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-26/2020-07-02T07:00:49-07:00https://dev.oncoprescribe.com/phesgo/2020-07-02T06:45:58-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-25/2020-07-02T06:22:50-07:00https://dev.oncoprescribe.com/xpovio-selinexor-2/2020-07-02T06:07:08-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2020-adjuvant-therapy-with-tagrisso-improves-survival-in-early-stage-egfr-mutated-non-small-cell-lung-cancer/2020-06-25T06:22:51-07:00https://dev.oncoprescribe.com/keytruda-superior-to-adcetris-in-relapsed-or-refractory-classical-hodgkin-lymphoma/2020-06-25T06:07:41-07:00https://dev.oncoprescribe.com/tazverik-tazemetostat-2/2020-06-18T15:37:55-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-24/2020-06-18T15:31:38-07:00https://dev.oncoprescribe.com/zepzelca-lurbinectedin/2020-06-18T15:23:02-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-14/2020-06-18T15:13:23-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2020-first-line-keytruda-superior-to-chemotherapy-in-metastatic-msi-h-dmmr-colorectal-cancer/2020-06-18T06:21:04-07:00https://dev.oncoprescribe.com/fda-approves-retevmo-for-ret-altered-non-small-cell-lung-cancer-and-thyroid-cancers/2020-07-07T06:33:37-07:00https://dev.oncoprescribe.com/oral-relugolix-superior-to-leuprolide-in-advanced-prostate-cancer/2020-06-11T06:07:19-07:00https://dev.oncoprescribe.com/fda-approves-cyramza-plus-tarceva-for-egfr-mutated-nsclc/2020-06-11T05:43:27-07:00https://dev.oncoprescribe.com/fda-approves-tecentriq-in-combination-with-avastin-for-hepatocellular-carcinoma/2020-06-04T06:51:32-07:00https://dev.oncoprescribe.com/covid-19-associated-coagulopathy-diagnosis-and-management/2020-06-04T06:39:39-07:00https://dev.oncoprescribe.com/tecentriq-atezolizumab-plus-avastin-bevacizumab/2020-06-03T10:37:18-07:00https://dev.oncoprescribe.com/cyramza-ramucirumab-and-tarceva-erlotinib/2020-06-03T10:28:39-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-plus-yervoy-ipilimumab/2020-05-28T13:49:24-07:00https://dev.oncoprescribe.com/alunbrig-brigatinib-2/2020-05-28T13:51:51-07:00https://dev.oncoprescribe.com/dietary-supplement-use-during-adjuvant-chemotherapy-may-increase-risk-for-breast-cancer-recurrence/2020-05-28T06:14:57-07:00https://dev.oncoprescribe.com/fda-approves-alunbrig-for-first-line-treatment-of-alk-positive-non-small-cell-lung-cancer/2020-05-28T05:50:16-07:00https://dev.oncoprescribe.com/fda-approves-chemotherapy-free-first-line-immunotherapy-combination-in-advanced-nsclc/2020-05-20T21:05:26-07:00https://dev.oncoprescribe.com/fda-approves-rubraca-for-brca-mutated-metastatic-castrate-resistant-prostate-cancer/2020-05-27T21:47:07-07:00https://dev.oncoprescribe.com/lynparza-olaparib-7/2020-05-20T06:06:33-07:00https://dev.oncoprescribe.com/tecentriq-atezolizumab-7/2020-05-28T13:56:40-07:00https://dev.oncoprescribe.com/qinlock-ripretinib/2020-05-17T08:00:09-07:00https://dev.oncoprescribe.com/rubraca-rucaparib-3/2020-05-17T07:54:08-07:00https://dev.oncoprescribe.com/opvido-nivolumab-plus-yervoy-ipilimumab/2020-05-15T12:52:58-07:00https://dev.oncoprescribe.com/pomalyst-pomalidomide-2/2020-05-15T12:40:20-07:00https://dev.oncoprescribe.com/lynparza-olaparib-6/2020-05-15T12:34:05-07:00https://dev.oncoprescribe.com/retevmo-selpercatinib/2020-05-15T12:23:45-07:00https://dev.oncoprescribe.com/fda-approves-tabrecta-for-metastatic-non-small-cell-lung-cancer/2020-05-14T06:47:34-07:00https://dev.oncoprescribe.com/proton-based-chemoradiotherapy-significantly-decreases-toxicities-without-compromising-efficacy/2020-05-14T06:33:36-07:00https://dev.oncoprescribe.com/fda-approves-zejula-for-newly-diagnosed-patients-with-advanced-ovarian-cancer/2020-05-07T06:48:32-07:00https://dev.oncoprescribe.com/fda-approves-subcutaneous-darzalex-in-multiple-myeloma/2020-05-07T06:44:13-07:00https://dev.oncoprescribe.com/tabrecta-capmatinib/2020-05-06T20:29:37-07:00https://dev.oncoprescribe.com/darzalex-faspro-daratumumab-and-hyaluronidase-fihj/2020-05-06T20:26:33-07:00https://dev.oncoprescribe.com/zejula-niraparib-3/2020-05-06T20:22:33-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-23/2020-05-06T19:55:40-07:00https://dev.oncoprescribe.com/fda-approves-trodelvy-for-advanced-triple-negative-breast-cancer/2020-04-30T07:08:44-07:00https://dev.oncoprescribe.com/eliquis-may-be-safer-for-the-treatment-of-venous-thromboembolism-associated-with-cancer/2020-04-30T06:37:51-07:00https://dev.oncoprescribe.com/trodelvy-sacituzumab-govitecan-hziy/2020-04-25T15:42:16-07:00https://dev.oncoprescribe.com/imbruvica-imbruvica/2020-04-24T08:01:29-07:00https://dev.oncoprescribe.com/pemazyre-pemigatinib/2020-04-24T08:01:04-07:00https://dev.oncoprescribe.com/fda-approves-tukysa-for-her2-breast-cancer/2020-04-22T21:19:49-07:00https://dev.oncoprescribe.com/fda-approves-pemazyre-first-targeted-therapy-for-cholangiocarcinoma/2020-04-22T21:08:14-07:00https://dev.oncoprescribe.com/jelmyto-mitomycin/2020-04-20T09:56:27-07:00https://dev.oncoprescribe.com/tukysa-tucatinib/2020-04-20T08:38:59-07:00https://dev.oncoprescribe.com/fda-approves-braftovi-in-combination-with-erbitux-for-metastatic-colorectal-cancer/2020-04-16T20:03:33-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-for-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/2020-04-15T20:55:56-07:00https://dev.oncoprescribe.com/braftovi-encorafenib-and-erbitux-cetuximab/2020-04-15T20:27:43-07:00https://dev.oncoprescribe.com/reblozyl-luspatercept-aamt-2/2020-04-09T16:20:43-07:00https://dev.oncoprescribe.com/fda-approves-imfinzi-for-advanced-small-cell-lung-cancer-2/2020-04-09T08:15:59-07:00https://dev.oncoprescribe.com/fda-approves-reblozyl-for-patients-with-lower-risk-myelodysplastic-syndromes/2020-04-09T08:16:34-07:00https://dev.oncoprescribe.com/imfinzi-durvalumab-3/2020-04-15T19:53:11-07:00https://dev.oncoprescribe.com/opdivo-and-yervoy/2020-06-03T10:38:33-07:00https://dev.oncoprescribe.com/nerlynx-neratinib-2/2020-04-15T19:53:37-07:00https://dev.oncoprescribe.com/sarclisa-isatuximab-irfc/2020-04-09T16:03:07-07:00https://dev.oncoprescribe.com/tazverik-tazemetostat/2020-04-09T16:12:08-07:00https://dev.oncoprescribe.com/ayvakit-avapritinib/2020-04-09T15:59:16-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-22/2020-04-12T13:51:59-07:00https://dev.oncoprescribe.com/enhertu-highly-effective-in-heavily-pretreated-her2-positive-advanced-breast-cancer/2020-04-19T19:25:08-07:00https://dev.oncoprescribe.com/bone-targeting-radioisotope-xofigo-improves-overall-survival-in-crpc-patients-with-bone-metastases/2020-04-06T13:04:17-07:00https://dev.oncoprescribe.com/antibiotic-use-significantly-decreases-efficacy-of-checkpoint-inhibitors-in-patients-with-advanced-cancer/2020-04-06T13:03:43-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-yervoy-combination-for-advanced-hepatocellular-carcinoma/2020-04-06T13:02:53-07:00https://dev.oncoprescribe.com/fda-approves-sarclisa-for-relapsed-refractory-multiple-myeloma/2020-05-05T15:21:17-07:00https://dev.oncoprescribe.com/combination-of-mri-targeted-and-systematic-biopsy-increases-detection-of-clinically-significant-prostate-cancer/2020-04-06T13:00:53-07:00https://dev.oncoprescribe.com/fda-approves-ayvakit-a-precision-therapy-for-gastrointestinal-stromal-tumors/2020-04-06T13:00:21-07:00https://dev.oncoprescribe.com/adjuvant-therapy-with-low-dose-yervoy-improves-overall-survival-in-resected-high-risk-melanoma/2020-04-06T12:59:34-07:00https://dev.oncoprescribe.com/fda-approves-nerlynx-for-advanced-her2-positive-breast-cancer/2020-04-06T12:58:59-07:00https://dev.oncoprescribe.com/lonsurf-plus-avastin-combination-for-chemo-refractory-metastatic-colorectal-cancer/2020-04-06T12:58:17-07:00https://dev.oncoprescribe.com/neoadjuvant-keytruda-plus-chemotherapy-improves-pathological-complete-response-in-triple-negative-breast-cancer-2/2020-04-06T12:57:46-07:00https://dev.oncoprescribe.com/improved-quality-of-life-and-efficacy-with-braftovi-mektovi-and-erbitux-triplet-therapy-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer-2/2020-04-13T05:51:08-07:00https://dev.oncoprescribe.com/blood-based-screening-test-identifies-gastrointestinal-cancers/2020-04-06T15:50:59-07:00https://dev.oncoprescribe.com/biomarkers-may-predict-response-to-braf-and-mek-inhibitors-in-malignant-melanoma/2020-04-06T16:00:19-07:00https://dev.oncoprescribe.com/kisqali-plus-faslodex-improve-overall-survival-in-advanced-breast-cancer/2020-04-06T13:15:07-07:00https://dev.oncoprescribe.com/nelson-trial-confirms-that-low-dose-ct-screening-reduces-lung-cancer-mortality/2020-04-06T13:12:26-07:00https://dev.oncoprescribe.com/assessment-of-molecular-relapse-detection-in-early-stage-breast-cancer/2020-04-06T13:12:15-07:00https://dev.oncoprescribe.com/h-pylori-eradication-treatment-reduces-the-risk-of-gastric-cancer-in-high-risk-population/2020-04-06T13:13:03-07:00https://dev.oncoprescribe.com/multigene-testing-for-all-patients-with-breast-cancer-could-identify-many-more-mutation-carriers/2020-04-06T15:57:40-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2019-darzalex-kyprolis-and-dexamethasone-combination-improves-pfs-in-relapsed-or-refractory-multiple-myeloma-2/2020-05-05T15:23:40-07:00https://dev.oncoprescribe.com/lung-immune-prognostic-index-lipi-is-an-important-prognostic-biomarker-for-patients-with-advanced-non-small-cell-lung-cancer/2020-04-06T15:49:50-07:00https://dev.oncoprescribe.com/reblozyl-reduces-blood-transfusion-requirements-in-patients-with-lower-risk-myelodysplastic-syndromes/2020-04-06T13:14:02-07:00https://dev.oncoprescribe.com/neoadjuvant-keytruda-plus-chemotherapy-improves-pathological-complete-response-in-triple-negative-breast-cancer/2020-04-06T09:56:40-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2019-darzalex-kyprolis-and-dexamethasone-combination-improves-pfs-in-relapsed-or-refractory-multiple-myeloma/2020-04-06T09:52:54-07:00https://dev.oncoprescribe.com/dermatologic-toxicities-of-cancer-treatment/2020-04-04T22:16:56-07:00https://dev.oncoprescribe.com/chemotherapy-induced-anemia/2020-04-04T22:16:25-07:00https://dev.oncoprescribe.com/myeloid-growth-factors/2020-09-14T15:53:24-07:00https://dev.oncoprescribe.com/pain-management/2020-04-04T22:14:51-07:00https://dev.oncoprescribe.com/chemotherapy-induced-nausea-and-vomiting-cinv/2020-09-14T15:52:35-07:00https://dev.oncoprescribe.com/prose-randomized-proteomic-stratified-phase-iii-study-of-second-line-erlotinib-versus-chemotherapy-in-patients-with-inoperable-non-small-cell-lung-cancer-nsclc/2020-04-05T19:05:45-07:00https://dev.oncoprescribe.com/ttp-hus-and-ahus-different-diseases-different-treatments/2020-05-24T08:35:13-07:00https://dev.oncoprescribe.com/mucositis/2020-09-14T15:52:58-07:00https://dev.oncoprescribe.com/medication-related-osteonecrosis-of-the-jaw-mascc-isoo-asco-clinical-practice-guideline-summary/2020-01-19T14:54:24-07:00https://dev.oncoprescribe.com/cdk4-6-inhibitors-may-replace-chemotherapy-in-hr-positive-her2-negative-metastatic-breast-cancer/2020-01-19T14:52:37-07:00https://dev.oncoprescribe.com/circulating-tumor-dna-in-the-peripheral-blood-predicts-recurrence-risk-after-surgery-and-adjuvant-chemotherapy-in-stage-iii-colon-cancer/2020-04-04T20:36:54-07:00https://dev.oncoprescribe.com/association-between-pseudoprogression-and-outcomes-in-men-with-metastatic-castration-resistant-prostate-cancer-treated-with-xtandi/2020-01-19T14:43:10-07:00https://dev.oncoprescribe.com/idhifa-plus-vidaza-significantly-improves-complete-remission-and-overall-response-in-newly-diagnosed-idh2-mutated-aml/2020-04-06T09:30:13-07:00https://dev.oncoprescribe.com/FDA-Approves-LYNPARZA-for-Germline-BRCA-Mutated-Metastatic-Pancreatic-Adenocarcinoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/lynparza-olaparib-2/2020-04-04T18:18:46-07:00https://dev.oncoprescribe.com/enhertu-fam-trastuzumab-deruxtecan-nxki/2020-04-05T10:17:21-07:00https://dev.oncoprescribe.com/padcev-enfortumab-vedotin-ejfv/2020-04-12T13:44:33-07:00https://dev.oncoprescribe.com/xtandi-enzalutamide-2/2020-04-05T10:18:05-07:00https://dev.oncoprescribe.com/tecentriq-atezolizumab-2/2020-04-05T10:18:34-07:00https://dev.oncoprescribe.com/fda-approves-enhertu-for-advanced-her2-positive-breast-cancer/2020-04-04T12:23:45-07:00https://dev.oncoprescribe.com/fda-grants-accelerated-approval-to-padcev-for-metastatic-urothelial-cancer/2020-04-06T09:29:39-07:00https://dev.oncoprescribe.com/darzalex-combination-improves-overall-survival-in-transplant-ineligible-myeloma-patients/2020-04-06T08:53:41-07:00https://dev.oncoprescribe.com/long-term-breast-cancer-preventive-benefit-with-arimidex/2020-04-04T12:22:09-07:00https://dev.oncoprescribe.com/Supplemental-MRI-Screening-for-Women-with-Extremely-Dense-Breast-Tissue/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/fda-approves-frontline-tecentriq-with-carboplatin-and-nab-paclitaxel-for-metastatic-non-squamous-nsclc/2020-04-04T21:30:45-07:00https://dev.oncoprescribe.com/Overall-Survival-Benefit-with-ONIVYDE-and-Characteristics-of-Long-Term-Survivors-in-Metastatic-Pancreatic-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Isatuximab-Combination-Significantly-Improves-Progression-Free-Survival-in-Relapsed/Refractory-Myeloma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/reblozyl-luspatercept-aamt/2020-05-04T10:07:28-07:00https://dev.oncoprescribe.com/brukinsa-zanubrutinib/2020-04-05T10:21:13-07:00https://dev.oncoprescribe.com/adakveo-crizanlizumab-tmca/2020-04-05T10:21:40-07:00https://dev.oncoprescribe.com/givlaari-givosiran/2020-05-04T10:09:20-07:00https://dev.oncoprescribe.com/calquence-acalabrutinib-2/2020-04-05T10:22:56-07:00https://dev.oncoprescribe.com/oxbryta-voxelotor/2020-04-05T10:23:34-07:00https://dev.oncoprescribe.com/FDA-Approves-CALQUENCE-for-Chronic-Lymphocytic-Leukemia/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/first-line-combination-of-tecentriq-and-avastin-improves-survival-in-hepatocellular-carcinoma/2020-04-04T21:45:48-07:00https://dev.oncoprescribe.com/Higher-Levels-of-IGF-1-and-Free-Testosterone-Increase-the-Risk-of-Prostate-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/fda-approves-adakveo-a-new-targeted-therapy-for-sickle-cell-disease/2020-04-04T20:31:35-07:00https://dev.oncoprescribe.com/late-breaking-abstract-astro-2019-detectable-hpv-circulating-tumor-dna-in-post-operative-oropharyngeal-squamous-cell-carcinoma-patients-is-associated-with-progression/2020-04-07T07:12:56-07:00https://dev.oncoprescribe.com/Early-Adjuvant-Chemotherapy-Dose-Reductions-Can-Impact-Breast-Cancer-Survival/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2019-opdivo-improves-overall-survival-in-advanced-esophageal-cancer-regardless-of-pd-l1-expression/2020-04-06T09:25:12-07:00https://dev.oncoprescribe.com/Single-Agent-XOSPATA-for-FLT3-Mutated-AML/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/zejula-niraparib-2/2020-04-05T10:23:57-07:00https://dev.oncoprescribe.com/darzalex-daratumumab-2/2020-04-05T11:09:13-07:00https://dev.oncoprescribe.com/NCCN-updates-Colorectal-Cancer-Testing-and-Treatment-Guidelines/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2019-first-line-treatment-with-tagrisso-improves-overall-survival-in-egfr-positive-nsclc/2020-04-06T09:24:41-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2019-verzenio-plus-faslodex-combination-improves-overall-survival-in-hr-advanced-breast-cancer/2020-04-06T09:23:06-07:00https://dev.oncoprescribe.com/tecentriq-in-combination-with-chemotherapy-improves-overall-survival-in-extensive-stage-small-cell-lung-cancer-2/2020-04-06T09:24:05-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2019-chemotherapy-free-first-line-immunotherapy-combination-improves-overall-survival-in-advanced-nsclc/2020-04-06T09:21:12-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2019-ripretinib-shows-dramatic-improvement-in-pfs-in-heavily-pretreated-gist-patients/2020-04-06T09:22:23-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2019-tibsovo-improves-survival-in-idh1-mutated-advanced-cholangiocarcinoma/2020-04-06T09:19:40-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2019-targeted-therapy-with-lynparza-delays-progression-of-advanced-prostate-cancer/2020-04-06T09:20:34-07:00https://dev.oncoprescribe.com/primary-breast-tumor-surgery-improves-overall-survival-in-her2-positive-advanced-breast-cancer/2020-04-06T09:18:51-07:00https://dev.oncoprescribe.com/Duration-of-Oxaliplatin-Containing-Adjuvant-Therapy-for-Stage-III-Colon-Cancer-ASCO-Clinical-Practice-Guideline/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/clinical-utility-of-netest-a-liquid-biopsy-assay-for-diagnosis-monitoring-therapy-and-prognosis-in-patients-with-neuroendocrine-tumors/2020-04-04T20:34:06-07:00https://dev.oncoprescribe.com/updated-analysis-keytruda-doubles-overall-survival-compared-with-chemotherapy-in-advanced-nsclc/2020-04-04T21:33:53-07:00https://dev.oncoprescribe.com/erleada-apalutamide-2/2020-04-05T11:10:10-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-and-lenvima-lenvatinib/2020-04-05T11:12:48-07:00https://dev.oncoprescribe.com/antibiotic-treatment-prior-to-immune-checkpoint-inhibitor-therapy-has-a-detrimental-effect-on-response-rates-and-overall-survival/2020-04-04T21:17:30-07:00https://dev.oncoprescribe.com/Maintenance-LYNPARZA-Improves-Progression-Free-Survival-in-BRCA-Mutated-Metastatic-Pancreatic-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/SBRT-Superior-to-Standard-Radiotherapy-in-Stage-I-Non-Small-Cell-Lung-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/liquid-biopsy-dna-methylation-assay-highly-specific-for-cancer-detection-and-prognosis/2020-04-06T09:18:07-07:00https://dev.oncoprescribe.com/IMBRUVICA-and-RITUXAN-Combination-Superior-to-FCR-in-Patients-with-CLL/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/KISQALI-Improves-Overall-Survival-in-Advanced-Breast-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-INREBIC-for-Myelofibrosis/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/US-Preventive-Services-Task-Force-Recommendations-on-BRCA-Mutation-Testing/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/dramatic-increase-in-colorectal-cancer-incidence-among-young-adults/2019-12-28T14:14:32-07:00https://dev.oncoprescribe.com/fda-approves-rozlytrek-for-ntrk-positive-tumors-and-ros1-positive-non-small-cell-lung-cancer/2020-05-04T10:11:54-07:00https://dev.oncoprescribe.com/Periprocedural-Bridging-Increases-Bleeding-Risk-without-Reduction-in-VTE-Rates-for-Patients-on-Long-Term-Anticoagulants/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/inrebic-fedratinib/2020-04-05T11:13:21-07:00https://dev.oncoprescribe.com/rozlytrek-entrectinib-2/2020-04-05T11:13:49-07:00https://dev.oncoprescribe.com/rozlytrek-entrectinib/2020-05-04T10:13:33-07:00https://dev.oncoprescribe.com/turalio-pexidartinib/2020-05-04T10:14:38-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-2/2020-04-05T11:16:19-07:00https://dev.oncoprescribe.com/nubeqa-darolutamide/2020-04-05T11:16:46-07:00https://dev.oncoprescribe.com/Telomerase-Inhibitor-Imetelstat-Provides-Durable-Transfusion-Independence-in-Myelodysplastic-Syndrome/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Adjuvant-Treatment-with-PROLIA-Improves-Disease-Free-Survival-in-Early-Stage-Breast-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Association-between-Androgen-Deprivation-Therapy-and-Diagnosis-of-Alzheimer-Disease-or-Dementia-in-Patients-with-Prostate-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/anticonvulsant-prophylaxis-and-steroid-use-in-adults-with-metastatic-brain-tumors-asco-and-sno-endorsement-of-the-congress-of-neurological-surgeons-guidelines/2020-05-04T10:18:09-07:00https://dev.oncoprescribe.com/survival-benefit-with-keytruda-after-locally-ablative-therapy-lat-for-oligometastatic-nsclc/2020-04-04T21:34:51-07:00https://dev.oncoprescribe.com/asco-ash-update-on-erythropoiesis-stimulating-agents-for-cancer-associated-anemia/2020-05-04T10:19:52-07:00https://dev.oncoprescribe.com/Dramatic-Increase-in-ColoRectal-Cancer-Incidence-among-Young-Adults/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/platelet-antibody-testing-in-patients-with-itp/2021-01-12T13:26:00-07:00https://dev.oncoprescribe.com/vitiligo-associated-with-reduced-risk-of-internal-malignancies/2020-05-04T10:20:53-07:00https://dev.oncoprescribe.com/clinical-and-genomic-risk-to-guide-the-use-of-adjuvant-therapy-for-breast-cancer/2020-04-04T20:42:32-07:00https://dev.oncoprescribe.com/Darolutamide-in-Nonmetastatic-Castration-Resistant-Prostate-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Low-Provider-Knowledge-Associated-with-Less-Lung-Cancer-Screening/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/prognostic-value-of-progesterone-receptor-in-estrogen-receptorae%c2%90positive-herae%c2%902-negative-breast-cancer/2020-04-27T19:48:25-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-for-advanced-small-cell-lung-cancer/2020-04-04T21:44:22-07:00https://dev.oncoprescribe.com/xpovio-selinexor/2020-04-05T11:17:11-07:00https://dev.oncoprescribe.com/darzalex-daratumumab-3/2020-04-05T11:18:22-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-3/2020-04-05T11:19:49-07:00https://dev.oncoprescribe.com/braftovi-mektovi-and-erbitux-triplet-therapy-for-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer/2020-04-04T20:35:38-07:00https://dev.oncoprescribe.com/Anti-BCMA-CAR-T-Cell-Therapy-in-Relapsed-or-Refractory-Multiple-Myeloma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-Antibody-Drug-Conjugate-POLIVY-for-Diffuse-Large-B-Cell-Lymphoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2019-front-line-keytruda-monotherapy-for-patients-with-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma/2020-04-06T09:16:23-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2019-xtandi-improves-overall-survival-in-metastatic-hormone-sensitive-prostate-cancer/2020-04-06T09:15:28-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-4/2020-05-04T10:46:48-07:00https://dev.oncoprescribe.com/five-year-outcomes-with-tafinlar-plus-mekinist-in-metastatic-melanoma/2020-04-04T20:38:27-07:00https://dev.oncoprescribe.com/polivy-polatuzumab-vedotin-piiq/2020-04-05T11:20:51-07:00https://dev.oncoprescribe.com/xospata-gilteritinib-2/2020-04-05T11:21:13-07:00https://dev.oncoprescribe.com/REVLIMID-plus-RITUXAN-R2-Significantly-Improves-Progression-Free-Survival-in-Relapsed-or-Refractory-Indolent-Lymphoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2019-five-year-survival-data-for-keytruda-in-advanced-nsclc/2020-04-06T09:14:54-07:00https://dev.oncoprescribe.com/fda-approves-first-pi3k-inhibitor-piqray-for-breast-cancer/2020-04-04T20:41:06-07:00https://dev.oncoprescribe.com/fda-approves-jakafi-for-acute-gvhd/2020-05-04T10:48:40-07:00https://dev.oncoprescribe.com/revlimid-lenalidomide-2/2020-04-05T14:12:13-07:00https://dev.oncoprescribe.com/piqray-alpelisib/2020-04-05T14:13:00-07:00https://dev.oncoprescribe.com/jakafi-ruxolitinib-2/2020-05-04T10:52:21-07:00https://dev.oncoprescribe.com/FDA-Approves-Fixed-Duration-VENCLEXTA-for-Frontline-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/eliquis-for-thromboprophylaxis-in-ambulatory-patients-with-cancer/2020-04-27T20:55:44-07:00https://dev.oncoprescribe.com/fragmin-dalteparin-sodium/2020-04-05T14:15:41-07:00https://dev.oncoprescribe.com/venclexta-venetoclax-2/2020-04-05T14:15:52-07:00https://dev.oncoprescribe.com/bavencio-and-inlyta/2020-04-05T14:17:48-07:00https://dev.oncoprescribe.com/cyramza-ramucirumab-2/2020-04-05T14:18:18-07:00https://dev.oncoprescribe.com/Concomitant-Use-of-Direct-Oral-Anticoagulants-with-Antiplatelet-Agents-Associated-with-Lower-Risk-of-Major-Bleeding-Compared-with-Concomitant-Warfarin-and-Antiplatelet-Agents/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-KADCYLA-for-Early-Breast-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/kadcyla-ado-trastuzumab-emtansine-the-fda-on-may-3-2019-approved-kadcyla-for-the-adjuvant-treatment-of-patients-with-her2-positive-early-breast-cancer-ebc-who-have-residual-invasive/2020-04-07T19:46:48-07:00https://dev.oncoprescribe.com/FDA-Approves-TIBSOVO-for-Newly-Diagnosed-AML-Patients-Ineligible-for-Intensive-Chemotherapy/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Six-Prognostic-Factors-That-Predict-Invasive-Breast-Cancer-Recurrence-after-DCIS/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/tibsovo-ivosidenib-2/2020-04-05T14:20:07-07:00https://dev.oncoprescribe.com/IMBRUVICA-plus-GAZYVA-is-a-Safe-and-Effective-Alternative-First-Line-Treatment-Option-for-CLL-Patients-with-Comorbidities-and-High-Risk-Disease/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/keytruda-versus-chemotherapy-as-second-line-treatment-for-advanced-esophageal-cancer/2020-04-06T09:14:19-07:00https://dev.oncoprescribe.com/high-body-fat-level-increases-breast-cancer-risk-in-postmenopausal-women-with-normal-bmi/2019-04-30T15:13:40-07:00https://dev.oncoprescribe.com/High-Body-Fat-Level-Increases-Breast-Cancer-Risk-in-Postmenopausal-Women-with-Normal-BMI/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Androgen-Suppression-for-18-Months-plus-Radiotherapy-is-an-Effective-Treatment-Option-for-Locally-Advanced-Intermediate-and-High-Risk-Prostate-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/keytruda-and-inlyta/2020-04-05T14:20:12-07:00https://dev.oncoprescribe.com/fda-lowers-pd-l1-expression-threshold-for-keytruda-and-expands-indication-for-frontline-treatment-of-nsclc/2020-04-04T21:37:18-07:00https://dev.oncoprescribe.com/FDA-Approves-BALVERSA-for-Metastatic-Urothelial-Carcinoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/balversa-erdafitinib/2020-04-05T14:20:25-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-5/2020-04-05T14:24:17-07:00https://dev.oncoprescribe.com/2019-nccn-pancreatic-cancer-guideline-update-draw-attention-to-germline-testing-and-molecular-profiling/2020-04-06T09:12:05-07:00https://dev.oncoprescribe.com/aacr-late-breaking-research-predicting-response-to-anti-pd1-pdl1-therapy-beyond-tumor-mutational-burden/2020-04-06T09:13:31-07:00https://dev.oncoprescribe.com/fda-approves-tecentriq-and-abraxane-combination-for-advanced-triple-negative-breast-cancer/2020-05-04T10:57:12-07:00https://dev.oncoprescribe.com/immune-checkpoint-inhibitor-combination-efficacious-in-high-grade-neuroendocrine-tumors/2020-04-06T09:11:12-07:00https://dev.oncoprescribe.com/nccn-establishes-tki-discontinuation-criteria-in-updated-cml-guideline/2020-04-06T09:10:39-07:00https://dev.oncoprescribe.com/AR-V7-in-the-Peripheral-Blood-Liquid-Biopsy-Can-Guide-Treatment-in-Castrate-Resistant-Prostate-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Substantial-Benefit-with-Maintenance-LYNPARZA-in-Patients-with-Newly-Diagnosed-Advanced-Ovarian-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/liquid-biopsy-accurate-reliable-and-rapid-in-identifying-biomarker-mutations-in-newly-diagnosed-advanced-lung-cancer/2020-04-06T09:00:39-07:00https://dev.oncoprescribe.com/tecentriq-atezolizumab-3/2020-04-05T14:29:34-07:00https://dev.oncoprescribe.com/fda-approves-tecentriq-and-abraxane-combination-for-advanced-triple-negative-breast-cancer-2/2020-04-04T21:22:04-07:00https://dev.oncoprescribe.com/Metastatic-Pancreatic-Cancer-ASCO-Clinical-Practice-Guideline-Update/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/tecentriq-atezolizumab-4/2020-04-05T14:30:05-07:00https://dev.oncoprescribe.com/herceptin-hylecta-trastuzumab-and-hyaluronidase-oysk/2020-04-05T14:30:42-07:00https://dev.oncoprescribe.com/lonsurf-trifluridine-tipiracil/2020-04-05T14:31:48-07:00https://dev.oncoprescribe.com/adjuvant-kadcyla-superior-to-herceptin-in-high-risk-her2-positive-breast-cancer-2/2020-04-06T08:53:00-07:00https://dev.oncoprescribe.com/FDA-Approves-Single-Agent-XOSPATA-for-FLT3-Positive-Acute-Myeloid-Leukemia/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/aspirin-lowers-risk-for-ovarian-and-hepatocellular-carcinoma/2020-05-04T11:00:28-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-for-adjuvant-treatment-of-melanoma/2020-04-04T21:25:02-07:00https://dev.oncoprescribe.com/increased-risk-of-breast-cancer-after-recent-childbirth/2019-02-23T13:07:24-07:00https://dev.oncoprescribe.com/Increased-Risk-of-Breast-Cancer-after-Recent-Childbirth/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2018-new-simplified-practice-changing-protocol-for-interrupting-direct-oral-anticoagulants-for-surgery-procedure/2020-04-06T08:59:56-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-6/2020-04-05T14:32:01-07:00https://dev.oncoprescribe.com/FDA-Approves-CABLIVI-for-Thrombotic-Thrombocytopenic-Purpura/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Late-Breaking-Abstract-ESMO-2018-Radiation-Therapy-to-the-Primary-Tumor-Improves-Overall-Survival-in-a-Subgroup-of-Metastatic-Prostate-Cancer-Patients/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/cablivi-caplacizumab-yhdp/2020-04-05T14:33:13-07:00https://dev.oncoprescribe.com/maintenance-therapy-with-ninlaro-extends-progression-free-survival-in-multiple-myeloma/2020-04-06T08:59:16-07:00https://dev.oncoprescribe.com/antimicrobial-prophylaxis-for-adult-patients-with-cancer-related-immunosuppression-asco-and-idsa-clinical-practice-guideline-update/2020-05-04T11:01:58-07:00https://dev.oncoprescribe.com/Late-Breaking-Abstract-ESMO-2018-Treatment-with-a-Combination-of-XOFIGO-and-ZYTIGA-NOT-Recommended-in-Metastatic-Prostate-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Late-Breaking-Abstract-ESMO-2018-LONSURF-Improves-Overall-Survival-in-Heavily-Pretreated-Gastric-and-GE-Junction-Cancers/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-CABOMETYX-for-Hepatocellular-Carcinoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Radical-Prostatectomy-Lowers-the-Risk-of-Death-in-Clinically-Detected-Localized-Prostate-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/ontruzant-trastuzumab-dttb/2020-05-04T11:05:36-07:00https://dev.oncoprescribe.com/cabometyx-cabozantinib-2/2020-04-05T14:33:25-07:00https://dev.oncoprescribe.com/771-2/2020-05-02T17:14:54-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2018-frontline-keytruda-improves-overall-survival-in-advanced-head-and-neck-cancer/2020-05-02T13:42:26-07:00https://dev.oncoprescribe.com/ash-2018-four-cycles-of-chemotherapy-equally-effective-as-six-cycles-in-diffuse-large-b-cell-lymphoma/2020-04-06T08:58:09-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2018-first-line-bavencio-plus-inlyta-highly-effective-in-advanced-renal-cell-carcinoma/2020-04-04T21:57:20-07:00https://dev.oncoprescribe.com/Late-Breaking-Abstract-ESMO-2018-Targeting-PIK3CA-Mutations-Improves-Outcomes-in-Advanced-Breast-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2018-imbruvica-and-rituxan-combination-superior-to-fcr-in-younger-patients-with-cll/2020-04-06T08:57:19-07:00https://dev.oncoprescribe.com/STIVARGA-Dose-Optimization-Improves-Outcomes-in-Patients-with-Metastatic-Colorectal-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Baseline-Corticosteroid-Use-at-Start-of-PD-1/PD-L1-Inhibitor-Therapy-Negatively-Affects-Outcomes-in-NSCLC/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/radiotherapy-plus-erbitux-inferior-to-radiotherapy-plus-cisplatin-in-hpv-positive-oropharyngeal-squamous-cell-carcinoma/2020-05-04T11:08:20-07:00https://dev.oncoprescribe.com/elzonris-tagraxofusp-erzs/2020-05-04T11:15:12-07:00https://dev.oncoprescribe.com/ultomiris-ravulizumab-cwvz/2020-04-05T14:34:14-07:00https://dev.oncoprescribe.com/asparlas-calaspargase-pegol-mknl/2020-04-05T14:34:32-07:00https://dev.oncoprescribe.com/lynparza-olaparib-3/2020-04-05T14:35:15-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-7/2020-04-05T14:35:21-07:00https://dev.oncoprescribe.com/HERZUMA-Trastuzumab-pkrb/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/nplate-romiplostim/2020-04-05T14:35:55-07:00https://dev.oncoprescribe.com/tecentriq-atezolizumab-5/2020-04-05T14:36:18-07:00https://dev.oncoprescribe.com/Late-Breaking-Abstract-ASH-2018-Frontline-DARZALEX-with-REVLIMID-and-Dexamethasone-A-New-Standard-for-Transplant-Ineligible-Myeloma-Patients/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/axillary-radiotherapy-is-an-alternative-to-complete-lymph-node-dissection-in-early-stage-breast-cancer/2020-04-06T08:56:30-07:00https://dev.oncoprescribe.com/Adjuvant-KADCYLA-Superior-to-HERCEPTIN-in-High-Risk-HER2-Positive-Breast-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/TECENTRIQ-in-Combination-with-Chemotherapy-Improves-Overall-Survival-in-Extensive-Stage-Small-Cell-Lung-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/fda-approves-vitrakvi-a-novel-tumor-agnostic-therapy-for-trk-fusion-positive-cancers/2020-05-04T11:26:55-07:00https://dev.oncoprescribe.com/luspatercept-reduces-blood-transfusion-requirements-in-mds-and-beta-thalassemia/2020-04-06T08:52:15-07:00https://dev.oncoprescribe.com/FDA-Approves-VENCLEXTA-for-Elderly-Patients-with-AML/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/The-International-Association-for-the-Study-of-Lung-Cancer-Issues-Statement-on-Lung-Cancer-Screening-CALL-TO-ACTION/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/xospata-gilteritinib/2020-04-05T14:36:23-07:00https://dev.oncoprescribe.com/truxima-rituximab-abbs/2020-04-05T14:36:30-07:00https://dev.oncoprescribe.com/vitrakvi-larotrectinib/2020-05-04T11:28:22-07:00https://dev.oncoprescribe.com/venclexta-venetoclax-3/2020-04-05T14:37:01-07:00https://dev.oncoprescribe.com/daurismo-glasdegib/2020-04-05T14:37:05-07:00https://dev.oncoprescribe.com/gamifant-emapalumab/2020-05-04T11:29:36-07:00https://dev.oncoprescribe.com/adcetris-brentuximab-vedotin-2/2020-04-05T15:27:48-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-8/2020-04-05T15:27:56-07:00https://dev.oncoprescribe.com/lorbrena-lorlatinib/2020-04-05T15:28:02-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-9/2020-04-05T15:28:07-07:00https://dev.oncoprescribe.com/talzenna-talazoparib/2020-04-05T15:30:12-07:00https://dev.oncoprescribe.com/testing-for-brca1-and-brca2-mutations-may-not-be-adequate-in-breast-cancer-patients/2020-05-20T13:36:37-07:00https://dev.oncoprescribe.com/radioactive-iodine-increases-risk-of-myeloid-malignancies-in-patients-with-thyroid-cancer/2020-05-02T13:25:17-07:00https://dev.oncoprescribe.com/FDA-Approves-EMPLICITI-Combination-for-Relapsed-Refractory-Multiple-Myeloma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/ASCO-Endorses-Complementary-Therapy-Guidelines-for-Breast-Cancer-Patients/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Circulating-Tumor-DNA-Liquid-Biopsy-Can-Predict-Outcomes-in-Diffuse-Large-B-Cell-Lymphoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/BRAF-V600E-Mutation-is-a-Very-Poor-Prognostic-Factor-in-Metastatic-Colorectal-Carcinoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/imfinzi-after-chemoradiotherapy-significantly-improves-overall-survival-in-stage-iii-nsclc/2019-04-30T15:10:49-07:00https://dev.oncoprescribe.com/survival-benefit-significantly-more-in-north-america-with-frontline-adcetris-chemotherapy-combination-in-advanced-classical-hodgkin-lymphoma/2020-04-06T08:47:48-07:00https://dev.oncoprescribe.com/IMFINZI-after-Chemoradiotherapy-Significantly-Improves-Overall-Survival-in-Stage-III-NSCLC/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/First-line-treatment-with-KEYTRUDA-and-INLYTA-Combination-Significantly-Improves-Survival-in-advanced-Renal-Cell-Carcinoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/TECENTRIQ-and-ABRAXANE-Significantly-Prolonged-Survival-in-Advanced-Triple-Negative-Breast-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Evaluation-of-Urine-May-Aid-in-the-Diagnosis-of-Lambda-Light-Chain-Myeloma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/First-Line-KEYTRUDA-plus-Chemotherapy-Improves-Overall-Survival-in-Advanced-Squamous-NSCLC/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-COPIKTRA-for-Chronic-Lymphocytic-Leukemia-and-Follicular-Lymphoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Selection-of-Optimal-Adjuvant-Chemotherapy-and-Targeted-Therapy-for-Early-Breast-Cancer-ASCO-Clinical-Practice-Guideline-Focused-Update/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/microrna-31-3p-expression-is-a-predictive-biomarker-of-anti-egfr-efficacy-in-patients-with-ras-wild-type-metastatic-colorectal-cancer/2018-10-09T06:03:27-07:00https://dev.oncoprescribe.com/Immunotherapy-Effective-for-Melanoma-Metastatic-to-the-Brain/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/MicroRNA-31-3p-Expression-is-a-Predictive-Biomarker-of-Anti-EGFR-Efficacy-in-Patients-with-RAS-Wild-type-Metastatic-Colorectal-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/hemlibra-emicizumab-kxwh/2020-04-05T15:30:17-07:00https://dev.oncoprescribe.com/libtayo-cemiplimab-rwlc/2020-04-05T15:30:22-07:00https://dev.oncoprescribe.com/her2-testing-in-breast-cancer-american-society-of-clinical-oncology-college-of-american-pathologists-clinical-practice-guideline-focused-update/2020-05-24T08:32:05-07:00https://dev.oncoprescribe.com/dual-inhibition-improves-outcomes-for-patients-with-braf-mutated-colorectal-tumors-2/2023-09-17T14:42:18-07:00https://dev.oncoprescribe.com/vizimpro-dacomitinib/2020-04-05T15:30:29-07:00https://dev.oncoprescribe.com/copiktra-duvelisib-2/2020-04-05T15:30:33-07:00https://dev.oncoprescribe.com/copiktra-duvelisib/2020-04-05T15:30:38-07:00https://dev.oncoprescribe.com/XARELTO-in-Cancer-Patients-Associated-with-Fewer-Episodes-of-VTE-Compared-with-FRAGMIN-but-Increase-in-Nonmajor-Bleeding/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Hyperprogressive-Disease-after-Immunotherapy-in-Advanced-Non-Small-Cell-Lung-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Smoking-Associated-with-Increased-Risk-of-Recurrence-and-Mortality-among-Prostate-Cancer-Patients-after-Curative-Therapy/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-for-cervical-cancer/2020-04-06T08:47:14-07:00https://dev.oncoprescribe.com/american-cancer-society-updates-colorectal-cancer-screening-guideline-for-average-risk-adults/2018-09-17T20:35:11-07:00https://dev.oncoprescribe.com/lumoxiti-moxetumomab-pasudotox-tdfk/2020-04-05T15:31:07-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-10/2020-04-05T15:31:11-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-and-tecentriq-atezolizumab/2020-04-05T15:31:16-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-2/2020-04-05T15:31:22-07:00https://dev.oncoprescribe.com/lenvima-lenvatinib-2/2020-04-05T15:31:28-07:00https://dev.oncoprescribe.com/poteligeo-mogamulizumab-kpkc/2020-04-05T15:31:32-07:00https://dev.oncoprescribe.com/mulpleta-lusutrombopag/2020-05-04T11:45:46-07:00https://dev.oncoprescribe.com/azedra-iobenguane-i131/2020-04-05T15:32:05-07:00https://dev.oncoprescribe.com/Role-of-Bone-Modifying-Agents-in-Multiple-Myeloma-American-Society-of-Clinical-Oncology-Clinical-Practice-Guideline-Update/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/HER2-Testing-in-Breast-Cancer-American-Society-of-Clinical-Oncology/College-of-American-Pathologists-Clinical-Practice-Guideline-Focused-Update/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/A-Completely-Oral-Chemotherapy-Free-Regimen-for-Acute-Promyelocytic-Leukemia/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/chronic-diseases-associated-with-increased-cancer-risk/2020-05-04T11:47:18-07:00https://dev.oncoprescribe.com/kisqali-plus-faslodex-improve-progression-free-survival-in-advanced-breast-cancer/2020-04-06T08:45:56-07:00https://dev.oncoprescribe.com/FDA-Approves-DOPTELET-for-Thrombocytopenia-in-Chronic-Liver-Disease/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-OPDIVO-for-Metastatic-Small-Cell-Lung-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-LENVIMA-for-Unresectable-Hepatocellular-Carcinoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Tumor-Mutation-Burden-is-a-Predictive-Biomarker-for-Response-to-Immune-Checkpoint-Inhibitors/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/American-Cancer-Society-Updates-Colorectal-Cancer-Screening-Guideline-for-Average-Risk-Adults/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2018-broad-range-of-msi-h-tumors-linked-with-lynch-syndrome/2020-04-06T08:44:59-07:00https://dev.oncoprescribe.com/pomalyst-combination-significantly-improves-progression-free-survival-in-relapsed-refractory-myeloma/2020-04-06T08:45:26-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2018-chemoprevention-of-esophageal-cancer-with-nexium-and-aspirin/2020-04-06T08:40:52-07:00https://dev.oncoprescribe.com/AR-V7-in-Circulating-Tumor-Cells-Liquid-Biopsy-Can-Guide-Treatment-in-Castrate-Resistant-Prostate-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/first-line-tecentriq-plus-chemotherapy-in-advanced-squamous-nsclc/2018-07-30T05:55:55-07:00https://dev.oncoprescribe.com/FDA-Approves-TIBSOVO-for-Patients-with-Relapsed-or-Refractory-Acute-Myeloid-Leukemia/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/six-months-adjuvant-herceptin-safer-and-efficacious-in-early-stage-her2-breast-cancer/2020-04-06T08:40:21-07:00https://dev.oncoprescribe.com/kisqali-ribociclib-2/2020-04-05T15:32:09-07:00https://dev.oncoprescribe.com/tibsovo-ivosidenib/2020-04-05T15:32:36-07:00https://dev.oncoprescribe.com/xtandi-enzalutamide-3/2020-04-05T15:32:42-07:00https://dev.oncoprescribe.com/yervoy-and-opdivo/2020-04-05T15:32:46-07:00https://dev.oncoprescribe.com/Updated-Chronic-Lymphocytic-Leukemia-Guidelines/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-OPDIVO-and-YERVOY-Combination-for-Metastatic-Colorectal-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2018-blood-test-demonstrates-high-specificity-for-detection-of-early-stage-lung-cancer/2020-04-06T08:39:26-07:00https://dev.oncoprescribe.com/Optimizing-Anticancer-Therapy-in-Metastatic-Non-Castrate-Prostate-Cancer-ASCO-Clinical-Practice-Guideline/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2018-first-line-tecentriq-plus-chemotherapy-in-advanced-squamous-nsclc/2020-04-06T08:37:12-07:00https://dev.oncoprescribe.com/revlimid-plus-rituxan-a-potential-chemo-free-frontline-therapy-for-follicular-lymphoma/2020-04-06T08:38:14-07:00https://dev.oncoprescribe.com/Higher-Plasma-Vitamin-D-Levels-Associated-with-Lower-Colorectal-Cancer-Risk/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-DARZALEX-/VMP-Combination-for-Newly-Diagnosed-Multiple-Myeloma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/braftovi-encorafenib-and-mektovi-binimetinib/2020-04-05T15:32:55-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-11/2020-04-05T15:33:13-07:00https://dev.oncoprescribe.com/avastin-bevacizumab-2/2020-04-05T15:33:23-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-12/2020-04-05T15:33:27-07:00https://dev.oncoprescribe.com/venclexta-venetoclax-4/2020-04-05T15:34:06-07:00https://dev.oncoprescribe.com/mircera-methoxy-polyethylene-glycol-epoetin-beta/2020-05-04T11:48:55-07:00https://dev.oncoprescribe.com/fulphila-pegfilgrastim-jmdb/2020-05-04T11:49:47-07:00https://dev.oncoprescribe.com/doptelet-avatrombopag/2020-05-04T11:50:56-07:00https://dev.oncoprescribe.com/retacrit-epoetin-alfa-epbx/2020-04-05T15:34:30-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2018-first-line-keytruda-superior-to-chemotherapy-in-nsclc/2020-04-06T08:35:41-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2018-mfolfirinox-regimen-significantly-improves-overall-survival-in-resected-pancreatic-cancer/2020-04-06T08:36:37-07:00https://dev.oncoprescribe.com/FDA-Approves-BCL2-Inhibitor-VENCLEXTA-for-Chronic-Lymphocytic-Leukemia/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2018-endocrine-therapy-alone-is-adequate-for-early-stage-breast-cancer-patients-with-intermediate-risk-recurrence-score/2020-04-06T08:34:30-07:00https://dev.oncoprescribe.com/mri-targeted-biopsy-superior-to-standard-trus-guided-biopsy-for-prostate-cancer-diagnosis/2018-06-12T04:31:39-07:00https://dev.oncoprescribe.com/MRI-Targeted-Biopsy-Superior-to-Standard-TRUS-Guided-Biopsy-for-Prostate-Cancer-Diagnosis/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Elevated-Postoperative-CEA-is-an-Early-Indicator-of-Colon-Cancer-Recurrence/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Lung-Immune-Prognostic-Index-LIPI-Identifies-Advanced-Non-Small-Cell-Lung-Cancer-Patients-Unlikely-to-Benefit-from-Treatment-with-Immune-Checkpoint-Inhibitors/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Infection-is-an-Independent-Risk-Factor-for-Venous-Thromboembolism/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-TAFINLAR-and-MEKINIST-Combination-for-Locally-Advanced-or-Metastatic-BRAF-V600E-Mutant-Anaplastic-Thyroid-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Increased-Risk-of-Anaplastic-Large-Cell-Lymphoma-with-Breast-Implants/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/fda-approves-kymriah-for-relapsed-or-refractory-large-b-cell-lymphoma/2020-04-06T08:33:30-07:00https://dev.oncoprescribe.com/KEYTRUDA-Plus-Standard-Chemotherapy-Improves-Overall-Survival-in-Newly-Diagnosed-Metastatic-Non-Small-Cell-Lung-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/fda-approves-andexxa-the-first-antidote-for-factor-xa-inhibitors/2020-04-05T15:34:51-07:00https://dev.oncoprescribe.com/FDA-Approves-Adjuvant-TAFINLAR-plus-MEKINIST-for-Stage-III-BRAF-Mutated-Melanoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-AndexXa-,-The-First-Antidote-for-Factor-Xa-Inhibitors/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/tafinlar-and-mekinist-2/2020-04-05T15:35:40-07:00https://dev.oncoprescribe.com/andexxa-andexanet-alfa/2020-04-05T15:35:44-07:00https://dev.oncoprescribe.com/kymriah-tisagenlecleucel-2/2020-04-05T15:35:51-07:00https://dev.oncoprescribe.com/KYPROLIS-along-with-REVLIMID-and-Dexamethasone-Improves-Overall-Survival-in-Relapsed-or-Refractory-Multiple-Myeloma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Dual-HER2-Blockade-Along-with-an-Aromatase-Inhibitor-is-an-Effective-Chemotherapy-Sparing-Alternative-Treatment-in-Advanced-Breast-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/tafinlar-and-mekinist/2020-04-05T15:35:57-07:00https://dev.oncoprescribe.com/tagrisso-osimertinib-2/2020-04-05T15:36:07-07:00https://dev.oncoprescribe.com/tavalisse-fostamatinib-disodium-hexahydrate/2020-04-05T15:36:12-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-and-yervoy-ipilimumab/2020-04-05T15:36:16-07:00https://dev.oncoprescribe.com/FDA-Approves-TAVALISSE-for-Chronic-ITP/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-TAGRISSO-for-First-Line-Treatment-of-Metastatic-NSCLC/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/FDA-Approves-OPDIVO-plus-YERVOY-Combination-Immunotherapy-for-intermediate-or-Poor-risk-Advanced-Renal-Cell-Carcinoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Shorter-Duration-of-Adjuvant-Chemotherapy-for-Stage-III-Colon-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/afinitor-everolimus-2/2020-04-05T15:36:46-07:00https://dev.oncoprescribe.com/rubraca-rucaparib-2/2020-04-05T15:36:51-07:00https://dev.oncoprescribe.com/blincyto-blinatumomab-2/2020-04-05T15:36:55-07:00https://dev.oncoprescribe.com/tasigna-nilotinib-2/2020-04-05T15:37:00-07:00https://dev.oncoprescribe.com/adcetris-brentuximab-vedotin-3/2020-04-05T15:37:04-07:00https://dev.oncoprescribe.com/FDA-Approves-RUBRACA-for-Maintenance-Treatment-of-Recurrent-Ovarian-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Frontline-TECENTRIQ-along-with-AVASTIN-and-Chemotherapy-Improves-Survival-in-Advanced-NSCLC/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/verzenio-abemaciclib-2/2020-04-05T15:37:17-07:00https://dev.oncoprescribe.com/imfinzi-durvalumab-2/2020-04-05T15:37:55-07:00https://dev.oncoprescribe.com/CABOMETYX-Improves-Overall-Survival-in-Advanced-Hepatocelluar-Carcinoma/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/fda-approves-4-week-dosing-schedule-for-opdivo/2020-05-04T11:52:17-07:00https://dev.oncoprescribe.com/ASTRO-Issues-New-Updated-Clinical-Guideline-for-Whole-Breast-Radiation-Therapy/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Gut-Bacteria-May-Promote-Pancreatic-Cancer-by-Inducing-Immune-Suppression/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/treatment-sequencing-with-stivarga-before-erbitux-improves-survival-in-metastatic-colorectal-cancer/2020-04-06T08:27:18-07:00https://dev.oncoprescribe.com/fda-approves-erleada-for-non-metastatic-castrate-resistant-prostate-cancer/2020-04-06T08:27:51-07:00https://dev.oncoprescribe.com/larotrectinib-a-novel-age-and-tumor-agnostic-therapy-for-trk-fusion-positive-cancers/2018-03-20T16:06:40-07:00https://dev.oncoprescribe.com/Adjuvant-Chemotherapy-May-Improve-Overall-Survival-Following-Preoperative-Chemoradiotherapy-and-Surgery-in-GastroEsophageal-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Long-Term-Survival-Outcomes-with-OPDIVO-in-Advanced-NSCLC/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Germline-Testing-with-NGS-Multigene-Cancer-Panels-Recommended-for-All-Young-Patients-with-Colorectal-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Circulating-Tumor-Cells-Predict-Late-Recurrence-in-Early-Stage-HR-Positive-Breast-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Monoclonal-Gammopathy-of-Undetermined-Significance-Associated-with-Shorter-Survival/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/larotrectinib-a-novel-age-and-tumor-agnostic-therapy-for-trk-fusion-positive-cancers-2/2020-05-04T11:53:49-07:00https://dev.oncoprescribe.com/fda-approves-zytiga-for-high-risk-metastatic-castration-sensitive-prostate-cancer-2/2020-04-05T15:38:00-07:00https://dev.oncoprescribe.com/Long-Term-Disease-Free-Survival-Benefit-with-Adjuvant-NERLYNX-in-HER2-positive-Breast-Cancer/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/Perioperative-Interruption-of-Direct-Oral-Anticoagulants-in-Patients-with-Venous-Thromboembolic-Disease/-0001-11-29T17:00:00-07:00https://dev.oncoprescribe.com/erleada-apalutamide/2020-04-05T15:38:06-07:00https://dev.oncoprescribe.com/Incidental-Pancreatic-Cysts,-Malignant-Potential-and-Pancreatic-Cancer-Prevention/2020-01-02T19:47:06-07:00https://dev.oncoprescribe.com/FDA-Approves-ZYTIGA-for-High-Risk-Metastatic-Castration-Sensitive-Prostate-Cancer/2020-01-02T19:47:06-07:00https://dev.oncoprescribe.com/zytiga-abiraterone-acetate/2020-04-05T15:38:10-07:00https://dev.oncoprescribe.com/lutathera-lutetium-lu-177-dotatate/2020-04-05T15:38:18-07:00https://dev.oncoprescribe.com/gilotrif-afatinib-2/2020-04-05T15:38:23-07:00https://dev.oncoprescribe.com/guideline-for-human-papilloma-virus-testing-in-head-and-neck-carcinomas-2/2020-05-04T06:11:42-07:00https://dev.oncoprescribe.com/FDA-Approves-LUTATHERA-for-the-Treatment-of-Somatostatin-Receptor-Positive-GastroEnteroPancreatic-Neuroendocrine-Tumors/2019-12-12T18:01:57-07:00https://dev.oncoprescribe.com/Molecular-Testing-in-Lung-Cancer-Guideline-Update/2019-12-19T20:59:44-07:00https://dev.oncoprescribe.com/opdivo-and-yervoy-combination-improves-survival-in-metastatic-colorectal-cancer/2020-04-06T08:26:45-07:00https://dev.oncoprescribe.com/ADCETRIS-with-Chemotherapy-for-the-Frontline-Treatment-of-Advanced-Classical-Hodgkin-Lymphoma/2019-12-12T18:01:57-07:00https://dev.oncoprescribe.com/OPTUNE-Together-with-Temozolomide-Significantly-Improves-Overall-Survival-in-Newly-Diagnosed-Glioblastoma/2019-11-28T19:57:08-07:00https://dev.oncoprescribe.com/guideline-for-human-papilloma-virus-testing-in-head-and-neck-carcinomas/2020-05-04T11:55:38-07:00https://dev.oncoprescribe.com/lynparza-olaparib-4/2020-04-05T15:38:28-07:00https://dev.oncoprescribe.com/KEYTRUDA-Doubles-Overall-Survival-Compared-with-Chemotherapy-in-Advanced-NSCLC/2019-11-14T19:43:41-07:00https://dev.oncoprescribe.com/FDA-Approves-LYNPARZA-for-Germline-BRCA-Mutated-Metastatic-Breast-Cancer/2019-11-21T19:12:19-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-for-adjuvant-treatment-of-malignant-melanoma/2020-04-05T15:38:42-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2017-fda-approves-opdivo-for-adjuvant-treatment-of-malignant-melanoma/2020-04-06T08:25:07-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2017-venclexta-plus-rituxan-superior-to-bendamustine-plus-rituxan-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia/2020-04-06T08:26:13-07:00https://dev.oncoprescribe.com/a-potential-cure-for-hemophilia-using-gene-therapy/2020-04-06T08:23:47-07:00https://dev.oncoprescribe.com/Recombinant-Hyaluronidase-Significantly-Improves-Progression-Free-Survival-in-Metastatic-Pancreatic-Cancer/2019-10-31T17:10:25-07:00https://dev.oncoprescribe.com/Hormonal-Contraception-Increases-Breast-Cancer-Risk/2019-10-17T20:21:34-07:00https://dev.oncoprescribe.com/FDA-Approves-BOSULIF-for-Newly-Diagnosed-Chronic-Myeloid-Leukemia/2019-10-24T17:40:08-07:00https://dev.oncoprescribe.com/hormonal-contraception-increases-breast-cancer-risk/2017-12-28T10:01:12-07:00https://dev.oncoprescribe.com/tasigna-nilotinib/2020-04-05T15:38:47-07:00https://dev.oncoprescribe.com/siklos-hydroxyurea/2020-04-05T15:38:52-07:00https://dev.oncoprescribe.com/perjeta-pertuzumab-2/2020-04-05T15:38:56-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-3/2020-04-05T15:39:01-07:00https://dev.oncoprescribe.com/ogivri-trastuzumab-dkst/2020-05-04T11:57:21-07:00https://dev.oncoprescribe.com/cabometyx-cabozantinib-3/2020-04-05T15:39:12-07:00https://dev.oncoprescribe.com/bosulif-bosutinib-2/2020-04-05T15:39:53-07:00https://dev.oncoprescribe.com/direct-oral-anticoagulant-savaysa-noninferior-to-subcutaneous-fragmin-for-cancer-associated-venous-thromboembolism/2020-04-06T08:23:11-07:00https://dev.oncoprescribe.com/Consolidation-with-IMFINZI-after-Chemoradiotherapy-Improves-Outcomes-in-Patients-with-Unresectable-Stage-III-Non-Small-Cell-Lung-Cancer/2019-09-19T17:49:00-07:00https://dev.oncoprescribe.com/foundationone-cdx-f1cdx/2020-05-04T11:58:37-07:00https://dev.oncoprescribe.com/platelet-transfusion-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update/2020-05-04T11:59:36-07:00https://dev.oncoprescribe.com/fda-approves-ogivri-as-a-biosimilar-to-herceptin/2020-05-04T12:00:39-07:00https://dev.oncoprescribe.com/fda-approves-foundationone-cdx-next-generation-sequencing-based-assay-to-tailor-cancer-therapies/2020-05-04T12:59:29-07:00https://dev.oncoprescribe.com/FDA-Approves-Adjuvant-Therapy-with-SUTENT-in-High-Risk-Renal-Cell-Carcinoma-after-Nephrectomy/2019-09-06T05:23:24-07:00https://dev.oncoprescribe.com/FDA-Approves-ADCETRIS-for-Cutaneous-T-Cell-Lymphoma/2019-08-22T17:22:36-07:00https://dev.oncoprescribe.com/Long-Term-Risk-of-Breast-Cancer-Recurrence-after-Stopping-Endocrine-Therapy-at-5-Years/2019-08-29T17:45:31-07:00https://dev.oncoprescribe.com/tagrisso-superior-to-first-generation-egfr-tkis-in-advanced-non-small-cell-lung-cancer/2017-11-27T07:03:20-07:00https://dev.oncoprescribe.com/MisMatch-Repair-Deficiency-and-MicroSatellite-Instability-May-Predict-Perioperative-Chemotherapy-Benefit-in-Operable-GastroEsophageal-Cancers/2019-08-15T16:39:59-07:00https://dev.oncoprescribe.com/TAGRISSO-Superior-to-First-Generation-EGFR-TKIs-in-Advanced-Non-Small-Cell-Lung-Cancer/2019-08-22T17:22:36-07:00https://dev.oncoprescribe.com/alcohol-and-cancer-a-statement-of-the-american-society-of-clinical-oncology/2017-11-17T17:49:42-07:00https://dev.oncoprescribe.com/sutent-sunitinib-malate/2020-04-05T15:40:06-07:00https://dev.oncoprescribe.com/gazyva-obinutuzumab-2/2020-04-05T15:40:10-07:00https://dev.oncoprescribe.com/sprycel-dasatinib/2020-04-05T15:40:16-07:00https://dev.oncoprescribe.com/adcetris-brentuximab-vedotin-4/2020-04-05T15:40:20-07:00https://dev.oncoprescribe.com/alecensa-alectinib-2/2020-04-05T15:40:24-07:00https://dev.oncoprescribe.com/zelboraf-vemurafenib/2020-05-04T13:00:45-07:00https://dev.oncoprescribe.com/fda-grants-approval-to-calquence-for-mantle-cell-lymphoma/2020-04-06T08:22:35-07:00https://dev.oncoprescribe.com/alcohol-and-cancer-a-statement-of-the-american-society-of-clinical-oncology-2/2020-05-04T13:01:40-07:00https://dev.oncoprescribe.com/calquence-acalabrutinib/2020-04-05T15:40:56-07:00https://dev.oncoprescribe.com/yescarta-axicabtagene-ciloleucel/2020-04-05T15:41:00-07:00https://dev.oncoprescribe.com/Non-V600-BRAF-Mutations-Define-a-Clinically-Distinct-Molecular-Subtype-of-Metastatic-Colorectal-Cancer-with-Excellent-Prognosis/2019-06-27T16:55:24-07:00https://dev.oncoprescribe.com/OPDIVO-and-YERVOY-Combination-Improves-Overall-Survival-in-Advanced-Melanoma/2019-07-04T18:58:22-07:00https://dev.oncoprescribe.com/KEYTRUDA-Improves-Overall-Survival-in-Advanced-Urothelial-Carcinoma/2019-06-20T22:31:05-07:00https://dev.oncoprescribe.com/ASCO-Clinical-Practice-Guideline-Update-for-Stage-IV-Non-Small-Cell-Lung-Cancer/2019-06-27T16:55:24-07:00https://dev.oncoprescribe.com/fda-approves-verzenio-for-hormone-receptor-positive-her2-negative-breast-cancer/2020-04-05T15:41:05-07:00https://dev.oncoprescribe.com/fda-approves-aliqopa-a-pi3k-inhibitor-for-follicular-lymphoma/2020-04-05T15:41:09-07:00https://dev.oncoprescribe.com/Circulating-Tumor-Cells-in-the-Peripheral-Blood-May-Predict-Outcomes-in-Breast-Cancer/2019-06-13T17:48:08-07:00https://dev.oncoprescribe.com/FDA-Approves-CAR-T-Cell-Therapy-for-Non-Hodgkin-Lymphoma/2019-06-20T22:31:05-07:00https://dev.oncoprescribe.com/gazyva-superior-to-rituxan-for-first-line-treatment-of-follicular-lymphoma/2020-04-05T20:27:08-07:00https://dev.oncoprescribe.com/Targeting-AKT-Improves-Outcomes-in-a-Subset-of-Triple-Negative-Breast-Cancer-Patients/2019-06-13T17:48:08-07:00https://dev.oncoprescribe.com/FDA-Approves-OPDIVO-for-Advanced-Hepatocellular-Carcinoma/2019-05-30T19:05:22-07:00https://dev.oncoprescribe.com/African-American-Women-with-Benign-Breast-Disease-and-Triple-Negative-Breast-Cancer/2019-06-06T20:41:19-07:00https://dev.oncoprescribe.com/FDA-Approves-TAFINLAR-and-MEKINIST-Combo-for-BRAF-V600E-Mutant-Non-Small-Cell-Lung-Cancer/2019-05-23T17:06:01-07:00https://dev.oncoprescribe.com/FDA-Approves-VERZENIO-for-Hormone-Receptor-Positive,-HER2-Negative-Breast-Cancer/2019-05-30T19:05:22-07:00https://dev.oncoprescribe.com/verzenio-abemaciclib/2020-04-05T15:41:14-07:00https://dev.oncoprescribe.com/OPDIVO-Nivolumab/2019-05-16T17:21:16-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-13/2020-04-05T15:41:19-07:00https://dev.oncoprescribe.com/ALIQOPA-Copanlisib/2019-05-09T16:14:50-07:00https://dev.oncoprescribe.com/jevtana-cabazitaxel/2020-04-05T15:41:45-07:00https://dev.oncoprescribe.com/besponsa-inotuzumab-ozogamicin/2020-04-05T15:41:49-07:00https://dev.oncoprescribe.com/lynparza-olaparib-5/2020-04-05T15:41:52-07:00https://dev.oncoprescribe.com/mylotarg-gemtuzumab-ozogamicin/2020-04-05T15:41:57-07:00https://dev.oncoprescribe.com/FDA-Approves-ALIQOPA-,-a-PI3K-Inhibitor,-for-Follicular-Lymphoma/2019-04-18T17:15:10-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-for-advanced-gastric-cancer/2020-04-06T08:22:06-07:00https://dev.oncoprescribe.com/fda-approves-nerlynx-for-adjuvant-treatment-of-her2-positive-breast-cancer-2/2020-04-05T15:42:21-07:00https://dev.oncoprescribe.com/fda-approves-first-biosimilar-for-cancer-treatment/2020-05-04T13:03:09-07:00https://dev.oncoprescribe.com/E-Cigarettes-Can-Increase-the-Risk-of-Bladder-Cancer/2019-04-11T18:58:50-07:00https://dev.oncoprescribe.com/mvasi-bevacizumab-awwb/2020-05-04T13:04:19-07:00https://dev.oncoprescribe.com/kymriah-tisagenlecleucel/2020-04-05T15:42:30-07:00https://dev.oncoprescribe.com/fda-approves-first-biosimilar-for-cancer-treatment-2/2020-04-05T15:42:35-07:00https://dev.oncoprescribe.com/Guideline-for-HER2-Testing-in-Gastroesophageal-Adenocarcinoma/2018-05-31T17:16:19-07:00https://dev.oncoprescribe.com/maintenance-therapy-with-revlimid-prolongs-pfs-in-high-risk-cll/2020-04-05T20:31:53-07:00https://dev.oncoprescribe.com/screening-mammography-starting-at-age-40-years-may-reduce-breast-cancer-deaths-by-40-percent/2017-09-12T20:32:20-07:00https://dev.oncoprescribe.com/first-car-t-cell-immunotherapy-approved-by-the-fda-for-acute-lymphoblastic-leukemia-2/2020-04-05T15:42:40-07:00https://dev.oncoprescribe.com/First-CAR-T-Cell-Immunotherapy-Approved-by-the-FDA-for-Acute-Lymphoblastic-Leukemia/2019-03-28T18:54:40-07:00https://dev.oncoprescribe.com/antibiotics-may-impair-the-efficacy-of-immune-checkpoint-inhibitors/2020-04-06T08:21:34-07:00https://dev.oncoprescribe.com/Study-Finds-Dramatic-Increase-in-ColoRectal-Cancer-Incidence-among-Young-Adults/2019-03-21T19:56:06-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2017-single-dose-radiation-therapy-as-effective-as-multiple-fractions-for-metastatic-spinal-cord-compression/2020-04-06T08:20:51-07:00https://dev.oncoprescribe.com/Screening-Mammography-Starting-at-Age-40-years-May-Reduce-Breast-Cancer-Deaths-by-40-percent/2019-03-14T18:31:17-07:00https://dev.oncoprescribe.com/DACOGEN-May-Be-Superior-to-VIDAZA-in-Higher-Risk-MDS-Patients/2019-03-21T19:56:06-07:00https://dev.oncoprescribe.com/fda-approves-darzalex-in-combination-with-pomalyst-and-dexamethasone-for-relapsed-or-refractory-multiple-myeloma-2/2020-04-05T15:42:46-07:00https://dev.oncoprescribe.com/fda-approves-idhifa-for-patients-with-relapsed-or-refractory-acute-myeloid-leukemia/2020-04-06T08:20:16-07:00https://dev.oncoprescribe.com/ASTRO-Guideline-for-Stereotactic-Body-Radiation-Therapy-in-Early-Stage-Lung-Cancer/2019-03-14T18:31:17-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-for-msi-h-or-dmmr-metastatic-colorectal-cancer-2/2020-04-05T15:43:11-07:00https://dev.oncoprescribe.com/FDA-Approves-OPDIVO-for-MSI-H-or-dMMR-Metastatic-Colorectal-Cancer/2019-02-28T17:49:07-07:00https://dev.oncoprescribe.com/FDA-Approves-DARZALEX-in-Combination-with-POMALYST-and-Dexamethasone-for-Relapsed-or-Refractory-Multiple-Myeloma/2019-03-07T19:59:05-07:00https://dev.oncoprescribe.com/vyxeos-liposome-encapsulated-combination-of-daunorubicin-and-cytarabine/2020-04-05T15:43:15-07:00https://dev.oncoprescribe.com/imbruvica-ibrutinib-2/2020-05-04T13:07:21-07:00https://dev.oncoprescribe.com/idhifa-enasidenib/2020-04-05T15:43:23-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-4/2020-04-05T15:43:27-07:00https://dev.oncoprescribe.com/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update-part-ii/2020-05-04T13:10:15-07:00https://dev.oncoprescribe.com/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update/2020-05-04T13:08:43-07:00https://dev.oncoprescribe.com/fda-approves-rydapt-for-flt3-mutated-acute-myeloid-leukemia/2020-04-05T15:43:31-07:00https://dev.oncoprescribe.com/FDA-Approves-NERLYNX-for-Adjuvant-Treatment-of-HER2-Positive-Breast-Cancer/2019-01-24T18:52:59-07:00https://dev.oncoprescribe.com/Maintenance-Treatment-with-REVLIMID-Improves-Progression-Free-Survival-in-Diffuse-Large-B-Cell-Lymphoma/2019-01-24T18:52:59-07:00https://dev.oncoprescribe.com/blincyto-blinatumomab-3/2020-04-05T15:43:35-07:00https://dev.oncoprescribe.com/nerlynx-neratinib/2020-04-05T15:44:04-07:00https://dev.oncoprescribe.com/fdas-first-tissuesite-agnostic-approval/2020-04-05T15:45:20-07:00https://dev.oncoprescribe.com/fda-approves-endari-for-sickle-cell-disease/2020-04-05T15:45:34-07:00https://dev.oncoprescribe.com/BAVENCIO-First-FDA-Approved-Agent-for-Merkel-Cell-Carcinoma/2019-01-17T18:38:15-07:00https://dev.oncoprescribe.com/Brachytherapy-for-Patients-With-Prostate-Cancer-American-Society-of-Clinical-Oncology/Cancer-Care-Ontario-Joint-Guideline-Update-Summary/2019-01-17T18:38:15-07:00https://dev.oncoprescribe.com/Weight-Gain-Increases-the-Risk-for-Postmenopausal-Breast-cancer/2019-01-10T20:35:51-07:00https://dev.oncoprescribe.com/fda-approves-endari-a-new-treatment-for-sickle-cell-disease/2023-09-17T14:37:40-07:00https://dev.oncoprescribe.com/three-months-of-adjuvant-therapy-adequate-for-stage-iii-colon-cancer/2017-07-13T21:00:35-07:00https://dev.oncoprescribe.com/endari-l-glutamine-oral-powder/2020-04-05T15:45:38-07:00https://dev.oncoprescribe.com/Praxis-Extended-RAS-Panel/2019-01-03T19:25:40-07:00https://dev.oncoprescribe.com/bevyxxa-betrixaban/2020-04-05T15:45:42-07:00https://dev.oncoprescribe.com/tafinlar-and-mekinist-dabrafenib-and-trametinib-the-fda-on-june-22-2017-granted-ular-approvals-to-tafinlar-and-mekinist-administered-in-combination-for-patients-with-metasta/2020-05-04T13:17:04-07:00https://dev.oncoprescribe.com/rituxan-hycela-rituximab-and-hyaluronidase-human-2/2020-04-05T15:46:30-07:00https://dev.oncoprescribe.com/rituxan-hycela-rituximab-and-hyaluronidase-human/2020-04-05T15:46:34-07:00https://dev.oncoprescribe.com/gleolan-aminolevulinic-acid-hydrochloride/2020-04-05T15:46:46-07:00https://dev.oncoprescribe.com/zykadia-ceritinib-2/2020-04-05T15:46:51-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-14/2020-05-04T13:12:03-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-15/2020-04-05T15:46:58-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-16/2020-04-05T15:47:21-07:00https://dev.oncoprescribe.com/FDA-Approves-Subcutaneous-RITUXAN-Formulation-for-CD20-Positive-Hematologic-Malignancies/2018-11-22T22:09:15-07:00https://dev.oncoprescribe.com/FDA-Approves-TAFINLAR-and-MEKINIST-Combination-for-BRAF-Positive-Non-Small-Cell-Lung-Cancer/2018-11-29T18:29:48-07:00https://dev.oncoprescribe.com/fda-approves-subcutaneous-rituxan-formulation-for-cd20-positive-hematologic-malignancies-2/2020-04-05T15:47:25-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ndash-asco-2017-adjuvant-dual-her2-regimen-of-perjeta-and-herceptin-improves-outcomes-in-early-stage-breast-cancer/2020-04-06T08:18:49-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ndash-asco-2017-dacomitinib-superior-to-iressa-in-egfr-mutant-non-small-cell-lung-cancer/2020-04-06T08:19:26-07:00https://dev.oncoprescribe.com/Late-Breaking-Abstract-ASCO-2017-ALECENSA-Superior-to-XALKORI-in-Untreated-ALK-Positive-Non-Small-Cell-Lung-Cancer/2018-11-08T18:04:53-07:00https://dev.oncoprescribe.com/adjuvant-therapy-with-xeloda-improves-overall-survival-in-biliary-tract-cancer/2020-04-06T08:18:14-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2017-three-months-of-adjuvant-therapy-adequate-for-stage-iii-colon-cancer-patients-with-t1-3-n1-disease/2020-04-05T20:56:10-07:00https://dev.oncoprescribe.com/Late-Breaking-Abstract-ASCO-2017-LYNPARZA-Improves-Progression-Free-Survival-in-BRCA-Positive-Breast-Cancer/2018-11-08T18:04:53-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2017-targeted-therapy-based-on-genomic-profiling-improves-overall-survival/2020-05-06T10:18:58-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2017-adding-zytiga-to-androgen-deprivation-therapy-improves-overall-survival-in-newly-diagnosed-advanced-prostate-cancer/2020-04-05T20:55:21-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-for-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors/2020-05-06T10:21:39-07:00https://dev.oncoprescribe.com/Final-Overall-Survival-Results-with-KADCYLA-in-Metastatic-Breast-Cancer/2018-10-18T17:01:27-07:00https://dev.oncoprescribe.com/genomic-prostate-score-gps-can-predict-prostate-cancer-mortality-and-risk-of-metastases-in-early-stage-prostate-cancer/2020-04-05T20:53:17-07:00https://dev.oncoprescribe.com/FDA-Approves-BAVENCIO-for-Merkel-Cell-Carcinoma/2018-10-11T16:54:27-07:00https://dev.oncoprescribe.com/-FDA-Approves-KEYTRUDA-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Metastatic-NSCLC/2018-10-11T16:54:27-07:00https://dev.oncoprescribe.com/fda-approves-imfinzi-for-advanced-bladder-cancer/2020-04-05T20:52:40-07:00https://dev.oncoprescribe.com/Late-Breaking-Abstract-ECCO-2017-Breast-Conserving-Therapy-Better-Than-Mastectomy-in-Some-Patients-with-Early-Stage-Breast-Cancer/2018-09-27T17:02:03-07:00https://dev.oncoprescribe.com/rituxan-maintenance-prolongs-survival-in-mantle-cell-lymphoma/2020-04-05T20:52:09-07:00https://dev.oncoprescribe.com/alunbrig-brigatinib/2020-04-05T15:47:29-07:00https://dev.oncoprescribe.com/rydapt-midostaurin/2020-04-05T15:47:34-07:00https://dev.oncoprescribe.com/stivarga-regorafenib-2/2020-04-05T15:47:39-07:00https://dev.oncoprescribe.com/ibrance-palbociclib-2/2020-04-05T15:47:45-07:00https://dev.oncoprescribe.com/tagrisso-osimertinib-3/2020-04-05T15:47:50-07:00https://dev.oncoprescribe.com/bavencio-avelumab-2/2020-04-05T15:48:19-07:00https://dev.oncoprescribe.com/imfinzi-durvalumab/2020-04-05T15:48:23-07:00https://dev.oncoprescribe.com/-FDA-Approves-RYDAPT-,-A-Targeted-Multikinase-Inhibitor-for-FLT3-Mutated-Acute-Myeloid-leukemia/2018-08-23T17:41:16-07:00https://dev.oncoprescribe.com/fda-approves-alunbrig-for-alk-positive-non-small-cell-lung-cancer/2020-05-27T21:43:02-07:00https://dev.oncoprescribe.com/management-of-localized-or-locally-advanced-oropharyngeal-squamous-cell-carcinoma-ndash-astro-clinical-practice-guideline/2020-05-02T13:46:24-07:00https://dev.oncoprescribe.com/PET-CT-in-Colorectal-Cancer-Patients-with-a-Rising-CEA-Can-Detect-Occult-Recurrent-Disease-Amenable-to-Curative-Therapy/2018-08-23T17:41:16-07:00https://dev.oncoprescribe.com/Pegylated-Form-of-Recombinant-Hyaluronidase-Significantly-Improves-Progression-Free-Survival-in-Metastatic-Pancreatic-Cancer/2018-08-09T17:20:53-07:00https://dev.oncoprescribe.com/Lower-Dose-of-XARELTO-Adequate-for-Prevention-of-Recurrent-Venous-Thromboembolism/2018-08-16T18:01:46-07:00https://dev.oncoprescribe.com/sequencing-therapies-in-metastatic-castrate-resistant-prostate-cancer/2020-04-05T20:51:06-07:00https://dev.oncoprescribe.com/Restricting-Indoor-Tanning-Can-Impact-Melanoma-Incidence-and-Treatment-Costs/2018-08-02T17:19:18-07:00https://dev.oncoprescribe.com/reduced-lung-cancer-mortality-with-low-dose-computed-tomographic-screening-br/2023-09-17T14:39:46-07:00https://dev.oncoprescribe.com/cabometyx-superior-to-sutent-in-metastatic-renal-cell-carcinoma/2020-04-05T20:36:31-07:00https://dev.oncoprescribe.com/location-of-primary-tumor-in-the-colon-predicts-survival-and-choice-of-treatment-in-metastatic-colorectal-cancer/2020-04-05T20:50:01-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-for-hodgkin-lymphoma/2020-04-05T20:35:29-07:00https://dev.oncoprescribe.com/Use-of-Adjuvant-Bisphosphonates-and-Other-Bone-Modifying-Agents-in-Breast-Cancer-A-Cancer-Care-Ontario-and-American-Society-of-Clinical-Oncology-Clinical-Practice-Guideline/2018-07-12T16:49:28-07:00https://dev.oncoprescribe.com/zejula-niraparib/2020-04-05T15:48:27-07:00https://dev.oncoprescribe.com/bavencio-avelumab/2020-04-05T15:48:31-07:00https://dev.oncoprescribe.com/fda-approves-kisqali-for-first-line-treatment-of-hormone-receptor-positive-advanced-breast-cancer/2020-04-05T20:34:20-07:00https://dev.oncoprescribe.com/Patients-with-Lung-Cancer-and-Liver-Metastases-May-Not-Benefit-from-OPDIVO/2018-07-05T17:13:04-07:00https://dev.oncoprescribe.com/fda-approves-imbruvica-for-marginal-zone-lymphoma/2020-04-05T20:32:39-07:00https://dev.oncoprescribe.com/chemoradiation-alone-without-surgery-does-not-compromise-survival-in-selected-patients-with-rectal-cancer/2020-04-05T20:33:26-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-17/2020-04-05T15:48:35-07:00https://dev.oncoprescribe.com/kisqali-ribociclib/2020-04-05T15:48:39-07:00https://dev.oncoprescribe.com/FDA-Approves-XERMELO-for-Carcinoid-Syndrome-Associated-Diarrhea/2018-06-14T17:23:47-07:00https://dev.oncoprescribe.com/niraparib-maintenance-therapy-significantly-improves-progression-free-survival-in-platinum-sensitive-ovarian-cancer/2020-04-05T20:31:14-07:00https://dev.oncoprescribe.com/revlimid-lenalidomide-3/2020-04-05T15:48:43-07:00https://dev.oncoprescribe.com/ibm-artificial-intelligence-platform-highly-concordant-with-physician-recommendations/2020-04-05T20:28:19-07:00https://dev.oncoprescribe.com/dual-inhibition-improves-outcomes-for-patients-with-braf-mutated-colorectal-tumors/2020-04-05T20:30:20-07:00https://dev.oncoprescribe.com/GAZYVA-Superior-to-RITUXAN-in-Follicular-Lymphoma/2018-05-10T16:43:13-07:00https://dev.oncoprescribe.com/White-Wine-May-Increase-Melanoma-Risk-in-UV-spared-sites/2018-05-17T16:22:05-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-for-bladder-cancer/2020-04-05T20:26:13-07:00https://dev.oncoprescribe.com/The-FDA-recommends-against-using-screening-tests-for-ovarian-cancer-screening-FDA-Safety-Communication/2018-04-26T17:33:33-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-5/2020-04-05T15:51:24-07:00https://dev.oncoprescribe.com/rubraca-rucaparib/2020-04-05T15:51:31-07:00https://dev.oncoprescribe.com/darzalex-daratumumab-4/2020-04-05T15:51:36-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-6/2020-05-06T10:24:14-07:00https://dev.oncoprescribe.com/deep-clinical-responses-and-mrd-negativity-with-darzalex-in-multiple-myeloma/2020-04-05T20:24:37-07:00https://dev.oncoprescribe.com/a-tool-to-predict-chemotherapy-related-toxicity-in-elderly-patients/2020-05-06T10:24:39-07:00https://dev.oncoprescribe.com/ESR1-Mutations-Predict-Response-to-Endocrine-Therapy-in-Advanced-Breast-Cancer/2018-04-05T18:37:24-07:00https://dev.oncoprescribe.com/xarelto-for-heparin-induced-thrombocytopenia/2020-04-05T20:23:33-07:00https://dev.oncoprescribe.com/first-line-keytruda-superior-to-chemotherapy-in-advanced-nsclc/2020-04-05T20:22:50-07:00https://dev.oncoprescribe.com/bone-metastases-zometa-every-12-weeks-non-inferior-to-every-4-weeks-schedule/2020-05-06T10:25:26-07:00https://dev.oncoprescribe.com/A-New-Treatment-Algorithm-for-the-Upfront-Treatment-of-Chronic-Lymphocytic-Leukemia/2018-03-22T17:13:46-07:00https://dev.oncoprescribe.com/vistogard-an-antidote-for-5-fu-overexposure/2020-05-06T10:25:41-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2016-rova-t-first-targeted-treatment-for-small-cell-lung-cancer/2020-04-05T20:01:43-07:00https://dev.oncoprescribe.com/ASCO-Guideline-Adjuvant-Systemic-Therapy-Decision-Making-for-Early-Stage-Operable-Breast-Cancer/2018-03-22T17:13:46-07:00https://dev.oncoprescribe.com/Influence-of-Tumor-Genetics-MSI-on-Prognostic-Effect-of-BRAF-and-KRAS-Mutations-in-Patients-with-Colon-Cancer/2018-03-15T17:15:17-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2016-dramatic-responses-in-patients-with-refractory-diffuse-large-b-cell-lymphoma-dlbcl-with-anti-cd19-car-t-cells/2020-04-05T20:21:48-07:00https://dev.oncoprescribe.com/FDA-Approves-AVASTIN-for-Platinum-Sensitive-Ovarian-Cancer/2018-03-01T17:31:42-07:00https://dev.oncoprescribe.com/axillary-lymph-node-dissection-can-be-avoided-in-some-high-risk-breast-cancer-patients/2020-04-05T20:20:56-07:00https://dev.oncoprescribe.com/fda-approves-tecentriq-for-non-small-cell-lung-cancer/2020-04-05T20:18:30-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ash-2016-superior-efficacy-data-with-pacritinib-in-myelofibrosis/2020-04-05T20:19:32-07:00https://dev.oncoprescribe.com/late-breaking-abstract-esmo-2016-faslodex-superior-to-arimidex-as-initial-therapy-in-advanced-breast-cancer/2020-04-05T20:15:52-07:00https://dev.oncoprescribe.com/ash-2016-discontinuing-tyrosine-kinase-inhibitors-is-feasible-in-some-patients-with-cml/2020-04-05T20:16:34-07:00https://dev.oncoprescribe.com/Immediate-Androgen-Deprivation-Therapy-Confers-Survival-Benefit-in-Prostate-Cancer-Patients-with-Biochemical-Recurrence/2018-02-01T18:12:01-07:00https://dev.oncoprescribe.com/Prolonged-Survival-with-FOLFIRINOX-Regimen-in-Locally-Advanced-Pancreatic-Cancer/2018-02-08T17:33:51-07:00https://dev.oncoprescribe.com/IBRANCE-plus-FEMARA-A-New-Standard-for-Previously-Untreated-Advanced-Breast-Cancer/2018-01-25T19:00:44-07:00https://dev.oncoprescribe.com/Superior-Outcomes-with-REVLIMID-and-Dexamethasone-in-Elderly-Patients-with-Multiple-Myeloma/2018-02-01T18:12:01-07:00https://dev.oncoprescribe.com/fda-approves-opdivo-for-head-and-neck-cancer/2020-05-04T06:26:31-07:00https://dev.oncoprescribe.com/neoadjuvant-chemotherapy-in-advanced-ovarian-cancer-asco-clinical-practice-guideline/2020-04-05T20:13:43-07:00https://dev.oncoprescribe.com/FDA-Approves-PDGFR-alpha-Antagonist-LARTRUVO-for-Soft-Tissue-Sarcoma/2018-01-11T17:48:51-07:00https://dev.oncoprescribe.com/vyxeos-a-novel-first-line-treatment-for-high-risk-acute-myeloid-leukemia/2020-04-05T20:11:11-07:00https://dev.oncoprescribe.com/FDA-Approves-KEYTRUDA-for-Treatment-Na-iuml-ve-Patients-with-Advanced-NSCLC/2017-12-21T17:48:20-07:00https://dev.oncoprescribe.com/Adjuvant-Therapy-with-SUTENT-in-High-Risk-Renal-Cell-Carcinoma-after-Nephrectomy/2017-12-21T17:48:20-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-18/2020-04-05T15:51:44-07:00https://dev.oncoprescribe.com/lartruvo-olaratumab/2020-04-05T15:51:48-07:00https://dev.oncoprescribe.com/tecentriq-atezolizumab-6/2020-04-05T15:51:53-07:00https://dev.oncoprescribe.com/tarceva-erlotinib-2/2020-04-05T15:51:57-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-7/2020-04-05T15:52:01-07:00https://dev.oncoprescribe.com/Postmastectomy-Radiotherapy-ASCO-Guideline-Update/2017-12-14T19:31:28-07:00https://dev.oncoprescribe.com/DARZALEX-Combination-Demonstrates-Impressive-Efficacy-in-Relapsed-or-Refractory-Myeloma/2017-12-14T19:31:28-07:00https://dev.oncoprescribe.com/CDK4-and-CDK6-Inhibitor-ABEMACICLIB-Highly-Effective-in-Refractory-Hormone-Receptor-Positive-Breast-Cancer/2017-12-07T18:31:17-07:00https://dev.oncoprescribe.com/Adjuvant-Therapy-with-YERVOY-Improves-Overall-Survival-in-Stage-III-Melanoma/2017-12-07T18:31:17-07:00https://dev.oncoprescribe.com/ASCO-Guidelines-on-Adjuvant-Targeted-Therapy-for-HER2-Positive-Breast-Cancers/2017-11-30T17:42:54-07:00https://dev.oncoprescribe.com/FDA-Approves-TAGRISSO-Osimertinib-Blood-Based-T790M-Companion-Diagnostic-Test/2017-11-30T17:42:54-07:00https://dev.oncoprescribe.com/MammaPrint-Identifies-Women-with-Early-Stage-Breast-Cancer-Who-Can-Avoid-Adjuvant-Chemotherapy/2017-11-26T21:54:25-07:00https://dev.oncoprescribe.com/Location-of-Primary-Tumor-Predicts-Survival-and-Choice-of-Treatment-in-Metastatic-Colorectal-Cancer/2017-11-26T21:54:25-07:00https://dev.oncoprescribe.com/Andexanet-Alfa-An-Antidote-for-Acute-Major-Bleeding-Associated-with-New-Oral-Anticoagulants/2017-11-16T23:22:50-07:00https://dev.oncoprescribe.com/Clinically-Localized-Prostate-Cancer-Treatment-or-Active-Monitoring/2017-11-16T23:22:50-07:00https://dev.oncoprescribe.com/proton-beam-therapy-may-improve-survival-compared-to-conventional-radiation-in-stage-ii-and-iii-nsclc-patients/2020-04-05T20:10:30-07:00https://dev.oncoprescribe.com/STIVARGA-Improves-Overall-Survival-in-Advanced-Hepatocellular-Carcinoma/2017-11-10T00:06:55-07:00https://dev.oncoprescribe.com/long-term-survival-in-advanced-renal-cell-carcinoma-with-opdivo/2020-04-05T20:09:41-07:00https://dev.oncoprescribe.com/New-NCCN-Guidelines-for-the-Diagnosis-and-Treatment-of-Multiple-Myeloma/2017-11-03T06:17:58-07:00https://dev.oncoprescribe.com/anthracycline-regimen-superior-in-high-risk-early-stage-breast-cancer/2020-04-05T20:08:39-07:00https://dev.oncoprescribe.com/Long-Term-Data-Confirms-Durable-Efficacy-and-Safety-of-JAKAFI-in-Myelofibrosis/2017-10-27T03:37:45-07:00https://dev.oncoprescribe.com/GAZYVA-in-Combination-with-TREANDA-for-RITUXAN-Refractory-Indolent-Lymphoma/2017-10-20T07:32:06-07:00https://dev.oncoprescribe.com/fda-approves-sustol-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting/2020-05-06T10:30:02-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2016-biosimilar-of-herceptin-equally-effective-and-safe/2020-04-05T20:07:17-07:00https://dev.oncoprescribe.com/TASIGNA-Maintains-Durable-Deep-Molecular-Responses-Even-after-Treatment-Discontinuation-in-Chronic-Phase-CML/2017-10-13T02:26:20-07:00https://dev.oncoprescribe.com/Influence-of-MSI-on-Prognostic-Effect-of-BRAF-and-KRAS-Mutations-in-Patients-with-Stage-III-Colon-Cancer/2017-10-05T22:01:58-07:00https://dev.oncoprescribe.com/SOMATULINE-Tumor-Growth-Rate-TGR-a-Better-Indicator-of-Therapeutic-Activity-than-RECIST-in-NeuroEndocrine-Tumors/2017-10-05T22:01:58-07:00https://dev.oncoprescribe.com/fda-approves-keytruda-for-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma/2020-05-04T09:52:38-07:00https://dev.oncoprescribe.com/Ovarian-Suppression-in-Premenopausal-Women-with-ER-Positive-Breast-Cancer-ASCO-Clinical-Practice-Guideline-Update/2017-09-28T22:50:43-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-19/2020-05-06T10:27:27-07:00https://dev.oncoprescribe.com/detection-of-hpv-dna-in-the-oral-cavity-increases-the-risk-of-head-and-neck-cancer/2020-05-04T09:57:07-07:00https://dev.oncoprescribe.com/XARELTO-Safe-and-Effective-for-Cancer-Patients-with-Venous-ThromboEmbolism/2017-09-21T21:39:55-07:00https://dev.oncoprescribe.com/cobas-egfr-mutation-test-v2/2020-04-05T15:52:30-07:00https://dev.oncoprescribe.com/tecentriq-atezolizumab/2020-04-05T15:52:35-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-8/2020-04-05T15:52:40-07:00https://dev.oncoprescribe.com/lenvima-lenvatinib/2020-04-05T15:52:44-07:00https://dev.oncoprescribe.com/cabometyx-cabozantinib/2020-04-05T15:52:48-07:00https://dev.oncoprescribe.com/venclexta-venetoclax/2020-04-05T15:52:52-07:00https://dev.oncoprescribe.com/defitelio-defibrotide-sodium/2020-05-06T10:31:01-07:00https://dev.oncoprescribe.com/xalkori-crizotinib/2020-04-05T15:53:00-07:00https://dev.oncoprescribe.com/afinitor-everolimus-3/2020-05-06T10:39:31-07:00https://dev.oncoprescribe.com/gazyva-obinutuzumab-3/2020-04-05T15:53:11-07:00https://dev.oncoprescribe.com/ibrance-palbociclib-3/2020-04-05T15:53:37-07:00https://dev.oncoprescribe.com/halaven-eribulin/2020-04-05T15:53:42-07:00https://dev.oncoprescribe.com/zyprexa-combination-significantly-reduces-nausea-and-vomiting-in-patients-receiving-highly-emetogenic-chemotherapy/2020-05-06T10:40:06-07:00https://dev.oncoprescribe.com/Impressive-5-Year-Survival-Rates-for-Patients-with-Metastatic-Melanoma-Treated-with-OPDIVO/2017-07-27T22:31:25-07:00https://dev.oncoprescribe.com/arzerra-ofatumumab-2/2020-04-05T15:53:44-07:00https://dev.oncoprescribe.com/Short-Course-Neoadjuvant-Radiation-Therapy-Effective-and-Less-Toxic-in-Advanced-Rectal-Cancer/2017-07-13T22:20:30-07:00https://dev.oncoprescribe.com/increased-physical-activity-associated-with-lower-risk-of-13-different-cancer-types/2020-05-06T10:40:29-07:00https://dev.oncoprescribe.com/FDA-Approves-AXUMIN-to-Identify-Prostate-Cancer-Recurrence-in-Patients-with-Rising-PSA/2017-07-06T22:11:47-07:00https://dev.oncoprescribe.com/ASCO-Guidelines-on-Use-of-Biomarkers-in-Early-Stage-Breast-Cancer-Part-II/2017-07-13T22:20:30-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-20/2020-04-05T15:53:55-07:00https://dev.oncoprescribe.com/alecensa-alectinib/2020-04-05T15:54:47-07:00https://dev.oncoprescribe.com/vistogard-uridine-triacetate/2020-05-06T10:40:54-07:00https://dev.oncoprescribe.com/empliciti-elotuzumab/2020-04-05T15:54:56-07:00https://dev.oncoprescribe.com/Interim-PET-Scan-may-Define-Prognosis-and-Provide-Treatment-Guidance-for-Patients-with-Advanced-Hodgkin-Lymphoma/2017-06-15T14:55:49-07:00https://dev.oncoprescribe.com/asco-guidelines-on-use-of-biomarkers-in-early-stage-breast-cancer-ndash-part-1/2022-12-27T16:15:43-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ndash-asco-2016-liquid-biopsy-can-rapidly-detect-certain-gene-mutations-with-high-specificity/2020-04-05T20:04:42-07:00https://dev.oncoprescribe.com/YONDELIS-A-Marine-Derived-Drug-for-Soft-Tissue-Sarcomas/2017-06-15T14:55:49-07:00https://dev.oncoprescribe.com/Updated-Survival-Analysis-of-ONIVYDE-,-5-FU-and-Leucovorin-Combination-in-Metastatic-Pancreatic-Carcinoma/2017-06-01T22:13:52-07:00https://dev.oncoprescribe.com/First-Oral-Triplet-Combination-NINLARO-,-REVLIMID-and-Dexamethasone-for-Multiple-Myeloma/2017-06-08T22:11:22-07:00https://dev.oncoprescribe.com/recurrent-vte-in-cancer-patients-treated-with-xarelto/2020-04-05T20:02:40-07:00https://dev.oncoprescribe.com/Daily-Aspirin-May-Improve-Survival-after-Diagnosis-of-Colorectal-Cancer/2017-05-19T11:01:37-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2016-extended-adjuvant-ai-therapy-improves-dfs-in-postmenopausal-hormone-receptor-positive-breast-cancer/2020-04-05T19:59:53-07:00https://dev.oncoprescribe.com/portrazza-necitumumab/2020-04-05T15:55:01-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-9/2020-04-05T15:55:06-07:00https://dev.oncoprescribe.com/mekinist-trametinib-and-tafinlar-dabrafenib/2020-04-05T15:55:38-07:00https://dev.oncoprescribe.com/ninlaro-ixazomib/2020-04-05T15:55:44-07:00https://dev.oncoprescribe.com/darzalex-daratumumab/2020-04-05T15:55:48-07:00https://dev.oncoprescribe.com/tagrisso-osimertinib/2020-04-05T15:55:53-07:00https://dev.oncoprescribe.com/cotellic-cobimetinib/2020-04-05T15:55:57-07:00https://dev.oncoprescribe.com/imlygic-talimogene-laherparepvec/2020-04-05T15:56:06-07:00https://dev.oncoprescribe.com/Adjuvant-AROMASIN-Most-Beneficial-for-Premenopausal-Women-with-High-Risk-Breast-Cancer/2017-04-14T05:45:06-07:00https://dev.oncoprescribe.com/FOLFIRINOX-Associated-with-Prolonged-Survival-in-Locally-Advanced-Pancreatic-Cancer/2017-04-14T05:45:06-07:00https://dev.oncoprescribe.com/FDA-Approves-TECENTRIQ-for-Advanced-Urothelial-Carcinoma/2017-04-07T05:50:51-07:00https://dev.oncoprescribe.com/FDA-Approves-OPDIVO-for-Relapsed-Classical-Hodgkin-Lymphoma/2017-04-07T05:50:51-07:00https://dev.oncoprescribe.com/FDA-Approves-Combination-of-LENVIMA-and-AFINITOR-for-Advanced-Renal-Cell-Carcinoma/2017-03-31T05:06:59-07:00https://dev.oncoprescribe.com/FDA-Approves-IMBRUVICA-as-Initial-Therapy-for-Patients-with-Chronic-Lymphocytic-Leukemia/2017-03-31T05:06:59-07:00https://dev.oncoprescribe.com/FDA-Approves-GILOTRIF-for-Squamous-Cell-Carcinoma-of-the-Lung/2017-03-24T05:17:25-07:00https://dev.oncoprescribe.com/Five-Year-Follow-up-Data-without-Adjuvant-Chemotherapy,-Utilizing-Oncotype-DX-21-gene-Recurrence-Score-Assay/2017-03-24T05:17:25-07:00https://dev.oncoprescribe.com/opdivo-granted-breakthrough-designation-by-fda-for-head-and-neck-cancer/2020-05-04T10:01:33-07:00https://dev.oncoprescribe.com/Left-Sided-Colon-Cancer-Patients-Have-Better-Outcomes-than-Those-with-Right-Sided-Tumors/2017-03-21T04:56:43-07:00https://dev.oncoprescribe.com/Impact-of-Treatment-Delay-on-Clinical-Outcomes-in-Breast-Cancer-Patients/2017-09-14T23:59:37-07:00https://dev.oncoprescribe.com/Liquid-Biopsy-Can-Rapidly-Detect-EGFR-Mutations-and-KRAS-mutations-with-High-Specificity/2017-03-10T05:08:11-07:00https://dev.oncoprescribe.com/FDA-Approves-VENCLEXTA-,-a-BCL2-Inhibitor-for-the-Treatment-of-Chronic-Lymphocytic-Leukemia/2017-03-03T08:21:48-07:00https://dev.oncoprescribe.com/clinical-guidelines-for-the-evaluation-of-hematuria-as-a-marker-of-occult-urinary-tract-cancer/2020-05-06T10:42:14-07:00https://dev.oncoprescribe.com/Aromatase-Inhibitors-Induced-Carpal-Tunnel-Syndrome/2017-02-24T05:18:13-07:00https://dev.oncoprescribe.com/Caplacizumab,-a-Novel-Anti-vWF-targeted-Nanobody,-for-Acquired-TTP/2017-02-24T05:18:13-07:00https://dev.oncoprescribe.com/EGFR-Inhibition-may-not-be-Effective-Immediately-after-VEGF-blockade-in-Metastatic-ColoRectal-Cancer/2017-02-17T05:51:51-07:00https://dev.oncoprescribe.com/IMBRUVICA-in-Combination-with-BR-Regimen-Shows-Significant-Benefit-in-Relapsed-CLL-patients/2017-02-17T05:51:51-07:00https://dev.oncoprescribe.com/BRAF-Inhibitors-versus-Immunotherapy-in-Patients-with-BRAF-V600-Mutant-Metastatic-Melanoma/2017-02-10T05:08:53-07:00https://dev.oncoprescribe.com/BCR-ABL-Transcript-Type-May-Predict-Outcomes-in-Patients-with-Chronic-Phase-CML-Treated-with-Tyrosine-Kinase-Inhibitors/2017-02-10T05:08:53-07:00https://dev.oncoprescribe.com/XTANDI-Superior-to-CASODEX-in-Advanced-Prostate-Cancer/2017-02-03T16:27:36-07:00https://dev.oncoprescribe.com/intravenous-immunoglobulin-and-thromboembolic-events/2020-05-06T10:42:43-07:00https://dev.oncoprescribe.com/FDA-Approves-XALKORI-for-ROS1-Rearranged-Non-Small-Cell-Lung-Cancer/2017-01-27T06:19:31-07:00https://dev.oncoprescribe.com/COMETRIQ-Benefits-All-Patient-Subgroups-with-Advanced-Renal-Cell-Carcinoma/2017-01-27T06:19:31-07:00https://dev.oncoprescribe.com/cancer-death-rate-declines-in-the-us/2020-05-06T10:43:04-07:00https://dev.oncoprescribe.com/FDA-Approves-AFINITOR-for-Advanced-NeuroEndocrine-Tumors-of-GI-or-Lung-Origin/2017-01-20T05:19:41-07:00https://dev.oncoprescribe.com/FDA-Approves-IBRANCE-in-Combination-with-FASLODEX-for-Advanced-Breast-Cancer/2017-01-13T05:21:53-07:00https://dev.oncoprescribe.com/FDA-Approves-GAZYVA-in-Combination-with-TREANDA-for-Follicular-Lymphoma/2017-01-13T05:21:53-07:00https://dev.oncoprescribe.com/fda-approves-vistogard-an-antidote-for-5-fu-overexposure/2020-05-06T10:43:23-07:00https://dev.oncoprescribe.com/Lobectomy-Superior-to-Sublobar-Resection-in-Early-Stage-Non-Small-Cell-Lung-Cancer/2017-01-06T05:17:36-07:00https://dev.oncoprescribe.com/Cardiac-Outcomes-of-Patients-Receiving-Adjuvant-Weekly-TAXOL-and-HERCEPTIN/2016-12-23T05:38:01-07:00https://dev.oncoprescribe.com/Adjuvant-GLEEVEC-Improves-Overall-Survival-in-High-Risk-GI-Stromal-Tumors/2016-12-30T05:04:19-07:00https://dev.oncoprescribe.com/unique-toxicities-of-immunotherapy-for-the-practicing-physician/2020-05-06T10:43:43-07:00https://dev.oncoprescribe.com/Preoperative-Chemoradiotherapy-for-Esophageal-or-Junctional-Cancer-Improves-Overall-Survival/2016-12-23T05:38:01-07:00https://dev.oncoprescribe.com/varubi-now-approved-for-delayed-chemotherapy-induced-nausea-and-vomiting/2020-05-06T10:44:05-07:00https://dev.oncoprescribe.com/FDA-Approves-HALAVEN-for-Advanced-Liposarcoma/2016-12-16T05:46:48-07:00https://dev.oncoprescribe.com/FDA-Approves-ARZERRA-Maintenance-Therapy-in-Chronic-Lymphocytic-Leukemia/2016-12-09T15:43:42-07:00https://dev.oncoprescribe.com/XELOX-Adjuvant-Chemotherapy-Regimen-Improves-Overall-Survival-in-Stage-III-Colorectal-Cancer/2016-12-16T05:46:48-07:00https://dev.oncoprescribe.com/Use-of-Biomarkers-to-Guide-Decisions-on-Systemic-Therapy-for-Women-with-Metastatic-Breast-Cancer-American-Society-of-Clinical-Oncology-Clinical-Practice-Guideline/2016-12-02T05:31:31-07:00https://dev.oncoprescribe.com/Direct-Oral-Anticoagulants-Versus-Vitamin-K-Antagonists-in-the-Frail-Elderly/2016-12-09T15:43:42-07:00https://dev.oncoprescribe.com/IMBRUVICA-as-Initial-Therapy-for-Patients-with-Chronic-Lymphocytic-Leukemia/2016-11-25T06:12:09-07:00https://dev.oncoprescribe.com/hepatitis-b-antiviral-prophylaxis-for-cancer-patients-with-solid-tumors-receiving-chemotherapy/2020-05-06T10:44:35-07:00https://dev.oncoprescribe.com/pacritinib-for-myelofibrosis-a-new-jak-2-inhibitor-with-a-better-toxicity-profile/2020-04-05T19:57:59-07:00https://dev.oncoprescribe.com/Continuous-Therapy-Significantly-Improves-Outcomes-compared-to-Fixed-Duration-of-Therapy-in-Patients-with-Newly-Diagnosed-Multiple-Myeloma/2016-11-25T06:12:09-07:00https://dev.oncoprescribe.com/ACP-Guidelines-for-Evaluation-of-Patients-with-Acute-Pulmonary-Embolism/2016-11-11T05:43:18-07:00https://dev.oncoprescribe.com/Adjuvant-PROLIA-Significantly-Reduces-Fracture-Risk-for-Breast-Cancer-Patients-on-Aromatase-Inhibitors/2016-11-18T05:19:25-07:00https://dev.oncoprescribe.com/ASCO-Recommends-Extended-RAS-Gene-Testing-in-Metastatic-Colorectal-Cancer/2016-11-04T05:29:09-07:00https://dev.oncoprescribe.com/fda-approves-dignicap-cooling-system-for-prevention-of-chemotherapy-induced-alopecia/2020-04-05T19:56:20-07:00https://dev.oncoprescribe.com/FDA-Approves-ALECENSA-for-Metastatic-ALK-Positive-Non-Small-Cell-Lung-Cancer/2016-10-28T05:26:03-07:00https://dev.oncoprescribe.com/FDA-Approves-Antidote-PRAXBIND-to-Reverse-the-Anticoagulant-Effects-of-PRADAXA/2016-11-04T05:29:09-07:00https://dev.oncoprescribe.com/fda-approves-cotellic-in-combination-with-zelboraf-for-advanced-melanoma/2020-04-05T19:53:26-07:00https://dev.oncoprescribe.com/the-2015-ash-choosing-wisely-campaign-five-hematologic-tests-and-treatments-to-question/2020-04-05T19:55:20-07:00https://dev.oncoprescribe.com/Addition-of-Radiation-Therapy-to-Androgen-Deprivation-Therapy-Also-Benefits-Elderly-Patients-with-Locally-Advanced-Prostate-Cancer/2016-10-14T05:50:36-07:00https://dev.oncoprescribe.com/FDA-Approves-PORTRAZZA-for-Metastatic-Squamous-Non-Small-Cell-Lung-Cancer/2016-10-14T05:50:36-07:00https://dev.oncoprescribe.com/yervoy-ipilimumab/2020-04-05T15:56:29-07:00https://dev.oncoprescribe.com/yondelis-trabectedin/2020-04-05T15:56:33-07:00https://dev.oncoprescribe.com/onivyde-irinotecan-liposome-injection/2020-04-05T15:56:37-07:00https://dev.oncoprescribe.com/praxbind-idarucizumab/2020-04-05T15:56:41-07:00https://dev.oncoprescribe.com/FDA-Approves-OPDIVO-for-Renal-Cell-Carcinoma/2016-09-23T05:32:20-07:00https://dev.oncoprescribe.com/FDA-Approves-First-Oral-Triplet-Combination-NINLARO-,-REVLIMID-and-Dexamethasone-for-Multiple-Myeloma/2016-09-23T05:32:20-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-10/2020-04-05T15:56:48-07:00https://dev.oncoprescribe.com/FDA-Approves-TAGRISSO-,-a-Third-Generation-TKI,-for-EGFR-T790M-Positive-Non-Small-Cell-Lung-Cancer/2016-09-09T05:08:38-07:00https://dev.oncoprescribe.com/FDA-Approves-YONDELIS-for-Soft-Tissue-Sarcomas/2016-09-16T05:31:58-07:00https://dev.oncoprescribe.com/IMLYGIC-a-Novel-Oncolytic-Immunotherapy-Demonstrates-Significant-Responses-in-Advanced-Melanoma/2016-09-02T05:43:42-07:00https://dev.oncoprescribe.com/ONIVYDE-in-Combination-with-5-FU-and-Leucovorin-Improves-Overall-Survival-in-Metastatic-Pancreatic-Carcinoma/2016-09-09T05:08:38-07:00https://dev.oncoprescribe.com/Targeting-CD38-with-Daratumumab-Monotherapy-in-Multiple-Myeloma/2016-08-26T06:10:45-07:00https://dev.oncoprescribe.com/Molecular-Markers-Can-Predict-Response-to-Neoadjuvant-Cisplatin-based-Chemotherapy-in-Muscle-Invasive-Bladder-Cancer/2016-09-02T05:43:42-07:00https://dev.oncoprescribe.com/YERVOY-and-OPDIVO-Combination-Superior-to-YERVOY-Monotherapy-in-Advanced-Melanoma/2016-08-26T06:10:45-07:00https://dev.oncoprescribe.com/FDA-Approves-LONSURF-,-A-Novel-Oral-Agent-for-Refractory-Colorectal-Cancer/2016-08-19T05:54:17-07:00https://dev.oncoprescribe.com/Preserving-Fertility-with-ZOLADEX-in-Breast-Cancer/2016-08-19T05:54:17-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab-21/2020-04-05T15:57:13-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-11/2020-04-05T15:57:17-07:00https://dev.oncoprescribe.com/lonsurf-trifluridine-tipiracil-2/2020-04-05T15:57:21-07:00https://dev.oncoprescribe.com/promacta-eltrombopag/2020-04-05T15:57:26-07:00https://dev.oncoprescribe.com/adcetris-brentuximab-vedotin/2020-04-05T15:57:30-07:00https://dev.oncoprescribe.com/kyprolis-carfilzomib/2020-04-05T15:57:34-07:00https://dev.oncoprescribe.com/odomzo-sonidegib/2020-05-06T10:45:39-07:00https://dev.oncoprescribe.com/FDA-Approves-KEYTRUDA-for-Advanced-Lung-Cancer/2016-07-22T05:42:30-07:00https://dev.oncoprescribe.com/Breast-Cancer-Screening-Imaging-Modalities-A-Primer/2016-07-15T05:49:57-07:00https://dev.oncoprescribe.com/Genetics-of-Breast-Cancer-ndash-A-Primer/2016-07-15T05:49:57-07:00https://dev.oncoprescribe.com/First-Line-AVASTIN-plus-Chemotherapy-Combination-Improves-Overall-Survival-in-High-Risk-Ovarian-Cancer-Patients/2016-07-08T05:36:14-07:00https://dev.oncoprescribe.com/NCCN-Recommends-Universal-Screening-for-Lynch-Syndrome-in-Patients-with-Newly-Diagnosed-Colorectal-Cancer/2016-07-01T05:56:39-07:00https://dev.oncoprescribe.com/Superior-Outcomes-with-GAZYVA-and-TREANDA-Combo-in-Indolent-Non-Hodgkin-Lymphoma/2016-07-01T05:56:39-07:00https://dev.oncoprescribe.com/Stereotactic-Body-Radiation-Therapy-SBRT-Instead-of-Surgery-for-Patients-with-Early-Stage-Inoperable-or-Advanced-Oligometastatic-NSCLC/2016-06-24T05:09:42-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ndash-asco-2015-elective-neck-dissection-improves-overall-survival-and-disease-free-survival-in-early-oral-cavity-cancers/2020-04-05T19:51:52-07:00https://dev.oncoprescribe.com/Anticoagulation-Can-be-Safely-Stopped-for-Invasive-Procedures-in-Some-Patient-Groups/2017-01-06T05:17:36-07:00https://dev.oncoprescribe.com/nicotinamide-reduces-the-incidence-of-non-melanomatous-skin-cancers/2020-04-05T19:44:31-07:00https://dev.oncoprescribe.com/zometa-administered-every-12-weeks-is-non-inferior-to-every-4-weeks-for-bone-metastases/2020-04-05T19:43:54-07:00https://dev.oncoprescribe.com/Low-Serum-Vitamin-D-Levels-are-Associated-with-Inferior-Survival-in-Follicular-Lymphoma/2016-06-03T05:57:28-07:00https://dev.oncoprescribe.com/XTANDI-After-TAXOTERE-and-ZYTIGA-Treatment-in-Prostate-Cancer/2016-06-03T05:57:28-07:00https://dev.oncoprescribe.com/PRAXBIND-An-Antidote-to-Reverse-the-Anticoagulant-Effects-of-PRADAXA/2016-05-27T06:15:23-07:00https://dev.oncoprescribe.com/Intraperitoneal-Chemotherapy-Underused-in-Spite-of-Improved-Survival-in-Advanced-Ovarian-Cancer/2016-05-27T06:15:23-07:00https://dev.oncoprescribe.com/fda-approves-first-biosimilar-product-zarxio-a-primer-on-biosimilars/2020-05-06T10:47:47-07:00https://dev.oncoprescribe.com/Splanchnic-Venous-Thrombosis-is-a-Marker-of-Cancer-and-a-Prognostic-Factor-for-Cancer-Survival/2016-05-20T07:54:48-07:00https://dev.oncoprescribe.com/Modified-GEMZAR-and-ABRAXANE-Combination-May-Preserve-Efficacy-with-Less-Toxicity-in-Metastatic-Pancreatic-Cancer/2016-05-13T05:55:09-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2015-treating-cancer-based-on-genomics-regardless-of-tumor-type/2020-04-05T19:42:57-07:00https://dev.oncoprescribe.com/The-FDA-approves-IRESSA-for-metastatic-Non-Small-Cell-Lung-Cancer/2016-05-06T05:57:20-07:00https://dev.oncoprescribe.com/gilotrif-superior-to-tarceva-in-squamous-cell-carcinoma-of-the-lung/2020-04-05T19:42:15-07:00https://dev.oncoprescribe.com/Choosing-Appropriate-Therapy-in-Chronic-Myeloid-Leukemia/2016-04-29T05:52:15-07:00https://dev.oncoprescribe.com/iressa-gefitinib/2020-04-05T15:58:08-07:00https://dev.oncoprescribe.com/fish-oil-and-certain-species-of-fish-may-negate-the-effects-of-chemotherapy/2020-05-23T18:31:41-07:00https://dev.oncoprescribe.com/Radiation-Therapy-Added-to-Androgen-Deprivation-Therapy-Improves-Overall-Survival-in-Locally-Advanced-Prostate-Cancer/2016-04-22T06:07:18-07:00https://dev.oncoprescribe.com/tumor-genomics-may-predict-outcomes-with-first-line-therapy-in-metastatic-renal-cell-carcinoma/2020-04-05T19:41:42-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ndash-asco-2015-adjuvant-chemotherapy-improves-overall-survival-in-localized-high-risk-prostate-cancer/2020-07-28T18:35:51-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ndash-asco-2015-ibrance-more-than-doubles-progression-free-survival-in-hormone-receptor-positive-advanced-breast-cancer/2020-04-05T19:40:01-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2015-keytruda-an-anti-pd-1-antibody-for-advanced-head-and-neck-cancer/2020-04-05T19:39:05-07:00https://dev.oncoprescribe.com/asco-2015-selective-internal-radiation-therapy-with-y-90-improves-outcomes-in-metastatic-colorectal-cancer/2020-04-05T19:38:07-07:00https://dev.oncoprescribe.com/immediate-adt-confers-survival-benefit-in-prostate-cancer-patients-with-ldquo-biochemical-recurrence-rdquo/2020-04-05T19:37:14-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2015-imbruvica-in-combination-with-br-regimen-shows-significant-benefit-in-relapsed-cll-patients/2020-04-05T19:35:37-07:00https://dev.oncoprescribe.com/daily-aspirin-may-improve-survival-after-diagnosis-of-colorectal-cancer-2/2020-04-05T19:34:29-07:00https://dev.oncoprescribe.com/late-breaking-abstract-ndash-asco-2015-arimidex-may-be-a-better-treatment-option-compared-to-tamoxifen-in-postmenopausal-women-with-dcis/2020-04-05T19:33:00-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2015-adjuvant-whole-brain-radiation-therapy-not-recommended-after-stereotactic-radiosurgery/2020-05-06T10:48:35-07:00https://dev.oncoprescribe.com/late-breaking-abstract-asco-2015-opdivo-improves-overall-survival-in-non-squamous-nsclc-patients/2020-04-05T19:31:27-07:00https://dev.oncoprescribe.com/Role-of-Radiotherapy-in-Elderly-Patients-with-Low-Risk-Breast-Cancer-Following-Breast-Conserving-Surgery/2016-03-04T05:23:57-07:00https://dev.oncoprescribe.com/monoclonal-antibody-combination-significantly-improves-progression-free-survival-in-relapsed-and-refractory-multiple-myeloma/2020-04-05T19:30:00-07:00https://dev.oncoprescribe.com/higher-risk-of-fractures-in-hematopoietic-stem-cell-transplant-recipients/2020-05-23T18:32:10-07:00https://dev.oncoprescribe.com/Dual-Vaccine-Therapy-for-Metastatic-Pancreatic-Cancer-Improves-Overall-Survival/2016-02-19T05:25:21-07:00https://dev.oncoprescribe.com/Classical-Hodgkin-#39-s-Lymphoma-has-quot-Genetically-Defined-Sensitivity-to-PD-1-Blockade-quot-with-OPDIVO/2016-02-11T05:47:53-07:00https://dev.oncoprescribe.com/Targeting-ROS1-Molecular-Driver-Mutations-with-XALKORI-in-NSCLC/2016-02-05T05:13:52-07:00https://dev.oncoprescribe.com/cyramza-ramucirumab-3/2020-04-05T15:58:12-07:00https://dev.oncoprescribe.com/FDA-Approves-CYRAMZA-for-Metastatic-ColoRectal-Cancer/2016-01-29T05:26:19-07:00https://dev.oncoprescribe.com/e-cigarettes-a-policy-statement-from-the-american-association-for-cancer-research-and-the-american-society-of-clinical-oncology/2020-05-06T13:08:39-07:00https://dev.oncoprescribe.com/abraxane-superior-to-taxol-in-high-risk-breast-cancer-including-triple-negative-tumors/2020-05-23T18:00:22-07:00https://dev.oncoprescribe.com/Indolent-Non-Follicular-B-Cell-Lymphoma-Treatment-Guidelines/2016-01-15T05:57:21-07:00https://dev.oncoprescribe.com/platelet-transfusions-detrimental-in-ttp-and-hit/2020-05-23T18:32:46-07:00https://dev.oncoprescribe.com/Higher-Serum-Vitamin-D-Levels-May-Improve-Survival-in-Patients-with-Advanced-Colon-Cancer/2016-01-08T05:53:36-07:00https://dev.oncoprescribe.com/Long-Term-Survival-with-YERVOY-in-Advanced-Malignant-Melanoma/2016-01-08T05:53:36-07:00https://dev.oncoprescribe.com/Oral-Bisphosphonates-May-Decrease-the-Risk-of-Postmenopausal-Endometrial-Cancer/2016-01-01T09:33:13-07:00https://dev.oncoprescribe.com/Post-Operative-Radiation-Therapy-PORT-Improves-Survival-in-Resected-N2-Non-Small-Cell-Lung-Cancer/2016-01-01T09:33:13-07:00https://dev.oncoprescribe.com/Intraperitoneal-Chemotherapy-Superior-to-IV-Chemotherapy-in-Advanced-Ovarian-Cancer/2015-12-25T07:17:35-07:00https://dev.oncoprescribe.com/clinical-cancer-advances-2015-annual-report-on-progress-against-cancer-from-the-american-society-of-clinical-oncology-part-ii/2020-05-06T10:51:41-07:00https://dev.oncoprescribe.com/cancers-associated-with-brca1-and-brca2-mutations-other-than-breast-and-ovarian/2020-05-06T10:52:20-07:00https://dev.oncoprescribe.com/clinical-cancer-advances-2015-annual-report-on-progress-against-cancer-from-the-american-society-of-clinical-oncology-part-i/2020-05-06T10:52:46-07:00https://dev.oncoprescribe.com/goserelin-for-ovarian-protection-during-adjuvant-chemotherapy-for-breast-cancer/2020-05-06T13:08:50-07:00https://dev.oncoprescribe.com/AR-V7-in-Circulating-Tumor-Cells-may-become-a-Biomarker-for-Treatment-Selection-in-Metastatic-Castrate-Resistant-Prostate-Cancer/2015-12-11T06:28:10-07:00https://dev.oncoprescribe.com/Follicular-Lymphoma-Evidence-Based-Treatment-Guidelines/2015-12-04T06:41:51-07:00https://dev.oncoprescribe.com/OPDIVO-now-Approved-for-Advanced,-Refractory-Squamous-Non-Small-Cell-Lung-Cancer/2015-12-04T06:41:51-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-12/2020-04-05T15:58:15-07:00https://dev.oncoprescribe.com/Venous-Thromboembolism-Prophylaxis-and-Treatment-in-Patients-with-Cancer-American-Society-of-Clinical-Oncology-Clinical-Practice-Guideline-Update-2014/2015-11-27T05:16:31-07:00https://dev.oncoprescribe.com/KIT-and-PDGFRA-Mutations-and-the-Risk-of-GI-Stromal-Tumor-Recurrence/2015-11-20T05:31:31-07:00https://dev.oncoprescribe.com/efficacy-and-safety-based-on-duration-of-treatment-of-panobinostat-plus-bortezomib-and-dexamethasone-in-patients-with-relapsed-or-relapsed-and-refractory-multiple-myeloma-in-the-phase-3-panorama-1-stu/2020-05-23T18:46:22-07:00https://dev.oncoprescribe.com/Pertuzumab,-Trastuzumab,-and-Docetaxel-in-HER2-Positive-Metastatic-Breast-Cancer/2015-11-13T05:32:16-07:00https://dev.oncoprescribe.com/farydak-panobinostat/2020-04-05T15:58:20-07:00https://dev.oncoprescribe.com/lenvatinib-versus-placebo-in-radioiodine-refractory-thyroid-cancer/2020-05-23T18:34:51-07:00https://dev.oncoprescribe.com/A-Prospective-Multicenter-Study-Of-The-Bruton-rsquo-s-Tyrosine-Kinase-Inhibitor-Ibrutinib-In-Patients-With-Relapsed-Or-Refractory-Waldenstrom-rsquo-s-Macroglobulinemia/2015-11-06T05:24:59-07:00https://dev.oncoprescribe.com/lenvatinib-versus-placebo-in-radioiodine-refractory-thyroid-cancer-2/2020-05-23T18:34:21-07:00https://dev.oncoprescribe.com/ibrance-palbociclib/2020-04-05T15:58:32-07:00https://dev.oncoprescribe.com/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb/2020-05-06T11:03:26-07:00https://dev.oncoprescribe.com/The-cyclin-dependent-kinase-4/6-inhibitor-palbociclib-in-combination-with-letrozole-versus-letrozole-alone-as-first-line-treatment-of-oestrogen-receptor-positive,-HER2-negative,-advanced-breast-cancer/2015-10-07T22:52:46-07:00https://dev.oncoprescribe.com/pre-and-post-diagnosis-physical-activity-television-viewing-and-mortality-among-patients-with-colorectal-cancer-in-the-national-institutes-of-health-ndash-aarp-diet-and-health-study/2020-05-23T18:12:17-07:00https://dev.oncoprescribe.com/Abiraterone-acetate-plus-prednisone-versus-placebo-plus-prednisone-in-chemotherapy-naive-men-with-metastatic-castration-resistant-prostate-cancer-COU-AA-302-final-overall-survival-analysis-of-a-ran/2015-10-01T08:58:23-07:00https://dev.oncoprescribe.com/imbruvica-ibrutinib-3/2020-04-05T15:58:36-07:00https://dev.oncoprescribe.com/Improved-Overall-Survival-in-Melanoma-with-Combined-Dabrafenib-and-Trametinib/2015-10-01T08:36:21-07:00https://dev.oncoprescribe.com/p16-protein-expression-and-human-papillomavirus-status-as-prognostic-biomarkers-of-non-oropharyngeal-head-and-neck-squamous-cell-carcinoma/2020-05-06T11:02:35-07:00https://dev.oncoprescribe.com/aspirin-for-the-prevention-of-recurrent-venous-thromboembolism-the-inspire-collaboration/2020-05-23T18:38:54-07:00https://dev.oncoprescribe.com/Carfilzomib,-Lenalidomide,-and-Dexamethasone-for-Relapsed-Multiple-Myeloma/2015-09-16T23:55:50-07:00https://dev.oncoprescribe.com/Adjuvant-Paclitaxel-and-Trastuzumab-for-Node-Negative,-HER2-Positive-Breast-Cancer/2016-02-05T05:13:52-07:00https://dev.oncoprescribe.com/hereditary-hemochromatosis-missed-diagnosis-or-misdiagnosis/2020-05-02T13:33:14-07:00https://dev.oncoprescribe.com/Adjuvant-and-Salvage-Radiotherapy-after-Prostatectomy-American-Society-of-Clinical-Oncology-Clinical-Practice-Guideline-Endorsement/2015-09-10T00:05:02-07:00https://dev.oncoprescribe.com/opdivo-nivolumab-13/2020-05-06T11:01:43-07:00https://dev.oncoprescribe.com/lynparza-olaparib/2020-05-06T11:01:08-07:00https://dev.oncoprescribe.com/somatuline-depot-injection-lanreotide/2020-05-06T11:00:37-07:00https://dev.oncoprescribe.com/cyramza-ramucirumab-4/2020-05-06T11:00:14-07:00https://dev.oncoprescribe.com/the-second-ash-choosing-wisely-campaign-five-hematologic-tests-and-treatments-to-question/2020-05-06T11:03:43-07:00https://dev.oncoprescribe.com/A-phase-3-randomized,-open-label-study-of-nivolumab-anti-PD-1-BMS-936558-ONO-4538-versus-investigator-#39-s-choice-chemotherapy-ICC-in-patients-with-advanced-melanoma-after-prior-anti-CTLA-4-ther/2015-08-12T22:59:19-07:00https://dev.oncoprescribe.com/prognostic-significance-of-flt3-internal-tandem-duplication-nucleophosmin-1-and-cebpa-gene-mutations-for-acute-myeloid-leukemia-patients-with-normal-karyotype-and-younger-than-60-years-a-systematic/2020-05-23T18:17:26-07:00https://dev.oncoprescribe.com/Olaparib-Monotherapy-in-Patients-with-Advanced-Cancer-and-a-Germline-BRCA1/2-Mutation/2015-08-06T00:13:35-07:00https://dev.oncoprescribe.com/impact-on-overall-survival-os-with-chemohormonal-therapy-versus-hormonal-therapy-for-hormone-sensitive-newly-metastatic-prostate-cancer-mprca-an-ecog-led-phase-iii-randomized-trial/2020-05-20T13:35:54-07:00https://dev.oncoprescribe.com/confirmatory-open-label-single-arm-multicenter-phase-2-study-of-the-bite-antibody-blinatumomab-in-patients-pts-with-relapsed-refractory-b-precursor-acute-lymphoblastic-leukemia-r-r-all-2/2020-05-23T18:16:19-07:00https://dev.oncoprescribe.com/Results-of-a-prospective,-randomized,-open-label-phase-3-study-of-ruxolitinib-RUX-in-polycythemia-vera-PV-patients-resistant-to-or-intolerant-of-hydroxyurea-HU-the-RESPONSE-trial/2015-07-30T00:01:00-07:00https://dev.oncoprescribe.com/Molecular-Testing-for-Selection-of-Patients-with-Lung-Cancer-for-Epidermal-Growth-Factor-Receptor-and-Anaplastic-Lymphoma-Kinase-Tyrosine-Kinase-Inhibitors-American-Society-of-Clinical-Oncology-Endor/2015-07-23T01:16:26-07:00https://dev.oncoprescribe.com/jakafi-ruxolitinib/2020-05-06T10:59:22-07:00https://dev.oncoprescribe.com/blincyto-blinatumomab/2020-05-06T10:59:37-07:00https://dev.oncoprescribe.com/avastin-bevacizumab-3/2020-05-06T10:59:50-07:00https://dev.oncoprescribe.com/Sentinel-Lymph-Node-Biopsy-for-Patients-with-Early-Stage-Breast-Cancer-American-Society-of-Clinical-Oncology-Clinical-Practice-Guideline-Update/2015-07-08T23:16:13-07:00https://dev.oncoprescribe.com/Hepatitis-B-Reactivation-in-Patients-with-Previous-Hepatitis-B-Virus-Exposure-Undergoing-Rituximab-Containing-Chemotherapy-for-Lymphoma-A-Prospective-Study/2016-02-11T05:47:53-07:00https://dev.oncoprescribe.com/randomized-phase-3-study-of-rituximab-cyclophosphamide-doxorubicin-and-prednisone-plus-vincristine-r-chop-or-bortezomib-vr-cap-in-newly-diagnosed-mantle-cell-lymphoma-mcl-patients-pts-ineli/2020-04-05T19:28:16-07:00https://dev.oncoprescribe.com/Screening-for-Lung-Cancer-US-Preventive-Services-Task-Force-Recommendation-Statement/2015-06-30T23:53:58-07:00https://dev.oncoprescribe.com/chimeric-antigen-receptor-t-cells-for-sustained-remissions-in-leukemia/2020-04-30T20:40:07-07:00https://dev.oncoprescribe.com/Bevacizumab-Combined-With-Chemotherapy-for-Platinum-Resistant-Recurrent-Ovarian-Cancer-The-AURELIA-Open-Label-Randomized-Phase-III-Trial/2015-06-24T23:39:49-07:00https://dev.oncoprescribe.com/cyramza-ramucirumab-5/2020-05-06T10:58:57-07:00https://dev.oncoprescribe.com/Ipilimumab-Plus-Sargramostim-vs-Ipilimumab-Alone-for-Treatment-of-Metastatic-Melanoma-A-Randomized-Clinical-Trial/2015-06-17T23:37:11-07:00https://dev.oncoprescribe.com/rainbow-a-global-phase-iii-randomized-double-blind-study-of-ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-the-treatment-of-metastatic-gastroesophageal-junction-gej-and-gastric-ad-2/2020-05-23T18:27:33-07:00https://dev.oncoprescribe.com/promise-and-pitfalls-of-heavy-particle-therapy/2020-05-06T11:04:02-07:00https://dev.oncoprescribe.com/phase-ii-study-of-nivolumab-anti-pd-1-bms-936558-ono-4538-in-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer/2020-05-06T13:09:03-07:00https://dev.oncoprescribe.com/statin-use-after-colorectal-cancer-diagnosis-and-survival-a-population-based-cohort-study/2020-05-23T18:13:40-07:00https://dev.oncoprescribe.com/cancer-of-unknown-primary-site/2020-05-23T18:30:14-07:00https://dev.oncoprescribe.com/Clinical-and-Safety-Outcomes-Associated-With-Treatment-of-Acute-Venous-Thromboembolism-A-Systematic-Review-and-Meta-analysis/2015-05-27T23:33:53-07:00https://dev.oncoprescribe.com/phase-3-study-of-nepa-a-fixed-dose-combination-of-netupitant-and-palonosetron-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-during-repeated-moderately-emetogenic-chemotherapy-mec-cycl-2/2020-04-05T19:27:35-07:00https://dev.oncoprescribe.com/phase-3-study-of-nepa-a-fixed-dose-combination-of-netupitant-and-palonosetron-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-during-repeated-moderately-emetogenic-chemotherapy-mec-cycl/2020-04-05T19:26:47-07:00https://dev.oncoprescribe.com/AR-V7-and-Resistance-to-Enzalutamide-and-Abiraterone-in-Prostate-Cancer/2015-05-20T21:48:01-07:00https://dev.oncoprescribe.com/Rituximab-Extended-Schedule-or-Re-Treatment-Trial-for-Low-ndash-Tumor-Burden-Follicular-Lymphoma-Eastern-Cooperative-Oncology-Group-Protocol-E4402/2015-05-14T00:35:08-07:00https://dev.oncoprescribe.com/Everolimus-EVE-for-the-treatment-of-advanced-pancreatic-neuroendocrine-tumors-pNET-Final-overall-survival-OS-results-of-a-randomized,-double-blind,-placebo-PBO-controlled,-multicenter-Phase-I/2015-05-14T00:21:35-07:00https://dev.oncoprescribe.com/Epidermal-Growth-Factor-Receptor-Tyrosine-Kinase-Inhibitors-vs-Conventional-Chemotherapy-in-Non-ndash-Small-Cell-Lung-Cancer-Harboring-Wild-Type-Epidermal-Growth-Factor-Receptor-A-Meta-analysis/2015-05-06T23:05:21-07:00https://dev.oncoprescribe.com/final-overall-survival-analysis-from-the-cleopatra-study-of-first-line-pertuzumab-trastuzumab-and-docetaxel-in-patients-with-her2-positive-metastatic-breast-cancer/2020-05-23T17:58:30-07:00https://dev.oncoprescribe.com/The-association-of-indoor-tanning-and-melanoma-in-adults-systematic-review-and-meta-analysis/2015-04-30T00:59:27-07:00https://dev.oncoprescribe.com/A-phase-2,-randomized-trial-of-GVAX-pancreas-and-CRS-207-immunotherapy-versus-GVAX-alone-in-patients-with-metastatic-pancreatic-adenocarcinoma-Updated-results/2015-04-30T00:43:03-07:00https://dev.oncoprescribe.com/circulating-tumor-cells-and-response-to-chemotherapy-in-metastatic-breast-cancer-swog-s0500/2020-05-23T17:59:01-07:00https://dev.oncoprescribe.com/improved-survival-with-bevacizumab-in-advanced-cervical-cancer-2/2020-05-23T18:15:15-07:00https://dev.oncoprescribe.com/confirmatory-open-label-single-arm-multicenter-phase-2-study-of-the-bite-antibody-blinatumomab-in-patients-pts-with-relapsed-refractory-b-precursor-acute-lymphoblastic-leukemia-r-r-all/2020-04-30T20:36:33-07:00https://dev.oncoprescribe.com/keytruda-pembrolizumab/2020-05-06T13:10:59-07:00https://dev.oncoprescribe.com/keytruda-a-promising-immunotherapy-for-metastatic-melanoma/2014-09-13T08:37:28-07:00https://dev.oncoprescribe.com/comparative-outcomes-of-catheter-directed-thrombolysis-plus-anticoagulation-vs-anticoagulation-alone-to-treat-lower-extremity-proximal-deep-vein-thrombosis/2020-05-23T18:39:24-07:00https://dev.oncoprescribe.com/clinical-impact-of-delaying-initiation-of-adjuvant-chemotherapy-in-patients-with-breast-cancer/2020-05-23T17:59:30-07:00https://dev.oncoprescribe.com/panorama-1-a-randomized-double-blind-phase-3-study-of-panobinostat-or-placebo-plus-bortezomib-and-dexamethasone-in-relapsed-or-relapsed-and-refractory-multiple-myeloma/2020-04-05T19:20:51-07:00https://dev.oncoprescribe.com/electronic-cigarettes-a-position-statement-of-the-forum-of-international-respiratory-societies/2020-05-06T13:11:16-07:00https://dev.oncoprescribe.com/calcium-vitamin-d-dairy-products-and-mortality-among-colorectal-cancer-survivors-the-cancer-prevention-study-ii-nutrition-cohort/2020-05-06T13:11:33-07:00https://dev.oncoprescribe.com/randomized-controlled-double-blind-cross-over-trial-assessing-treatment-preference-for-pazopanib-versus-sunitinib-in-patients-with-metastatic-renal-cell-carcinoma-pisces-study/2020-05-23T18:37:05-07:00https://dev.oncoprescribe.com/zydelig-a-new-treatment-option-for-non-hodgkin-lymphoma/2014-08-24T09:09:00-07:00https://dev.oncoprescribe.com/phase-iii-trial-prevention-of-early-menopause-study-poems-swog-s0230-of-lhrh-analog-during-chemotherapy-ct-to-reduce-ovarian-failure-in-early-stage-hormone-receptor-negative-breast-cancer-an-i/2020-04-05T19:19:41-07:00https://dev.oncoprescribe.com/PI3K-delta-Inhibition-by-Idelalisib-in-Patients-with-Relapsed-Indolent-Lymphoma/2015-03-11T09:07:49-07:00https://dev.oncoprescribe.com/kadcyla-beneficial-for-patients-with-her2-positive-advanced-breast-cancer-who-had-previously-received-herceptin-and-tykerb/2014-08-16T08:21:06-07:00https://dev.oncoprescribe.com/avastin-bevacizumab-4/2020-05-06T13:12:49-07:00https://dev.oncoprescribe.com/Results-of-a-prospective,-randomized,-open-label-phase-3-study-of-ruxolitinib-RUX-in-polycythemia-vera-PV-patients-resistant-to-or-intolerant-of-hydroxyurea-HU-the-RESPONSE-trial/2015-03-04T19:09:35-07:00https://dev.oncoprescribe.com/nccn-guidelines-for-survivorship-expanded-to-address-two-common-conditions/2020-05-23T18:30:41-07:00https://dev.oncoprescribe.com/a-less-intense-schedule-of-zometa-for-patients-with-metastatic-breast-cancer/2014-08-08T10:00:18-07:00https://dev.oncoprescribe.com/Continuous-treatment-CT-versus-fixed-duration-of-therapy-FDT-in-newly-diagnosed-myeloma-patients-PFS1,-PFS2,-OS-endpoints/2015-02-25T19:21:28-07:00https://dev.oncoprescribe.com/Immediate-versus-deferred-initiation-of-androgen-deprivation-therapy-in-prostate-cancer-patients-with-PSA-only-relapse/2015-02-25T19:16:18-07:00https://dev.oncoprescribe.com/final-results-of-a-randomized-phase-2-study-showing-the-clinical-benefit-of-quizartinib-ac220-in-patients-with-flt3-itd-positive-relapsed-or-refractory-acute-myeloid-leukemia/2020-05-23T18:18:02-07:00https://dev.oncoprescribe.com/Belinostat,-a-novel-pan-histone-deacetylase-inhibitor-HDACi,-in-relapsed-or-refractory-peripheral-T-cell-lymphoma-R/R-PTCL-Results-from-the-BELIEF-trial/2015-02-18T23:50:37-07:00https://dev.oncoprescribe.com/zydelig-idelalisib-2/2020-05-06T13:04:50-07:00https://dev.oncoprescribe.com/zydelig-idelalisib/2020-05-06T13:05:04-07:00https://dev.oncoprescribe.com/beleodaq-belinostat/2020-05-06T13:05:19-07:00https://dev.oncoprescribe.com/efficacy-and-safety-of-continued-zoledronic-acid-every-4-weeks-versus-every-12-weeks-in-women-with-bone-metastases-from-breast-cancer-results-of-the-optimize-2-trial/2020-04-05T19:18:47-07:00https://dev.oncoprescribe.com/Increased-Risk-of-Pancreatic-Adenocarcinoma-After-Acute-Pancreatitis/2015-01-29T09:11:59-07:00https://dev.oncoprescribe.com/trastuzumab-emtansine-versus-treatment-of-physician-39-s-choice-for-pretreated-her2-positive-advanced-breast-cancer-th3resa-a-randomised-open-label-phase-3-trial/2020-05-06T13:09:16-07:00https://dev.oncoprescribe.com/efficacy-and-safety-of-the-anti-pd-1-monoclonal-antibody-mk-3475-in-411-patients-pts-with-melanoma-mel/2020-04-05T19:16:10-07:00https://dev.oncoprescribe.com/Long-term-treatment-with-testosterone-undecanoate-injections-and-its-effect-of-prostate-cancer-incidence-in-hypogonadal-men/2015-01-22T14:29:07-07:00https://dev.oncoprescribe.com/randomized-comparison-of-ibrutinib-versus-ofatumumab-in-relapsed-or-refractory-r-r-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-results-from-the-phase-iii-resonate-trial/2020-04-05T19:14:35-07:00https://dev.oncoprescribe.com/A-Multicenter,-Randomized,-Double-Blind,-Placebo-Controlled-Study-Of-The-Efficacy-and-Safety-Of-Siltuximab,-An-Anti-Interleukin-6-Monoclonal-Antibody,-In-Patients-With-Multicentric-Castleman-rsquo-s-D/2015-01-08T20:00:17-07:00https://dev.oncoprescribe.com/human-papillomavirus-and-overall-survival-after-progression-of-oropharyngeal-squamous-cell-carcinoma/2020-05-04T06:29:58-07:00https://dev.oncoprescribe.com/cyramza-improves-overall-survival-in-advanced-gastric-cancer/2020-05-06T13:09:29-07:00https://dev.oncoprescribe.com/Ramucirumab-monotherapy-for-previously-treated-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma-REGARD-an-international,-randomised,-multicentre,-placebo-controlled,-phase-3-trial/2015-01-01T14:24:38-07:00https://dev.oncoprescribe.com/Treatment-of-Advanced-Non-ndash-Small-Cell-Lung-Cancer-with-Epidermal-Growth-Factor-Receptor-EGFR-Mutation-or-ALK-Gene-Rearrangement-Results-of-an-International-Expert-Panel-Meeting-of-the-Italian/2015-01-01T14:20:31-07:00https://dev.oncoprescribe.com/calgb-swog-80405-phase-iii-trial-of-irinotecan-5-fu-leucovorin-folfiri-or-oxaliplatin-5-fu-leucovorin-mfolfox6-with-bevacizumab-bv-or-cetuximab-cet-for-patients-pts-with-kras-wild-type-wt/2020-04-05T19:14:01-07:00https://dev.oncoprescribe.com/randomized-comparison-of-adjuvant-aromatase-inhibitor-ai-exemestane-e-plus-ovarian-function-suppression-ofs-vs-tamoxifen-t-plus-ofs-in-premenopausal-women-with-hormone-receptor-positive-hr/2020-04-05T19:12:50-07:00https://dev.oncoprescribe.com/the-ash-choosing-wisely-campaign-five-hematologic-tests-and-treatments-to-question/2020-05-06T13:13:48-07:00https://dev.oncoprescribe.com/Multitarget-Stool-DNA-Testing-for-Colorectal-Cancer-Screening/2014-12-11T20:37:17-07:00https://dev.oncoprescribe.com/deep-molecular-response-is-reached-by-the-majority-of-patients-treated-with-imatinib-predicts-survival-and-is-achieved-more-quickly-by-optimized-high-dose-imatinib-results-from-the-randomized-cml-s/2020-04-04T10:24:16-07:00https://dev.oncoprescribe.com/Clinical-validity-of-circulating-tumour-cells-in-patients-with-metastatic-breast-cancer-a-pooled-analysis-of-individual-patient-data/2014-12-03T23:59:09-07:00https://dev.oncoprescribe.com/cd49d-is-the-strongest-flow-cytometry-ndash-based-predictor-of-overall-survival-in-chronic-lymphocytic-leukemia/2020-05-23T18:20:51-07:00https://dev.oncoprescribe.com/gaps-in-pre-rituximab-hepatitis-b-screening-an-institutional-experience/2020-05-06T13:14:19-07:00https://dev.oncoprescribe.com/15-year-post-treatment-follow-up-of-radium-223-dichloride-Ra-223-in-patients-with-castration-resistant-prostate-cancer-CRPC-and-bone-metastases-from-the-phase-3-ALSYMPCA-study/2014-11-27T13:02:24-07:00https://dev.oncoprescribe.com/nonleg-venous-thrombosis-in-critically-ill-adults-a-nested-prospective-cohort-study/2020-05-23T18:39:49-07:00https://dev.oncoprescribe.com/Bevacizumab-Combined-With-Chemotherapy-for-Platinum-Resistant-Recurrent-Ovarian-Cancer-The-AURELIA-Open-Label-Randomized-Phase-III-Trial/2014-11-20T01:00:09-07:00https://dev.oncoprescribe.com/afinitor-overcomes-endocrine-resistance-in-breast-cancer/2014-05-12T06:43:44-07:00https://dev.oncoprescribe.com/Analysis-of-KRAS/NRAS-mutations-in-phase-3-study-20050181-of-panitumumab-pmab-plus-FOLFIRI-versus-FOLFIRI-for-second-line-treatment-tx-of-metastatic-colorectal-cancer-mCRC/2014-11-13T00:21:38-07:00https://dev.oncoprescribe.com/everolimus-plus-exemestane-as-first-line-therapy-in-hr-her2-minus-advanced-breast-cancer-in-bolero-2/2020-05-23T17:54:38-07:00https://dev.oncoprescribe.com/zykadia-ceritinib/2020-05-06T13:28:55-07:00https://dev.oncoprescribe.com/purixan-mercaptopurine/2020-05-06T13:27:52-07:00https://dev.oncoprescribe.com/sylvant-siltuximab/2020-05-06T13:26:04-07:00https://dev.oncoprescribe.com/cyramza-ramucirumab/2020-05-06T13:24:50-07:00https://dev.oncoprescribe.com/yoga-can-improve-sense-of-well-being-in-breast-cancer-survivors/2014-05-04T18:59:07-07:00https://dev.oncoprescribe.com/yoga-39-s-impact-on-inflammation-mood-and-fatigue-in-breast-cancer-survivors-a-randomized-controlled-trial/2020-05-23T17:56:23-07:00https://dev.oncoprescribe.com/Survival,-Durable-Tumor-Remission,-and-Long-Term-Safety-in-Patients-With-Advanced-Melanoma-Receiving-Nivolumab/2014-10-23T01:20:31-07:00https://dev.oncoprescribe.com/arzerra-combination-for-frontline-treatment-of-cll/2014-04-27T08:30:47-07:00https://dev.oncoprescribe.com/chemotherapy-for-isolated-loco-ional-recurrence-of-breast-cancer-calor-a-randomised-trial/2020-05-23T17:55:09-07:00https://dev.oncoprescribe.com/Ofatumumab-+-Chlorambucil-versus-Chlorambucil-alone-in-Patients-with-Untreated-Chronic-Lymphocytic-Leukemia-CLL-Results-of-the-Phase-III-Study-Complement-1-OMB110911/2014-10-16T00:25:16-07:00https://dev.oncoprescribe.com/arzerra-ofatumumab/2020-05-06T13:23:50-07:00https://dev.oncoprescribe.com/zytiga-improves-survival-without-impacting-quality-of-life-in-crpc/2014-04-18T07:49:31-07:00https://dev.oncoprescribe.com/neoadjuvant-therapy-for-rectal-cancer-mature-results-from-nsabp-protocol-r-04/2020-05-06T13:23:07-07:00https://dev.oncoprescribe.com/Abiraterone-acetate-plus-prednisone-versus-prednisone-alone-in-chemotherapy-naive-men-with-metastatic-castration-resistant-prostate-cancer-patient-reported-outcome-results-of-a-randomised-phase-3-tri/2014-10-09T08:22:15-07:00https://dev.oncoprescribe.com/Rapid-Increase-in-Breast-Magnetic-Resonance-Imaging-Use-Trends-From-2000-to-2011/2014-10-02T22:49:04-07:00https://dev.oncoprescribe.com/definitive-chemoradiotherapy-with-folfox-versus-fluorouracil-and-cisplatin-in-patients-with-oesophageal-cancer-prodige5-accord17-final-results-of-a-randomised-phase-2-3-trial/2020-05-23T18:26:33-07:00https://dev.oncoprescribe.com/obinutuzumab-plus-chlorambucil-in-patients-with-cll-and-coexisting-conditions/2020-05-23T18:21:33-07:00https://dev.oncoprescribe.com/Ceritinib-in-ALK-Rearranged-Non-ndash-Small-Cell-Lung-Cancer/2014-09-24T08:47:50-07:00https://dev.oncoprescribe.com/newly-diagnosed-colorectal-cancer-ndash-nccn-recommends-universal-screening-for-lynch-syndrome/2020-05-23T18:03:52-07:00https://dev.oncoprescribe.com/efficacy-and-safety-of-neoadjuvant-pertuzumab-and-trastuzumab-in-women-with-locally-advanced-inflammatory-or-early-her2-positive-breast-cancer-neosphere-a-randomised-multicentre-open-label-phas-2/2020-05-23T17:57:37-07:00https://dev.oncoprescribe.com/the-role-of-human-papillomavirus-in-nongenital-cancers/2020-05-06T13:22:35-07:00https://dev.oncoprescribe.com/A-phase-2,-randomized-trial-of-GVAX-pancreas-and-CRS-207-immunotherapy-versus-GVAX-alone-in-patients-with-metastatic-pancreatic-adenocarcinoma-Updated-results/2014-09-10T08:35:20-07:00https://dev.oncoprescribe.com/rainbow-a-global-phase-iii-randomized-double-blind-study-of-ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-the-treatment-of-metastatic-gastroesophageal-junction-gej-and-gastric-ad/2020-05-06T13:21:58-07:00https://dev.oncoprescribe.com/Effects-of-bisphosphonate-treatment-on-recurrence-and-cause-specific-mortality-in-women-with-early-breast-cancer-a-meta-analysis-of-individual-patient-data-from-randomised-trials/2014-09-04T00:04:04-07:00https://dev.oncoprescribe.com/placebo-controlled-double-blind-prospective-randomized-study-on-the-effect-of-octreotide-lar-in-the-control-of-tumor-growth-in-patients-with-metastatic-neuroendocrine-midgut-tumors-promid-result/2020-04-05T19:08:28-07:00https://dev.oncoprescribe.com/Baseline-Selenium-Status-and-Effects-of-Selenium-and-Vitamin-E-Supplementation-on-Prostate-Cancer-Risk/2014-08-28T00:01:49-07:00https://dev.oncoprescribe.com/Oral-rivaroxaban-versus-standard-therapy-for-the-treatment-of-symptomatic-venous-thromboembolism-a-pooled-analysis-of-the-EINSTEIN-DVT-and-PE-randomized-studies/2014-08-18T11:16:40-07:00https://dev.oncoprescribe.com/Improved-Survival-with-Bevacizumab-in-Advanced-Cervical-Cancer/2014-08-18T10:59:03-07:00https://dev.oncoprescribe.com/impact-of-more-restrictive-blood-transfusion-strategies-on-clinical-outcomes-a-meta-analysis-and-systematic-review/2020-05-23T18:29:32-07:00https://dev.oncoprescribe.com/targeting-btk-with-ibrutinib-in-relapsed-chronic-lymphocytic-leukemia/2020-05-06T13:19:52-07:00https://dev.oncoprescribe.com/imbruvica-ibrutinib-4/2020-05-06T13:17:13-07:00https://dev.oncoprescribe.com/maintenance-treatment-with-capecitabine-and-bevacizumab-versus-observation-after-induction-treatment-with-chemotherapy-and-bevacizumab-in-metastatic-colorectal-cancer-mcrc-the-phase-iii-cairo3-stud/2020-05-23T18:04:47-07:00https://dev.oncoprescribe.com/clinical-cancer-advances-2013-annual-report-on-progress-against-cancer-from-the-american-society-of-clinical-oncology/2020-05-23T18:29:09-07:00https://dev.oncoprescribe.com/sorafenib-in-locally-advanced-or-metastatic-patients-with-radioactive-iodine-refractory-differentiated-thyroid-cancer-the-phase-iii-decision-trial-2/2020-05-02T13:35:27-07:00https://dev.oncoprescribe.com/sorafenib-in-locally-advanced-or-metastatic-patients-with-radioactive-iodine-refractory-differentiated-thyroid-cancer-the-phase-iii-decision-trial-3/2020-05-23T18:35:26-07:00https://dev.oncoprescribe.com/Enzalutamide-in-men-with-chemotherapy-naive-metastatic-prostate-cancer-mCRPC-Results-of-phase-III-PREVAIL-study/2014-07-23T22:56:11-07:00https://dev.oncoprescribe.com/anastrozole-for-prevention-of-breast-cancer-in-high-risk-postmenopausal-women-ibis-ii-an-international-double-blind-randomised-placebo-controlled-trial/2020-05-23T17:51:51-07:00https://dev.oncoprescribe.com/Ruxolitinib-for-Myelofibrosis-ndash-An-Update-of-Its-Clinical-Effects/2014-07-17T23:23:09-07:00https://dev.oncoprescribe.com/Randomized-Open-Label-Phase-II-Study-of-Decitabine-in-Patients-With-Low-or-Intermediate-Risk-Myelodysplastic-Syndromes/2014-07-07T16:04:40-07:00https://dev.oncoprescribe.com/effect-of-npm1-and-flt3-mutations-on-the-outcomes-of-elderly-patients-with-acute-myeloid-leukemia-receiving-standard-chemotherapy/2020-05-23T18:18:36-07:00https://dev.oncoprescribe.com/validation-of-the-12-gene-colon-cancer-recurrence-score-in-nsabp-c-07-as-a-predictor-of-recurrence-in-patients-with-stage-ii-and-iii-colon-cancer-treated-with-fluorouracil-and-leucovorin-fu-lv-and-f/2020-05-23T18:11:01-07:00https://dev.oncoprescribe.com/Combined-BRAF-and-MEK-Inhibition-in-Melanoma-with-BRAF-V600-Mutations/2014-07-02T20:59:52-07:00https://dev.oncoprescribe.com/mekinist-trametinib-in-combination-with-tafinlar-dabrafenib/2020-05-06T13:30:14-07:00https://dev.oncoprescribe.com/multiple-myeloma-international-staging-system-ldquo-staging-rdquo-or-simply-ldquo-aging-rdquo-system/2020-05-23T18:42:04-07:00https://dev.oncoprescribe.com/somatic-mutations-of-calreticulin-in-myeloproliferative-neoplasms/2020-05-02T13:29:46-07:00https://dev.oncoprescribe.com/multiple-myeloma-international-staging-system-an-aging-system/2014-01-08T22:21:34-07:00https://dev.oncoprescribe.com/safety-and-efficacy-of-everolimus-with-exemestane-vs-exemestane-alone-in-elderly-patients-with-her2-negative-hormone-receptor-positive-breast-cancer-in-bolero-2/2020-05-23T17:52:08-07:00https://dev.oncoprescribe.com/a-phase-3-randomized-double-blind-placebo-controlled-study-evaluating-the-efficacy-and-safety-of-idelalisib-and-rituximab-for-previously-treated-patients-with-chronic-lymphocytic-leukemia-cll/2020-04-05T19:06:37-07:00https://dev.oncoprescribe.com/american-society-of-clinical-oncology-2013-top-five-list-in-oncology/2020-05-06T13:30:31-07:00https://dev.oncoprescribe.com/safety-and-efficacy-of-weekly-nab-paclitaxel-in-combination-with-carboplatin-as-first-line-therapy-in-elderly-patients-with-advanced-non-small-cell-lung-cancer/2020-05-23T18:52:07-07:00https://dev.oncoprescribe.com/Venous-Thromboembolism-Prophylaxis-and-Treatment-in-Patients-With-Cancer-American-Society-of-Clinical-Oncology-Clinical-Practice-Guideline-Update/2014-05-29T09:12:16-07:00https://dev.oncoprescribe.com/Rituximab-Maintenance-Therapy-Until-Progression-After-Rituximab-and-Chemotherapy-Induction-in-Patients-With-Follicular-Lymphoma/2014-05-22T00:14:48-07:00https://dev.oncoprescribe.com/ICON7-Final-overall-survival-results-in-the-GCIG-phase-III-randomized-trial-of-bevacizumab-in-women-with-newly-diagnosed-ovarian-cancer/2014-05-21T01:02:45-07:00https://dev.oncoprescribe.com/bevacizumab-plus-capecitabine-versus-capecitabine-alone-in-elderly-patients-with-previously-untreated-metastatic-colorectal-cancer-avex-an-open-label-randomised-phase-3-trial/2020-05-23T18:11:24-07:00https://dev.oncoprescribe.com/crizotinib-versus-chemotherapy-in-advanced-alk-positive-lung-cancer/2020-05-23T18:52:32-07:00https://dev.oncoprescribe.com/gazyva-plus-leukeran-a-new-option-for-elderly-patients-with-cll/2013-12-05T18:47:12-07:00https://dev.oncoprescribe.com/nexavar-sorafenib/2020-05-06T13:36:01-07:00https://dev.oncoprescribe.com/sorafenib-in-locally-advanced-or-metastatic-patients-with-radioactive-iodine-refractory-differentiated-thyroid-cancer-the-phase-iii-decision-trial/2020-05-23T18:35:56-07:00https://dev.oncoprescribe.com/sorafenib-in-locally-advanced-or-metastatic-patients-with-radioactive-iodine-refractory-differentiated-thyroid-cancer-the-phase-iii-decision-trial-4/2020-05-06T13:31:22-07:00https://dev.oncoprescribe.com/Hereditary-Hemochromatosis-Missed-Diagnosis-or-Misdiagnosis?/2014-04-29T22:31:49-07:00https://dev.oncoprescribe.com/Targeting-BTK-with-Ibrutinib-in-Relapsed-or-Refractory-Mantle-Cell-Lymphoma/2014-04-24T00:26:08-07:00https://dev.oncoprescribe.com/imbruvica-ibrutinib/2020-05-06T13:34:25-07:00https://dev.oncoprescribe.com/Results-of-Initial-Low-Dose-Computed-Tomographic-Screening-for-Lung-Cancer/2014-04-18T00:21:39-07:00https://dev.oncoprescribe.com/pomalidomide-plus-low-dose-dexamethasone-versus-high-dose-dexamethasone-alone-for-patients-with-relapsed-and-refractory-multiple-myeloma-mm-003-a-randomised-open-label-phase-3-trial/2020-05-23T18:42:34-07:00https://dev.oncoprescribe.com/Adjuvant-Chemotherapy-With-Gemcitabine-and-Long-term-Outcomes-Among-Patients-With-Resected-Pancreatic-Cancer/2014-04-10T23:00:11-07:00https://dev.oncoprescribe.com/gazyva-obinutuzumab/2020-05-06T13:31:49-07:00https://dev.oncoprescribe.com/subcutaneous-omacetaxine-mepesuccinate-in-patients-with-chronic-phase-chronic-myeloid-leukemia-previously-treated-with-2-or-more-tyrosine-kinase-inhibitors-including-imatinib/2020-05-23T18:22:34-07:00https://dev.oncoprescribe.com/prose-randomized-proteomic-stratified-phase-iii-study-of-second-line-erlotinib-versus-chemotherapy-in-patients-with-inoperable-non-ndash-small-cell-lung-cancer-nsclc/2020-04-05T19:01:46-07:00https://dev.oncoprescribe.com/veristrat-a-novel-approach-to-nsclc/2013-10-28T17:11:41-07:00https://dev.oncoprescribe.com/Single-Agent-Lenalidomide-in-Patients-With-Mantle-Cell-Lymphoma-Who-Relapsed-or-Progressed-After-or-Were-Refractory-to-Bortezomib-Phase-II-MCL-001-EMERGE-Study/2014-03-28T00:59:58-07:00https://dev.oncoprescribe.com/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with-metastatic-lung-adenocarcinoma-with-egfr-mutations/2020-05-23T18:53:03-07:00https://dev.oncoprescribe.com/use-of-molecular-biomarkers-to-inform-adjuvant-therapy-for-colon-cancerbr/2023-09-17T14:43:10-07:00https://dev.oncoprescribe.com/perjeta-combination-improves-response-rates/2013-10-12T08:46:59-07:00https://dev.oncoprescribe.com/efficacy-and-safety-of-neoadjuvant-pertuzumab-and-trastuzumab-in-women-with-locally-advanced-inflammatory-or-early-her2-positive-breast-cancer-neosphere-a-randomised-multicentre-open-label-phas/2020-05-23T17:52:56-07:00https://dev.oncoprescribe.com/545/2013-10-12T08:38:27-07:00https://dev.oncoprescribe.com/perjeta-pertuzumab-the-fda-on-september-30-2013-approved-perjeta-for-use-in-combination-with-herceptin-trastuzumab-and-taxotere-docetaxel-for-the-neoadjuvant-treatment-of-p/2020-05-06T13:32:13-07:00https://dev.oncoprescribe.com/Oral-Apixaban-for-the-Treatment-of-Acute-Venous-Thromboembolism/2014-03-04T18:53:02-07:00https://dev.oncoprescribe.com/randomized-comparison-of-folfiri-plus-cetuximab-versus-folfiri-plus-bevacizumab-as-first-line-treatment-of-kras-wild-type-metastatic-colorectal-cancer-german-aio-study-krk-0306-fire-3/2020-04-05T18:56:50-07:00https://dev.oncoprescribe.com/obinutuzumab-ga101-plus-chlorambucil-clb-or-rituximab-r-plus-clb-versus-clb-alone-in-patients-with-chronic-lymphocytic-leukemia-cll-and-preexisting-medical-conditions-comorbidities-final-st/2020-04-05T18:55:55-07:00https://dev.oncoprescribe.com/safety-and-tumor-responses-with-lambrolizumab-anti-ndash-pd-1-in-melanoma/2020-04-05T18:55:18-07:00https://dev.oncoprescribe.com/randomized-phase-iii-study-of-weekly-nab-paclitaxel-plus-gemcitabine-versus-gemcitabine-alone-in-patients-with-metastatic-adenocarcinoma-of-the-pancreas-mpact/2020-04-05T18:54:33-07:00https://dev.oncoprescribe.com/abraxane-paclitaxel-albumin-bound-particles-2/2020-05-06T13:33:14-07:00https://dev.oncoprescribe.com/Long-Term-Survival-of-Participants-in-the-Prostate-Cancer-Prevention-Trial/2014-02-06T22:14:48-07:00https://dev.oncoprescribe.com/prostate-cancer-%e2%80%93-is-prevention-worthwhile/2013-08-30T08:02:40-07:00https://dev.oncoprescribe.com/lenalidomide-plus-dexamethasone-for-high-risk-smoldering-multiple-myeloma/2020-05-23T18:44:34-07:00https://dev.oncoprescribe.com/Alpha-Emitter-Radium-223-and-Survival-in-Metastatic-Prostate-Cancer/2014-02-06T21:34:54-07:00https://dev.oncoprescribe.com/lux-lung-3-a-randomized-open-label-phase-iii-study-of-afatinib-versus-pemetrexed-and-cisplatin-as-first-line-treatment-for-patients-with-advanced-adenocarcinoma-of-the-lung-harboring-egfr-activatin-2/2020-05-23T18:53:27-07:00https://dev.oncoprescribe.com/gilotrif%c2%ae-for-egfr-mutation-positive-lung-cancer/2013-07-14T16:53:05-07:00https://dev.oncoprescribe.com/gilotrif-afatinib/2020-05-06T13:32:42-07:00https://dev.oncoprescribe.com/Oncofetal-Gene-SALL4-in-Aggressive-Hepatocellular-Carcinoma/2014-01-24T00:31:57-07:00https://dev.oncoprescribe.com/revlimid-lenalidomide/2020-05-06T14:35:12-07:00https://dev.oncoprescribe.com/xgeva-denosumab/2020-05-06T14:36:14-07:00https://dev.oncoprescribe.com/advanced-melanoma-bringing-bench-research-to-the-patients-bedside/2013-06-14T07:42:33-07:00https://dev.oncoprescribe.com/mekinist-trametinib/2020-05-06T14:37:47-07:00https://dev.oncoprescribe.com/tafinlar-dabrafenib/2020-05-06T14:38:26-07:00https://dev.oncoprescribe.com/xofigo-radium-ra-223-dichloride/2020-05-06T14:39:33-07:00https://dev.oncoprescribe.com/tarceva-erlotinib/2020-05-06T14:40:41-07:00https://dev.oncoprescribe.com/myeloma-%e2%80%93-msmart-is-the-way-to-go/2013-05-14T14:33:06-07:00https://dev.oncoprescribe.com/2014-01-02T07:44:16-07:00https://dev.oncoprescribe.com/ttp-hus-and-ahus-different-diseases-different-treatmentsbr/2026-01-12T20:33:28-07:00https://dev.oncoprescribe.com/Efficacy-and-safety-of-orafenib-for-advanced-gastrointestinal-stromal-tumours-after-failure-of-imatinib-and-sunitinib-GRID-an-international,-multicentre,-randomised,-placebo-controlled,-phase-3/2013-12-26T01:57:21-07:00https://dev.oncoprescribe.com/stivarga-regorafenib-3/2020-05-06T14:45:57-07:00https://dev.oncoprescribe.com/stivarga-orafenib-for-advanced-gist/2020-05-06T14:41:31-07:00https://dev.oncoprescribe.com/895-2/2020-05-06T14:41:51-07:00https://dev.oncoprescribe.com/Primary-results-from-EMILIA,-a-phase-III-study-of-trastuzumab-emtansine-T-DM1-versus-capecitabine-X-and-lapatinib-L-in-HER2-positive-locally-advanced-or-metastatic-breast-cancer-MBC-previously/2013-12-12T00:43:20-07:00https://dev.oncoprescribe.com/kadcyla-ado-trastuzumab-emtansine-t-dm1-now-approved/2020-04-05T16:24:22-07:00https://dev.oncoprescribe.com/Proton-Versus-Intensity-Modulated-Radiotherapy-for-Prostate-Cancer-Patterns-of-Care-and-Early-Toxicit/2013-12-11T23:58:13-07:00https://dev.oncoprescribe.com/vitamin-d-deficiency-and-bladder-cancer/2013-02-17T22:05:43-07:00https://dev.oncoprescribe.com/pomalyst-pomalidomide/2020-05-06T14:42:13-07:00https://dev.oncoprescribe.com/proton-beam-radiation-therapy-pbrt-for-prostate-cancer/2013-02-10T14:09:39-07:00https://dev.oncoprescribe.com/avastin-bevacizumab/2020-05-06T14:47:04-07:00https://dev.oncoprescribe.com/reduced-lung-cancer-mortality-with-low-dose-computed-tomographic-screening/2020-05-23T18:53:57-07:00https://dev.oncoprescribe.com/final-results-of-a-phase-2-open-label-monotherapy-efficacy-and-safety-study-of-quizartinib-ac220-in-patients-with-flt3-itd-positive-or-negative-relapsed-refractory-acute-myeloid-leukemia-after-seco/2020-05-20T13:35:05-07:00https://dev.oncoprescribe.com/pomalidomide-in-combination-with-low-dose-dexamethasone-demonstrates-a-significant-progression-free-survival-and-overall-survival-advantage-in-relapsed-refractory-mm-a-phase-3-multicenter-randomi/2020-04-05T18:52:17-07:00https://dev.oncoprescribe.com/a-phase-1-2-study-of-weekly-mln9708-an-investigational-oral-proteasome-inhibitor-in-combination-with-lenalidomide-and-dexamethasone-in-patients-with-previously-untreated-multiple-myeloma-mm/2020-04-05T18:51:06-07:00https://dev.oncoprescribe.com/cardiovascular-events-and-intensity-of-treatment-in-polycythemia-vera/2020-04-05T18:50:27-07:00https://dev.oncoprescribe.com/the-bruton-rsquo-s-tyrosine-kinase-btk-inhibitor-ibrutinib-pci-32765-promotes-high-response-rate-durable-remissions-and-is-tolerable-in-treatment-na-iuml-ve-tn-and-relapsed-or-refractory-rr/2020-04-05T18:49:37-07:00https://dev.oncoprescribe.com/phase-ii-multicenter-study-of-single-agent-lenalidomide-in-subjects-with-mantle-cell-lymphoma-who-relapsed-or-progressed-after-or-were-refractory-to-bortezomib-the-mcl-001-ldquo-emerge-rdquo-study/2020-04-05T18:48:58-07:00https://dev.oncoprescribe.com/iclusig-ponatinib/2020-05-06T14:42:36-07:00https://dev.oncoprescribe.com/zytiga-abiraterone/2020-05-06T14:43:00-07:00https://dev.oncoprescribe.com/cometriq-cabozantinib/2020-05-06T14:52:14-07:00https://dev.oncoprescribe.com/results-of-a-randomized-phase-2-study-of-pd-0332991-a-cyclin-dependent-kinase-cdk-4-6-inhibitor-in-combination-with-letrozole-vs-letrozole-alone-for-first-line-treatment-of-er-her2-advanced-brea/2020-05-20T13:37:10-07:00https://dev.oncoprescribe.com/prospective-study-of-treatment-pattern-effectiveness-and-safety-of-zoledronic-acid-zol-therapy-beyond-24-months-subgroup-analysis-of-patients-pts-with-metastatic-bone-disease-mbd-from-breast/2020-04-05T18:45:17-07:00https://dev.oncoprescribe.com/final-analysis-of-overall-survival-for-the-phase-iii-confirm-trial-fulvestrant-500-mg-versus-250-mg/2020-04-05T18:44:08-07:00https://dev.oncoprescribe.com/neurocognitive-impact-in-adjuvant-chemotherapy-for-breast-cancer-linked-to-fatigue-a-prospective-functional-mri-study/2020-04-05T18:42:30-07:00https://dev.oncoprescribe.com/atlas-10-v-5-years-of-adjuvant-tamoxifen-tam-in-er-disease-effects-on-outcome-in-the-first-and-in-the-second-decade-after-diagnosis/2020-04-05T18:41:35-07:00https://dev.oncoprescribe.com/chemotherapy-prolongs-survival-for-isolated-local-or-ional-recurrence-of-breast-cancer-the-calor-trial-chemotherapy-as-adjuvant-for-locally-recurrent-breast-cancer-ibcsg-27-02-nsabp-b-37-big-1/2020-04-05T18:39:12-07:00https://dev.oncoprescribe.com/voraxaze-glucarpidase/2020-05-06T14:48:56-07:00https://dev.oncoprescribe.com/inlyta-axitinib/2020-05-06T14:43:22-07:00https://dev.oncoprescribe.com/erivedge-vismodegib/2020-05-06T14:53:25-07:00https://dev.oncoprescribe.com/gleevec-imatinib/2020-05-06T14:54:21-07:00https://dev.oncoprescribe.com/afinitor-everolimus-tablets-2/2020-05-06T14:55:13-07:00https://dev.oncoprescribe.com/votrient-pazopanib-tablets/2020-05-06T14:56:00-07:00https://dev.oncoprescribe.com/perjeta-pertuzumab/2020-05-06T14:43:43-07:00